Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells and related uses thereof

Isolation and expansion of stratified epithelial stem cells through specific medium formulations solves the problem of difficulty in maintaining stem cells immature state in the prior art, and achieves efficient amplification of stem cells and application in cancer treatment and regenerative medicine.

CN114945378BActive Publication Date: 2024-11-19UNIV HOUSTON SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080084841.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-10-10
Filing Date
2020-10-09
Publication Date
2024-11-19
Estimated Expiration
2040-10-09

AI Technical Summary

Technical Problem

The prior art is difficult to effectively isolate and maintain the immature state of stratified epithelial stem cells, limiting their long-term amplification and application in cancer treatment and regenerative medicine.

Method used

Specific medium formulas, including ROCK inhibitors, dysfunction growth factors, insulin or IGF, TrkA inhibitors and Oct4 activators, combined with VEGF inhibitors, TGFβ signaling pathway inhibitors and BMP antagonists, are used to resolve epithelial cells. Isolate and culture to isolate and amplify stratified epithelial stem cells.

Benefits of technology

Rapid isolation and cloning of stratified epithelial stem cells under the condition of retaining epigenetic memory is achieved, supporting their efficient amplification and application to patient-specific diagnostic and therapeutic strategies, enhancing the effectiveness of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114945378B_ABST
    Figure CN114945378B_ABST
Patent Text Reader

Abstract

The present invention relates to a culture medium system that can be used to isolate and epigenetically stably propagate normal stem cells in culture, wherein the stem cells are derived from stratified epithelial tissues, and cancer stem cells from epithelial cancers. In certain embodiments, the culture system is a feeder-free system.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority Claim

[0002] This application claims the benefit of priority to U.S. Provisional Application Serial No. 62 / 913,226, filed on October 10, 2020, the entire contents of which are hereby incorporated by reference. Background Art

[0003] Stratified epithelium differs from simple epithelium in that it is multilayered. Therefore, it is often found that body linings must withstand mechanical or chemical damage so that layers can be worn away and lost without exposing the underlying epithelial layers. As the cell layers become more apical, the cells become flatter, but in their most basal layers, the cells can be squamous or cuboidal.

[0004] Stratified epithelia include columnar, cuboidal, and squamous types. Squamous epithelia are found in lining surfaces (e.g., skin and alveoli in the lungs) to enable simple passive diffusion, which is also found in the alveolar epithelium in the lungs. Specialized squamous epithelia also form luminal linings, such as in blood vessels (e.g., endothelium) and in the pericardium (e.g., mesothelium) and other body cavities.

[0005] Cuboidal epithelial cells have a cube-like shape and show a square cross-section. The nucleus is large, spherical, and located in the center of the cell. Cuboidal epithelium is usually found in secretory tissues (such as exocrine glands), or absorptive tissues (such as pancreas), lining of renal tubules, and tubes of glands. The germinal epithelium covering the female ovaries and the germinal epithelium lining the walls of the seminiferous tubules in the testes are also cuboidal. Cuboidal cells provide protection and can actively pump material into or out of the lumen, or passively according to their position and specialization. Simple cuboidal epithelium usually differentiates to form the secretory and ductal parts of glands. Stratified cuboidal epithelium protects areas such as the ducts of sweat glands, mammary glands, and salivary glands.

[0006] Columnar epithelial cells are elongated and columnar, and are at least four times as tall as they are wide. Their nuclei are elongated and usually located near the base of the cell. Columnar epithelium forms the lining of the stomach and intestines. Cells here may have microvilli to maximize the surface area for absorption, and these microvilli may form a brush-like border. Other cells may have cilia to move mucus to function as mucociliary clearance. Other ciliated cells are found in the fallopian tubes, uterus, and central canal of the spinal cord. Some columnar cells are specialized for sensory reception, such as in the nose, ears, and taste buds. Hair cells in the inner ear have stereocilia that are similar to microvilli. Goblet cells are modified columnar cells and are found between columnar epithelial cells in the duodenum. They secrete mucus, which acts as a lubricant. Single-layered non-ciliated columnar epithelium tends to indicate absorptive function. Stratified columnar epithelium is rare, but is found in the lobar ducts of the eye, pharynx, sex organs, and salivary glands. This consists of a layer of cells that rests on at least one other epithelial cell layer, which may be squamous, cuboidal, or columnar.

[0007] The separation and long-term expansion of primary cells (especially stem / progenitor cell groups) are basic and important basic technologies in multiple biological fields including developmental biology and stem cell biology and medical science. Cells in stratified epithelial tissues are highly regenerative and disproportionately cause many human cancers and inflammatory diseases / autoimmune diseases; however, cloning epithelial stem cells is limited by the difficulty in maintaining these cells in an immature state. However, the immaturity of stem cell groups cannot be maintained in vitro, limiting the long-term expansion of various types of human epithelial stem cells.

[0008] For example, most human cancers originate from epithelial tissue. Since the concept of cancer stem cells ("cancer stem cell, CSC") was introduced in the late 1990s, it has been accepted as a mechanism for tumor initiation, proliferation, and eventual drug resistance; these stem cells have influenced all methods of cancer research and treatment because they help to mechanically explain the progression from more benign to more aggressive forms of cancer. Most cancer drugs, while killing most tumor cells, ultimately fail to induce a lasting clinical response because they are unable to eliminate key CSCs that are resistant to existing cancer treatments, including targeted drugs, chemotherapy, and radiotherapy. Surviving CSCs will produce new tumors and metastases, leading to disease recurrence. Recurrent tumors become more malignant, spread faster, and are resistant to radiotherapy and previously used drugs, resulting in a poor prognosis for cancer patients.

[0009] To complicate matters further, many tumors are thought to contain heterogeneous CSC populations, representing a range of tumor-promoting activities and a range of drug sensitivities. Therefore, the specific survival of CSCs or CSC subpopulations from heterogeneous CSC populations can provide an explanation for many treatment failures and highlight new directions for enhancing cancer therapy. In order to develop truly effective treatments that can produce lasting clinical responses, it is very important to develop drugs that can target and kill CSCs. CSCs have only recently begun to be accurately identified as technological advances have helped to identify, separate and interrogate different tumor cell subpopulations with different abilities to form and perpetuate tumors. Therefore, methods and reagents for isolating and stably passaged and amplifying stratified epithelial CSCs are needed so that they can be used in drug screening.

[0010] It is an object of the present invention to provide systems and reagents for rapid isolation / cloning of stratified epithelial stem cells (particularly from small biopsies) under conditions that preserve epigenetic memory and accurately retain the in vivo characteristics of the stem cells as they exist in the tissue biopsy through several rounds of expansion and passaging in culture, thereby being scalable, efficient and ultimately affordable enough to be done on a patient-by-patient basis for the purpose of achieving patient-specific diagnostic and therapeutic strategies (using inflammatory diseases and metaplasia / tumors as examples) or for the purpose of regenerative medicine. Summary of the invention

[0011] In one aspect, the present invention provides a method for isolating stem cells from epithelial tissue, preferably stratified epithelial tissue (eg, normal or diseased tissue), the method comprising:

[0012] (1) Cultivating epithelial cells dissociated from a stratified epithelial tissue sample to form stem cell colonies, wherein the dissociated cells and cell colonies are cultured in a culture medium comprising:

[0013] (a) ROCK (Rho kinase) inhibitor; (c) mitogenic growth factor; (d) insulin or IGF; (e) TrkA inhibitor (GW441756); and (h) Oct4 activator;

[0014] wherein the culture medium comprises at least one of a VEGF inhibitor, a tyrosine kinase inhibitor, and / or FGF10 or a FGF10 agonist;

[0015] wherein the culture medium optionally further comprises a TGFβ signaling pathway inhibitor (e.g., a TGFβ inhibitor or a TGFβ receptor inhibitor);

[0016] wherein the culture medium optionally further comprises a bone morphogenetic protein (BMP) antagonist;

[0017] wherein the culture medium optionally further comprises a Wnt agonist;

[0018] wherein cells from the tissue sample are optionally in fluid contact or direct contact with mitotically inactive feeder cells, but are preferably cultured in the absence of feeder cells;

[0019] wherein cells from the tissue sample are optionally contacted with an extracellular matrix (e.g., basement membrane matrix) or other biological or synthetic matrix;

[0020] (2) Isolation of single stem cells from cell colonies, and

[0021] (3) culturing the isolated single stem cells from step (2) individually to form culture-purified stem cell clones, optionally in contact with feeder cells and / or basement membrane matrix in a culture medium; wherein each stem cell clone represents a clonal expansion of an epithelial stem cell present in a stratified epithelial tissue sample, thereby isolating stratified epithelial stem cells.

[0022] In certain preferred embodiments, the culture medium comprises a VEGF inhibitor, preferably a VEGF inhibitor that is a small molecule tyrosine kinase inhibitor. In certain preferred embodiments, the culture medium comprises a VEGF inhibitor and lacks FGF10 or an FGF10 agonist. In certain preferred embodiments, the culture medium comprises both a VEGF receptor kinase inhibitor and a tyrosine kinase inhibitor, which may be the same or different compounds. In certain preferred embodiments, the culture medium comprises a VEGF receptor kinase inhibitor and a Pan-ABL1 kinase inhibitor, which may be the same or different compounds.

[0023] In some feeder-free embodiments of the invention, the culture medium further comprises (i) a SYK inhibitor; (j) an LPA receptor antagonist; (k) a GSK3 inhibitor; and (1) a CK2 inhibitor.

[0024] In certain embodiments, epithelial tissue from a patient suffering from a disease, disorder or abnormal condition is afflicted with a disease, disorder or abnormal condition. In certain embodiments, the stratified epithelial stem cell is an adult stratified epithelial stem cell. In certain embodiments, the stratified epithelial stem cell is a fetal stratified epithelial stem cell.

[0025] In certain embodiments, the culture medium optionally further comprises nicotinamide and / or comprises a Notch agonist.

[0026] In certain other embodiments, the culture medium specifically lacks one or both of nicotinamide and / or comprises a Notch agonist.

[0027] In certain embodiments, in step (1), the (epithelial) cells are dissociated from the tissue by enzymatic digestion with an enzyme. For example, the enzyme may comprise collagenase, protease, dispase, pronase, elastase, hyaluronidase, accutase or trypsin.

[0028] In certain embodiments, in step (1), the (epithelial) cells are dissociated from the tissue by dissolving the extracellular matrix surrounding the (epithelial) cells.

[0029] In certain embodiments involving contact with a feeder cell fluid, the mitotically inactivated cells are mitotically inactivated fibroblasts, preferably human or murine fibroblasts, such as 3T3-J2 cells. Mitotic inactivation can be accomplished by administering mitomycin C or other chemically based mitotic inhibitors, irradiation with gamma rays, irradiation with X-rays, and / or irradiation with UV light.

[0030] In certain embodiments involving contact with an extracellular matrix, the extracellular matrix is ​​a basement membrane matrix, such as a basement membrane matrix containing laminin (e.g., MATRIGEL TM Basement membrane matrix (BD Biosciences)) and is preferably growth factor reduced. In other embodiments, the biopolymer is selected from the group consisting of: collagen, chitosan; fibronectin, fibrin, and mixtures thereof.

[0031] In certain embodiments, the basement membrane matrix does not support 3-dimensional growth or does not form the 3-dimensional matrix necessary to support 3-dimensional growth.

[0032] In certain embodiments, the culture medium further comprises serum, preferably FBS (and even more preferably not heat-inactivated FBS), eg, at a concentration of 5% to 15%, eg, 10% FBS.

[0033] In certain embodiments, the ROCK inhibitor comprises Rho kinase inhibitor VI (Y-27632, (R)-(+)-trans-N-(4-pyridinyl)-4-(1-aminoethyl)-cyclohexanecarboxamide)), Fasudil or HA1077 (5-(1,4-diazepan-1-ylsulfonyl)isoquinoline), or HI 152 ((S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolyl)sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride).

[0034] In certain embodiments, the BMP antagonist comprises Noggin, DAN, DAN-like proteins (e.g., Cerberus and Gremlin) comprising a DAN cystine knot domain, Chordin, a tenascin-like protein comprising a tenascin domain, follistatin, follistatin-related protein comprising a follistatin domain, sclerostin / SOST, decorin or alpha-2 macroglobulin. In certain preferred embodiments, the BMP antagonist is Noggin.

[0035] In certain embodiments, the culture medium comprises a Wnt agonist, such as R-spondin 1, R-spondin 2, R-spondin 3, R-spondin 4, an R-spondin mimetic, a Wnt family protein (e.g., Wnt-3a, Wnt 5, Wnt-6a), Norrin, or a GSK inhibitor (e.g., CHIR99021).

[0036] In certain embodiments, the mitogenic growth factor comprises EGF, Keratinocyte Growth Factor (KGF), TGFa, BDNF, HGF and / or FGF (eg, FGF7 or FGF10).

[0037] In certain embodiments, the TGF-β receptor inhibitor comprises SB431542 (4-(4-(5-benzo[1,3]dioxol-5-yl)-4-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide), A83-01, SB505124, SB-525334, LY 364947, SD-208, or SJN 2511.

[0038] In certain embodiments, a TGF-β (signaling) inhibitor binds to and reduces the activity of one or more serine / threonine protein kinases selected from ALK5, ALK4, TGF-β receptor kinase 1, and ALK7.

[0039] In certain embodiments, the TGF-β (signaling) inhibitor is added at a concentration of 1 nM to 100 μM, 10 nM to 100 μM, 100 nM to 10 μM, or about 1 μM.

[0040] In certain embodiments, the VEGF inhibitor is selected from aflibercept, pegaptanib, tivozanib, 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hydrochloride, axitinib, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl-)methoxy]quinazolin-4-amine, V Inhibitors of EGF-R2 and VEGF-R1, axitinib, N,2-dimethyl-6-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)benzo[b]thiophene-3-carboxamide, tyrosine kinase inhibitors of RET / PTC oncogenic kinases, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine, pan-VEGF-R-kinase inhibitors; protein kinase inhibitors, multi-target human epidermal receptor (human epidermal receptor (HER) 1 / 2 and vascular endothelial growth factor receptor (VEGFR) 1 / 2 receptor family tyrosine kinase inhibitors, cediranib, sorafenib, vatalanib, glufanide disodium, VEGFR2 selective monoclonal antibodies, angiozyme, siRNA-based VEGFR1 inhibitors, 5-((7-benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol hydrochloride, any derivatives thereof, and any combination thereof.

[0041] In certain preferred embodiments, the VEGF inhibitor is a VEGF receptor inhibitor, and even more preferably a VEGF receptor kinase inhibitor, such as Tivozanib (AV-951), AZD2932, Midostaurin (pkc412), BAW2881 (NVP-BAW2881), Nintedanib (BIBF 1120), SU5402, SU1498, BFH772, Sorafenib, Sunitinib, Dovitinib (TKI258), Semaxanib (SU5416), Hypericin, Vatalanib, ZM306416, AAL993, SU4312, DMXAA or Foretinib.

[0042] In certain embodiments, the culture medium comprises a tyrosine kinase inhibitor, such as nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib). In certain preferred embodiments, the tyrosine kinase inhibitor is a pan-ABL1 kinase inhibitor, such as ponatinib or dasatinib.

[0043] In certain embodiments, the culture medium contains both a VEGF receptor kinase inhibitor and a tyrosine kinase inhibitor, which may be the same or different compounds, such as a combination of ponatinib and tivozanib.

[0044] In certain embodiments, the TrkA inhibitor is selected from: BMS-754807, GW441756, PF-06273340, Sitravatinib (MGCD516), ANA-12, GNF-5837, Belizatinib (TSR-011), Larotrectinib (LOXO-101) sulfate, Lestaurtinib, Entrectinib (RXDX-101), GNF 5837 and AG-879. Preferably, the TrkA inhibitor is selective for TrkA relative to TrkB or TrkC, such as GW441756 and Sitravatinib (MGCD516). Preferably, the TrkA inhibitor is a potent, selective inhibitor of TrkA with an IC50 of 10 nM or less, and an IC50 for inhibiting c-Raf 1 and CDK2 that is at least 100-fold higher than the IC50 for inhibiting TrkA, such as GW441756.

[0045] In certain embodiments, the Oct4 activator is an agent that can activate a reporter gene driven by the Oct4 promoter (e.g., a luciferase gene under the transcriptional control of the Oct4 promoter), and more preferably can activate both the reporter gene driven by the Oct4 promoter and the reporter gene driven by the Nanog promoter. In addition, when added to the reprogramming mixture together with the quadruple reprogramming factors (Oct4, Sox2, c-Myc, and Klf4), the Oct4 activator enhances the iPSC reprogramming efficiency and accelerates the reprogramming process. Exemplary Oct4 activators are taught, for example, in the following: U.S. Patent Application 20150191701 and Li et al. (2012) "Identification of Oct4-activating compounds that enhance reprogramming efficiency". PNAS 109 (51): 20853-8.

[0046] In certain embodiments, the Oct4 activator is represented by the formula:

[0047]

[0048] in,

[0049] X 1 is C(R 12 ) or N;

[0050] X 2 is C(R 4 ) or N;

[0051] X 3 is C(R 5 ) or N;

[0052] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 、R1 0 , R 11 and R 12 is independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R 2 and R 3 Optionally linked to form a substituted or unsubstituted heterocycloalkyl or a substituted or unsubstituted heteroaryl.

[0053] Particularly in those embodiments without a feeder layer, the culture medium may also include a SYK (spleen tyrosine kinase) inhibitor. Representative SYK inhibitors may be selected from: Entospletinib (GS-9973), Fostamatinib (R788), R406, Cerdulatinib (PRT062070) and TAK-659.

[0054] Particularly in those feeder-free embodiments, the culture medium may also include an LPA receptor antagonist, such as an antagonist that inhibits LPA1 and LPA3-induced inositol phosphate production (each with a Ki of 1000 μM or less), and significantly less inhibits LPA2, LPA4, LPA5, LPA6 (i.e., each with a Ki of 5000 μM or less). Ki16198 is a preferred LPA receptor antagonist and is the methyl ester of Ki16425.

[0055] Particularly in those embodiments without a feeder layer, the culture medium may also include a GSK3 inhibitor. Exemplary GSK3 inhibitors include CHIR-99021 (CT99021) HCl, SB216763, CHIR-98014, TWS119, Tideglusib, SB415286, CHIR-99021 (CT99021), AZD2858, AZD1080, AR-A014418, TDZD-8, LY2090314, BIO-acetone oxime, IM-12, 1-Azakenpaullone, indirubin, and 6-BIO.

[0056] Particularly in those feeder-free embodiments, the culture medium may also include a CK2 inhibitor, such as CX-4945 (Silmitasertib), CX-8184, DMAT, ellagic acid, or TTP22.

[0057] In another aspect, the invention provides a single cell clone of an epithelial stem cell, or an in vitro culture thereof, such as a culture comprising a subject culture medium, wherein the epithelial stem cell substantially lacks expression of markers associated with differentiated cell types in the epithelial tissue from which it is derived.

[0058] In another aspect, the present invention provides a single cell clone of a non-embryonic epithelial stem cell, or an in vitro culture thereof, such as a culture comprising a subject culture medium, wherein the non-embryonic epithelial stem cell has an immature, undifferentiated morphology characterized by a small round cell shape with a high nuclear to cytoplasmic ratio.

[0059] In a related aspect, the present invention also provides a library or collection of a subject single cell clone or its in vitro culture (e.g., a culture comprising a subject culture medium). In certain embodiments, a library or collection may include single cell clones from the same tissue / organ type. In certain embodiments, a library or collection may include single cell clones isolated from different members of a population but from the same type of tissue / organ type. In certain embodiments, one or more (preferably each) members of a population are homozygous for at least one tissue typing locus (e.g., HLA-A, HLA-B, and HLAD). In certain embodiments, at least one tissue typing locus (e.g., the above-mentioned HLA locus) is engineered in cloned stem cells by, for example, TALEN or CRISPR technology (see below) to produce a universal donor cell line (e.g., hepatocyte) lacking tissue antigens encoded by tissue typing loci (e.g., HLA-A, HLA-B, and HLA-D, etc.). See Torikai et al. (Blood, 122 (8): 1341-1349, 2013, incorporated by reference). In certain embodiments, a population can be defined by race, age, sex, disease state, or any common characteristic of a population. A library or collection can have at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 180, 200, 250, 300 or more members.

[0060] In another aspect, the present invention provides a method for treating a subject having a disease, disorder or abnormal condition and in need of treatment, comprising: (1) isolating epithelial stem cells from a tissue corresponding to the tissue affected by the disease, disorder or abnormal condition in the subject using any of the subject methods; (2) optionally, altering the expression of at least one gene in the epithelial stem cells to produce altered epithelial stem cells; (3) reintroducing the isolated epithelial stem cells or the altered epithelial stem cells or a clonal expansion thereof into the subject, wherein at least one adverse effect or symptom of the disease, disorder or abnormal condition is alleviated in the subject.

[0061] In certain embodiments, the expression of at least one gene in an epithelial stem cell is genetically, recombinantly, and / or epigenetically altered to produce an altered epithelial stem cell.

[0062] In certain embodiments, the tissue from which the epithelial stem cells are isolated is from a healthy adult or fetal (ie, non-embryonic) subject.

[0063] In certain embodiments, the tissue from which the epithelial stem cells are isolated is from a subject.In certain embodiments, the tissue from which the epithelial stem cells are isolated is an affected tissue affected by a disease, disorder, or abnormal condition.

[0064] In certain embodiments, the tissue from which the epithelial stem cells are isolated is adjacent to the affected tissue affected by the disease, disorder, or abnormal condition.

[0065] In certain embodiments, the at least one gene is under-expressed in a tissue affected by a disease, disorder, or abnormal condition in the subject, and expression of the at least one gene is enhanced in the altered epithelial stem cell.

[0066] In certain embodiments, the at least one gene is overexpressed in a tissue affected by the disease, disorder, or abnormal condition in the subject, and expression of the at least one gene is reduced in the altered epithelial stem cell.

[0067] In certain embodiments, step (2) is achieved by introducing exogenous DNA or RNA into epithelial stem cells.

[0068] In another aspect, the present invention provides a method for screening compounds, the method comprising: (1) isolating epithelial stem cells from a subject using any of the methods of the present invention; (2) generating a cell line of epithelial stem cells by single-cell clonal expansion; (3) contacting a test cell from the cell line with a plurality of candidate compounds; and (4) identifying one or more compounds that produce a predetermined phenotypic change in the test cell.

[0069] In the claims and / or the specification, a noun without a quantifier when used in conjunction with the term "comprising" may mean "one", but it is also consistent with the meaning of "one or more", "at least one", and "one or more than one". The word "about" means plus or minus 5% of the stated number.

[0070] It is contemplated that any method or composition described herein may be implemented relative to any other method or composition described herein. Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, although indicating some specific embodiments of the present disclosure, are given only by way of illustration, because through this detailed description, various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] The following drawings constitute part of this specification and are included to further illustrate certain aspects of the present disclosure. The present disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0072] Figure 1Representative images of clonal human epithelial stem cells derived from epidermal, upper airway, distal airway, bladder, esophageal, and ovarian tumors. Human epithelial tissues were digested and plated on irradiated 3T3-J2 feeder cells in the presence of SQM medium.

[0073] Figure 2A The single cell-derived pedigree of human bladder stem cells was seeded in an air-liquid interface system. A single bladder stem cell can differentiate into all cell types present in the bladder epithelium, including basal cells, transitional epithelium, and basal cells.

[0074] Figure 2B One thousand single bladder epithelial stem cells were plated on top of irradiated 3T3-J2 feeder cells in the presence of SQM medium and formed more than 500 colonies. After 7 passages, approximately 100 days of culture and 200 cell divisions, the clonogenic capacity did not change.

[0075] Figure 2C . The CNV, BAF (B allele frequency) and LRR (log R ratio) profiles of the P1 to P7 pedigrees show the genomic stability during generation.

[0076] Figure 3A Representative images of human distal airway stem cells at passage 5 and 25. CNV, BAF (B allele frequency), and LRR (log R ratio) profiles of human DASC P5 to P25 lineages demonstrate genome stability during passaging.

[0077] Figure 3B Single cell-derived lineages of human DASCs were seeded in ALI cultures and differentiated into clubcell (CC10), type I (AQP4), and type II (SEPTB) pneumocytes.

[0078] Figure 3C The generation of DASCs by the method of the present invention resulted in a high degree of clonogencity (clone forming capacity) which was maintained over multiple passages (compare passages 5 to 25) as was the observed genetic and epigenetic stability of these stem cell clones.

[0079] Figure 4A Single cell-derived lineages of human upper airway stem cells were seeded at the air-liquid interface for in vitro differentiation. Single cells differentiated into ciliated cells (TUBULIN) and goblet cells (MUC5AC).

[0080] Figure 4BLeft, representative images of human upper airway stem cell lineages grown on top of irradiated 3T3-J2 feeder cells in the presence of SQM medium. Right, cells from the lineages were transplanted into NSG mice and formed an upper airway epithelium containing ciliated and goblet cells.

[0081] Figure 5 . Stem cells of a single-cell derived lineage from human skin were inoculated into an air-liquid interface differentiation system and induced to differentiate into squamous epithelium similar to human skin.

[0082] Figure 6 Representative images of cloned human epithelial stem cells derived from epidermal, upper airway, distal airway, bladder, esophageal, and ovarian tumors. Human epithelial tissues were digested and plated in the presence of SGM-63+ medium without any mouse feeder cell support.

[0083] Figure 7 Stem cells of a single cell-derived lineage of the human upper airway epithelium were transplanted into NSG mice and generated structures that resembled normal human upper airway epithelium based on histology and immunostaining with markers specific for ciliated cells (tubulin), goblet cells (MUC5AC), and club cells (CC10).

[0084] Figure 8A to E. Representative images of clonal human epithelial stem cells derived from skin using the B1 medium system. Human skin tissue was digested and plated on irradiated 3T3-J2 feeder cells in the presence of specialized medium. A. Bright field image of human skin epithelial stem cells. B. Stem cell colonies stained positive with anti-p63 antibody. C. Stem cell colonies stained positive with anti-Krt5 antibody. D. Stem cell colonies stained positive with Ki67 antibody, indicating high cell proliferation. E. Single human skin stem cells were sorted into each well of a 384-well cell culture dish. Based on rhodamine staining, more than 60% of the cells were clonogenic.

[0085] Figure 9A to E. Representative images of cloned human epithelial stem cells derived from the bladder. Human bladder tissue was digested and plated on irradiated 3T3-J2 feeder cells in the presence of specialized culture medium. A. Bright field image of human bladder epithelial stem cells. B. Stem cell colonies stained positive with anti-p63 antibody. C. Stem cell colonies stained positive with anti-Krt5 antibody. D. Stem cell colonies stained positive with Ki67 antibody, indicating high cell proliferation. E. Single human bladder stem cells were sorted into each well of a 384-well cell culture dish. Based on rhodamine staining, more than 60% of the cells were clonogenic.

[0086] Figures 10A to E. Representative images of cloned human epithelial stem cells derived from salivary glands. Human salivary gland tissue was digested and plated on irradiated 3T3-J2 feeder cells in the presence of specialized culture medium. A. Bright field image of human salivary gland epithelial stem cells. B. Stem cell colonies stained positive with anti-p63 antibody. C. Stem cell colonies stained positive with anti-Krt5 antibody. D. Stem cell colonies stained positive with Ki67 antibody, indicating high cell proliferation. E. Single human salivary gland stem cells were sorted into each well of a 384-well cell culture dish. Based on rhodamine staining, more than 60% of the cells were clonogenic.

[0087] Figures 11A to D. Representative images of cloned human epithelial stem cells derived from the airway. Human airway tissue was digested and plated on irradiated 3T3-J2 feeder cells in the presence of specialized culture medium. A. Bright field image of human airway epithelial stem cells. B. Stem cell colonies stained positive with anti-p63 antibody. C. Stem cell colonies stained positive with anti-Krt5 antibody. D. Single human airway stem cells were sorted into each well of a 384-well cell culture dish. Based on rhodamine staining, more than 70% of the cells were clonogenic.

[0088] Figures 12A to 12B Single cell derived lineages of human upper or distal airway stem cells were induced to differentiate in an air-liquid interface system. 12A. Single cell derived lineages of human upper airway stem cells differentiated into ciliated cells (TUBULIN) and goblet cells (MUC5AC). 12B. Single cell derived lineages of human DASCs were seeded in ALI culture and differentiated into rod cells (CC10), type I (AQP4), and type II (SEPTB) pneumocytes. DETAILED DESCRIPTION

[0089] 1. Overview

[0090] Invention as herein described relates to separating non-embryonic (e.g., adult or fetus) epithelial stem cells from the stratified epithelium of an organ and / or maintaining the method for non-embryonic (e.g., adult or fetus) epithelial stem cells from the stratified epithelium of an organ in culture. Therefore, the epithelial stem cells separated from various tissues or organs can be self-renewal or infinitely propagated in vitro, are multipotent and can be differentiated into the various differentiated cell types that are usually present in the tissue or organ from which stem cells are separated. The culture (comprising in vitro culture) comprising the epithelial stem cells separated in this way is also within the scope of the present invention.

[0091] In addition, the isolated epithelial stem cells can be propagated by clonal expansion of a single isolated stem cell to produce such clones (e.g., as in vitro cultures), wherein at least about 40%, 70%, or 90% or more of the cells in the clones can be further passaged as clones of single cell origin. Therefore, the stem cells isolated using the methods of the present invention are uniquely capable of being manipulated in vitro by standard molecular biology techniques, such as the introduction of exogenous genetic material by infection or transfection.

[0092] As used herein, "epithelial stem cells" include adult stem cells isolated from adult tissues or organs, as well as fetal stem cells isolated from prenatal tissues or organs.

[0093] In a related embodiment, the methods of the invention described herein isolate fetal stem cells from fetal or prenatal tissue or organ. In certain embodiments, when fetal tissue or organ is the source of stem cells, the methods of the invention do not damage the fetus or otherwise impair the normal development of the fetus, especially when the fetus is a human fetus. In other embodiments, the source of fetal tissue is obtained from an aborted fetus, a stillbirth, macerated fetal material, or cells, tissues, or organs removed therefrom.

[0094] The methods of the present invention are applicable to any animal stratified epithelial tissue containing epithelial stem cells, including tissue from humans, non-human mammals, non-human primates, rodents (including but not limited to mice, rats, ferrets, hamsters, guinea pigs, rabbits), livestock animals (including but not limited to pigs, cattle, sheep, goats, horses, camels), birds, reptiles, fish, pets or other companion animals (such as cats, dogs, birds) or other vertebrates, etc.

[0095] The classification of stratified epithelium is based on the shape of the cells in the superficial layer. For example, if the superficial layer is made up of flat cells, it is part of the stratified squamous epithelium. Stratified epithelium is divided into three different forms.

[0096] "Stratified, non-keratinized squamous epithelium". The cells of stratified, non-keratinized squamous epithelium change in shape from base to free surface and are divided into four parts:

[0097] ○ Basal layer: Prismatic dark cells with round nuclei;

[0098] ○ Stratum parabasale: polygonal dark cells arranged in a layered organization;

[0099] ○Spinosomes: polyhedral and polygonal cells connected by desmosomes;

[0100] ○ Stratum superficiale: Flat cells degrade and fall off in the outermost layer.

[0101] This type of epithelium is found in the mucous membranes of the mouth and esophagus, as well as in the vagina and eye (corneal epithelium).

[0102] "Stratified, keratinized squamous epithelium". The outermost cell layer of the epithelium consists of flat cells without a nucleus, transformed into squamous. They are called stratum corneum, and their purpose is to mechanically protect the underlying tissue from dehydration. The stratified keratinized squamous epithelium is divided into five parts:

[0103] ○Basal layer

[0104] ○Spinosus

[0105] ○ Granular layer: Flat cells with transparent keratin granules

[0106] ○ Transparent layer: transformation zone

[0107] ○ Stratum corneum

[0108] "Transitional epithelium (urothelium)". The urothelium consists of a basal layer, several intermediate cell layers and an umbrella cell layer. The umbrella cells (surface cells) are large and usually have two nuclei. The crusta is a very dense network of cytoplasm located below its apical membrane. The plasma membrane consists mainly of rigid plaques containing uroplaque proteins (transmembrane proteins). The transitional epithelium is mainly found in the efferent urethra, i.e. the renal pelvis, ureters, bladder and the beginning of the urethra.

[0109] "Pseudostratified epithelium". The important feature of this type of epithelium is that their cells do touch the basement membrane, but not all of them reach the free surface. The cells that reach the free surface are of the columnar type. The cells that do not reach the free surface are located in the basal lamina and have round nuclei. The term pseudostratified derives from the appearance of this epithelium. Since the nuclei appear at different heights, it conveys the false impression that there is more than one layer of cells. For example, there is a non-ciliated pseudo-stratified epithelium in the epididymal duct and the vas deferens, and there is a ciliated pseudo-stratified epithelium with kinocilia in the respiratory tract (nasal cavity and bronchi).

[0110] In certain embodiments, the epithelial tissue is isolated from a healthy or normal individual.

[0111] In certain embodiments, the epithelial tissue is isolated from diseased tissue (eg, tissue affected by a disease), disordered tissue (eg, tissue affected by a disorder), or tissue having an abnormal disorder.

[0112] The term "disease" as used herein includes an abnormal or medical condition that affects the body of an organism and is usually associated with specific symptoms and signs. Disease can be caused by external factors (e.g., infectious diseases, including papillomavirus infection or sexually transmitted diseases) or internal dysfunction (e.g., autoimmune disease or cancer). Broadly speaking, "disease" can also include any condition that causes pain, dysfunction, pain, social problems or death in the afflicted person, or any condition that causes similar problems to people in contact with the person. In this broader sense, it can include injuries, disabilities, illnesses, syndromes, infections, isolated symptoms, abnormal behavior, and atypical changes in structure and function, while in other cases and for other purposes, these may be considered to be distinguishable categories. In certain preferred embodiments, stem cells are separated from tumor biopsies.

[0113] In certain embodiments, epithelial tissue is separated from individuals suffering from disease, disorder or other abnormal conditions, but the epithelial tissue itself may not suffer from disease, disorder or abnormal conditions. For example, epithelial tissue can be separated from patients suffering from inflammatory bowel disease or gastric cancer, but from healthy intestine (in the case of IBD) or stomach (in the case of tumor) parts that have not yet suffered from inflammatory conditions or cancer. In certain embodiments, epithelial tissue can be close to or away from disease, disorder or abnormal tissue.

[0114] In certain embodiments, epithelial tissue is isolated from an individual who is susceptible to developing a disease, disorder, or other abnormal condition, or who is at high risk of developing the disease, disorder, or other abnormal condition based on, for example, genetic makeup, family history, lifestyle choices (e.g., smoking, diet, exercise habits), the individual's previous viral infection, etc., even though the individual has not yet developed the disease, disorder, or other abnormal condition or exhibited detectable symptoms of the disease, disorder, or other abnormal condition.

[0115] Another aspect of the present invention provides epithelial stem cells isolated according to any one of the methods of the present invention, or an in vitro culture thereof.

[0116] In another aspect, the present invention also provides a single cell clone of isolated epithelial stem cells or an in vitro culture thereof, wherein at least about 40%, 50%, 60%, 70% or about 80% of the cells in the single cell clone are capable of proliferating to produce a single cell clone when isolated into single cells.

[0117] Depending on the growth phase and other growth conditions, each single cell clone may contain at least about 10, 100, 10 3 , 10 4 , 10 5 , 10 6 or more cells.

[0118] In a related aspect, the present invention provides an isolated single cell clone of an epithelial stem cell, or an in vitro culture thereof, wherein the epithelial stem cell is capable of self-renewal for more than about 50, 70, 100, 150, 200, 250, 300, 350 or about 400 or more generations when isolated as a single cell.

[0119] In certain embodiments, the in vitro culture comprises a culture medium of the present invention (e.g., a modified culture medium of the present invention as described below). See below for a description of the culture medium of the present invention, each culture medium described therein is incorporated herein by reference. In certain embodiments, epithelial stem cells are capable of differentiating into a differentiated cell type of the epithelial tissue from which their initial biopsy was derived, or in the case of cancer stem cells, can be differentiated into a tumor of the tissue origin. For example, the isolated epithelial stem cells of the present invention can be differentiated into one or more cell types that are typically present in the epithelial tissue of the biopsy from which it is derived.

[0120] In certain embodiments, epithelial stem cells are capable of differentiating into organized structures similar to structures or substructures present in the tissue from which such epithelial stem cells are derived. For example, isolated hepatic stem cells of the invention can differentiate into liver tissue-like structures similar to liver epithelium, and isolated gastrointestinal stem cells of the invention can differentiate into GI tissue-like structures similar to gastrointestinal epithelium.

[0121] In certain embodiments, epithelial stem cells have an immature, undifferentiated morphology characterized by a small round cell shape with a high nuclear to cytoplasmic ratio.

[0122] Another aspect of the invention provides a method for treating a subject suffering from a disease, disorder or abnormal condition and in need of treatment, the method comprising: (1) isolating non-embryonic (e.g., adult) stem cells from a regenerative tissue corresponding to a tissue affected by the disease, disorder or abnormal condition in the subject using any of the methods of the invention; (2) altering the expression of at least one gene in an epithelial stem cell to produce an altered epithelial stem cell; (3) reintroducing the altered epithelial stem cell or a tissue graft derived from a clonal expansion or culture thereof into the subject, wherein at least one adverse effect or symptom of the disease, disorder or abnormal condition is alleviated in the subject, or as a method for regenerating / replacing damaged reproductive tissue. In other cases, the transplanted cells / tissue can be genetically engineered to resist viral infection, such as papillomavirus infection.

[0123] For example, step (2) of the method can be achieved by introducing exogenous DNA or RNA that increases or decreases the expression of the target gene in the isolated epithelial stem cells into the epithelial stem cells. Any molecular biology techniques recognized in the art can be used to change gene expression in cells (e.g., in vitro or in vitro). Such methods may include, but are not limited to, transfection or infection by viral or non-viral vectors that encode the coding sequence of a dysfunctional or defective protein or its functional fragment in the target cell, or RNA (antisense RNA, siRNA, miRNA, shRNA, ribozyme, etc.) that can encode the function of the target gene.

[0124] In certain embodiments, the tissue from which the epithelial stem cells are isolated is from a healthy subject. Preferably, the healthy subject is of a matching HLA type to the subject in need of treatment.

[0125] In certain embodiments, the tissue from which the epithelial stem cells are isolated is from a subject, and the isolated epithelial stem cells are autologous to the subject.

[0126] In certain embodiments, the tissue from which the epithelial stem cells are isolated is an affected tissue affected by a disease, disorder, or abnormal condition.

[0127] In certain embodiments, the tissue from which the epithelial stem cells are isolated is adjacent to the affected tissue affected by the disease, disorder, or abnormal condition.

[0128] In certain embodiments, at least one gene is under-expressed in a tissue affected by a disease, disorder, or abnormal condition in a subject, and expression of the at least one gene is enhanced in the altered epithelial stem cell.

[0129] In certain embodiments, the at least one gene is overexpressed in a tissue affected by the disease, disorder, or abnormal condition in the subject, and expression of the at least one gene is reduced in the altered epithelial stem cell.

[0130] In another aspect, the present invention also provides a method for screening agents or conditions that change the "phenotype" of cells (e.g., differentiation, epigenetics, survival, etc. of reproductive tissue stem cells), whether normal or from a cancer / disease state. In an exemplary embodiment, the method comprises: (1) isolating epithelial stem cells (including cancer stem cells) from the reproductive tissue of a subject using any method of the present invention; (2) generating one or more stem cell lines from epithelial stem cells by single-cell clonal expansion; (3) contacting a test cell from the cell line with one or more candidate compounds; and (4) identifying a compound that produces a predetermined phenotypic change in the test cell. This screening method of the present invention can be used for target identification and validation. For example, a potential target gene in an epithelial stem cell isolated from a patient in need of treatment may be dysfunctional (overexpressed or underexpressed), resulting in a phenotype associated with a disease, disorder, or abnormal condition. The screening method of the present invention can be implemented on the clonal expansion of epithelial stem cells isolated using the method of the present invention to test a series of potential compounds (small molecule compounds, etc.) to identify one or more compounds that can correct, alleviate, or reverse the phenotype.

[0131] In another embodiment, epithelial stem cells can be isolated from regenerative tissue of a patient in need of treatment, such as from reproductive tissue affected by a disease, disorder or abnormal condition. The screening method of the present invention can be implemented to clone amplification of epithelial stem cells isolated using the method of the present invention to test a series of potential compounds (small molecule compounds, or any RNA-based antagonists, such as siRNA libraries, etc.) to identify one or more compounds that can correct, alleviate or reverse the phenotype. Target genes affected by effective compounds can be further identified by, for example, microarray, RNA-Seq or PCR-based expression profiling.

[0132] Epithelial stem cells isolated using the methods of the present invention and their clonal expansion can also be used for toxicology screening or research, so that any toxicology analysis and testing can be customized for individual patients receiving specific drugs or medical interventions.

[0133] Epithelial stem cells isolated using the method of the present invention and their clonal expansion can also be used in regenerative medicine, where autologous stem cells or stem cells isolated from HLA-matched healthy donors can be induced to differentiate into reproductive tissues or organs in vitro, ex vivo or in vivo to treat existing conditions or prevent / delay the occurrence of such conditions. Such stem cells can be genetically manipulated before inducing differentiation.

[0134] 2. Methods for obtaining and / or culturing stem cells

[0135] One aspect of the invention relates to a method for isolating epithelial stem cells from epithelial tissue, as generally described above.

[0136] To illustrate, one step of the method includes culturing epithelial cells dissociated from epithelial tissue, optionally in contact with a first mitotically inactive feeder cell population and / or an extracellular matrix (eg, basement membrane matrix), to form epithelial cell clones.

[0137] In certain embodiments, (epithelial) cells are dissociated from the tissue by enzymatic digestion with an enzyme including but not limited to any one or more of collagenase, protease, dispase, pronase, elastase, hyaluronidase, accutase and / or trypsin.

[0138] These enzymes or functional equivalents are well known in the art and in almost all cases are commercially available.

[0139] In other embodiments, the (epithelial) cells can be dissociated from the tissue sample by dissolving the extracellular matrix surrounding the (epithelial) cells. One reagent suitable for use in this embodiment of the invention includes BD Biosciences (San Jose, CA) as BD TM Cell Recovery Solution (BD Catalog No. 354253) is a non-enzymatic proprietary solution sold to allow recovery of cells in BDMATRIGEL TM Cells cultured on basement membrane matrix were used for subsequent biochemical analysis.

[0140] In certain embodiments, the feeder cells may comprise certain lethally irradiated fibroblasts, such as murine 3T3-J2 cells.The feeder cells may form a feeder cell layer on top of the basement membrane matrix.

[0141] Suitable 3T3-J2 cell clones are well known in the art (see, e.g., Todaro and Green, "Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines." / . Cell Biol. 17: 299-313, 1963) and are readily available to the public. For example, Waisman Biomanufacturing (Madison, Wisconsin) sells irradiated 3T3-J2 feeder cells produced and tested in accordance with cGMP guidelines. These cells were originally obtained from Dr. Howard Green's laboratory under a material transfer agreement, and according to the supplier, their quality is sufficient to support, for example, skin gene therapy and wound healing clinical trials. In addition, according to the supplier, each bottle of 3T3 cells contains at least 3×10 6The cells are manufactured in a fully compliant cleanroom and are certified mycoplasma-free and low in endotoxin. In addition, the cell bank has been thoroughly tested for adventitious agents, including murine viruses. The cells have been screened for keratinocyte culture support and are mitomycin C-free.

[0142] Method of the present invention provides feeder cells, for example purposes of mouse fibroblast 3T3J2 clone.Usually, without being limited to any specific phenotype, feeder cell layers are generally used to support the cultivation of stem cells and / or to inhibit their differentiation.Feeder cell layers are generally monolayer cells co-cultured with target cells and providing a surface suitable for the growth of the target cells.Feeder cell layers provide an environment in which target cells can grow.Feeder cells are generally inactivated by mitosis (for example, by (lethal) irradiation or with mitomycin C treatment) to prevent their proliferation.

[0143] In certain embodiments, the feeder cells are appropriately screened and are GMP grade human feeder cells, such as those sufficient to support the clinical grade stem cells of the present invention. For GMP grade human feeder cells grown in medium with GMP quality FBS, see Crook et al (Cell Stem Cell 1(5):490-494, 2007, incorporated by reference).

[0144] In certain embodiments, feeder cells can be labeled with markers that are lacking in stem cells, so that stem cells can be easily distinguished from feeder cells and separated. For example, feeder cells can be engineered to express fluorescent markers, such as GFP or other similar fluorescent markers. Fluorescently labeled feeder cells can be separated from stem cells using, for example, FACS sorting.

[0145] Any of a variety of physical separation methods known in the art can be used to separate the stem cells of the present invention from feeder cells. In addition to FACS, such physical methods can include a variety of immunoaffinity methods based on specifically expressed markers. For example, the stem cells of the present invention can be isolated based on the specific stem cell markers they express using antibodies specific for such markers.

[0146] In one embodiment, the stem cells of the present invention can be isolated by FACS using, for example, an antibody against one of these markers. Fluorescent-Activated Cell Sorting (FACS) can be used to detect markers characteristic of a particular cell type or lineage. As will be apparent to one skilled in the art, this can be accomplished by fluorescently labeled antibodies or by fluorescently labeled secondary antibodies that have binding specificity for the primary antibody. Examples of suitable fluorescent labels include, but are not limited to, FITC, Alexa Fluor ... 488, GFP, CFSE, CFDA-SE, DyLight 488, PE, PerCP, PE-Alexa 700, PE-Cy5 (TRI-COLOIT), PE-Cy5.5, PI, PE-Alexa Fluor* 750, and PE-Cy7. The list of fluorescent markers is provided by way of example only and is not intended to be limiting.

[0147] It will be apparent to those skilled in the art that FACS analysis using, for example, antibodies specific for stem cells will provide a purified stem cell population. However, in some embodiments, it may be preferred to further purify the cell population by performing another round of FACS analysis using one or more other identifiable markers (e.g., markers selected for feeder cells).

[0148] For some competitive methods, the use of feeder cells is considered undesirable because the presence of feeder cells can complicate the passage of cells in those competitive methods. For example, cells must be separated from feeder cells at each passage, and new feeder cells are required for each passage. In addition, the use of feeder cells may result in contamination of the desired cells with feeder cells.

[0149] However, the use of feeder layers is not necessarily a disadvantage of the present invention, since the isolated stem cells of the present invention can be passaged as single cells, and in fact are preferably passaged as single cell clones. Thus, the potential risk of contamination by feeder cells during passage is minimized, if not eliminated.

[0150] In certain embodiments, the basement membrane matrix is ​​a basement membrane matrix containing laminin (e.g., MATRIGEL TM Basement membrane matrix (BD Biosciences), preferably growth factor-reduced.

[0151] In certain embodiments, the basement membrane matrix does not support 3-dimensional growth, or does not form a 3-dimensional matrix necessary for supporting 3-dimensional growth. Therefore, when the basement membrane matrix is ​​plated, it is usually not necessary to deposit the basement membrane matrix on a support in a specific shape or form, such as forming a dome shape or form and maintaining such a shape or form after solidification, which may be required for supporting 3-dimensional growth. In certain embodiments, the basement membrane matrix is ​​evenly distributed or spread on a flat surface or a supporting structure (such as a flat-bottomed tissue culture dish or a hole).

[0152] In certain embodiments, the basement membrane matrix is ​​first thawed and diluted to an appropriate concentration (e.g., 10%) in cold (e.g., about 0 to 4° C.) feeder cell growth medium and plated on a flat surface and solidified, for example, by warming to 37° C. in a tissue culture incubator with an appropriate CO2 content (e.g., about 5%). The lethally irradiated feeder cells are then plated on top of the solidified basement membrane matrix at an appropriate density, allowing the settled feeder cells to form a subconfluent or confluent feeder cell layer on top of the basement membrane matrix overnight. Feeder cells are cultured in a feeder cell medium, such as a medium comprising (e.g., 3T3-J2 growth medium): preferably a basal tissue culture medium with high glucose (e.g., about 4.5 g / L), no L-glutamine, and no sodium pyruvate (e.g., DMEM (Invitrogen catalog number 11960; high glucose (4.5 g / L), no L-glutamine, no sodium pyruvate), 10% calf serum (not heat-inactivated), one or more antibiotics (e.g., 1% penicillin-streptomycin), and L-glutamine (e.g., about 1.5 mM, or 1 to 2 mM, or 0.5 to 5 mM, or 0.210 mM, or 0.1 to 20 mM).

[0153] According to the methods of the present invention, after culturing dissociated cells from a source tissue in a subject stem cell culture medium for several days (eg, 3 to 4 days, or about 10 days), epithelial cell colonies become detectable.

[0154] In certain embodiments, single cells can be separated from these epithelial cell colonies by, for example, enzymatic digestion. Suitable enzymes for this purpose include trypsin, such as warm 0.25% trypsin (Invitrogen, catalog number 25200056). In certain embodiments, enzymatic digestion is substantially complete so that substantially all cells in the epithelial cell clones are dissociated from other cells and become single cells. In certain embodiments, the method includes culturing the separated single cells (preferably after washing and resuspending the single cells) in a modified growth medium, the single cells are contacted with a second basement membrane matrix and a second lethally irradiated feeder cell group in the modified growth medium. Optionally, before the single cell plate is inoculated on the feeder cells and basement membrane matrix, the separated single cells can be passed through a cell filter of appropriate size (e.g., 40 microns).

[0155] In certain embodiments, the modified growth medium is replaced periodically (eg, once a day, once every 2, 3 or 4 days, etc.) until single cell clones are formed or clonal expansion of isolated single stem cells is achieved.

[0156] In certain embodiments, a single colony of stem cells can be isolated using, for example, cloning rings. Isolated stem cell clones can be expanded to develop lineage cell lines, i.e., cell lines derived from a single stem cell.

[0157] In certain embodiments, a single stem cell can be isolated from the clonal expansion of a single stem cell and can be passaged again as a single stem cell.

[0158] 3. Culture medium

[0159] The invention provides a variety of cell culture media for separation, cultivation and / or differentiation of subject stem cells, comprising a basal medium, wherein a number of factors have been added to produce a stem cell culture medium for reproductive tissue stem cells. The factors that may be added to the basal medium or modified medium are first described below. Several exemplary basal mediums and modified mediums of the present invention are then described in further detail to illustrate some specific non-limiting embodiments of the present invention.

[0160] Rock (Rho-kinase) inhibitors. While not wishing to be bound by any particular theory, the addition of Rock inhibitors can prevent anoikis, especially when culturing single stem cells. Rock inhibitors can be (R)-(+)-trans-N-(4-pyridinyl)-4-(1-aminoethyl)-cyclohexanecarboxamide) dihydrochloride monohydrate (Y-27632, SigmaAldrich), 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline (Fasudil or HA1077, Cayman Chemical), (1S,)-(+)-2-methyl-1-[(4-methyl-5-isoquinolyl)sulfonyl]-hexahydro-1H-1,4-diazepine Dihydrochloride (H1152, Tocris Bioscience) and N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-(4-(trifluoromethyl)phenyl)-1,4,5,6-tetrahydropyridine-3-carboxamide (GSK429286A, Stemgent). In certain embodiments, the final concentration of Y27632 is about 1 to 5 μM, or 2.5 μM. During the first 7 days of culturing stem cells, a Rho kinase inhibitor, such as Y-21632, can be added to the culture medium every 1, 2, 3, 4, 5, 6 or 7 days.

[0161] Wnt agonists. The Wnt signaling pathway is defined by a series of events that occur when a Wnt protein ligand binds to a cell surface receptor of a member of the Frizzled receptor family. This results in the activation of the Dish (Dsh) family of proteins, which inhibit the degradation of intracellular β-catenin by a protein complex comprising lacquer, GSK-3, and the protein APC. The resulting enriched nuclear β-catenin enhances transcription of the TCF / LEF family of transcription factors. "Wnt agonists" as used herein include agents that directly or indirectly activate TCF / LEF-mediated transcription in cells, such as by regulating the activity of any one protein / gene in the Wnt signaling cascade (e.g., enhancing the activity of a positive regulator of the Wnt signaling pathway, or inhibiting the activity of a negative regulator of the Wnt signaling pathway).

[0162] Wnt agonists are selected from true Wnt agonists that bind to and activate members of the Frizzled receptor family, including any and all Wnt family proteins, inhibitors of intracellular β-catenin degradation, and TCF / LEF activators. Wnt agonists can stimulate Wnt activity in cells by at least about 10%, at least about 20%, at least about 30%, at least about 50%, at least about 70%, at least about 90%, at least about 100%, at least about 2-fold, 3-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, or 1000-fold or more relative to the level of Wnt activity in the absence of the Wnt agonist. As known to those skilled in the art, Wnt activity can be determined by measuring the transcriptional activity of Wnt, for example, by pTOPFLASH and pFOPFLASH Tcf luciferase reporter constructs (see Korinek et ah, Science 275: 1784-1787, 1997, incorporated herein by reference).

[0163] Representative Wnt agonists may comprise secreted glycoproteins, including Wnt1 / Int-1, Wnt-2 / Irp (Int-1-related protein), Wnt-2b / 13, Wnt-3 / Int-4, Wnt-3a (R&D systems), Wnt4, Wnt-5a, Wnt-5b, Wnt-6 (Kirikoshi et al, Biochem. Biophys. Res. Com., 283:798805, 2001), Wnt-7a (R&D systems), Wnt-7b, Wnt-8a / 8d, Wnt-8b, Wnt-9a / 14, Wnt9b / 14b / 15, Wnt10a, Wnt10b / 12, Wnt11 and Wnt16. An overview of human Wnt proteins is provided in "The Wnt Family of Secreted Proteins," R&D Systems Catalog, 2004 (incorporated herein by reference).

[0164] Other Wnt agonists include the R-spondin family of secreted proteins, which are involved in the activation and regulation of the Wnt signaling pathway and include at least four members, namely R-spondin 1 (NU206, Nuvelo, San Carlos, CA), R-spondin 2 (R&D systems), R-spondin 3, and R-spondin 4. Wnt agonists also include Norrin (also known as Norrin disease protein or NDP) (R&D systems), which is a secreted regulatory protein that functions similarly to Wnt proteins in that it binds to the Frizzled-4 receptor with high affinity and induces activation of the Wnt signaling pathway (Kestutis Planutis et ah, BMC Cell Biol. 8: 12, 2007).

[0165] Wnt agonists also include small molecule agonists of the Wnt signaling pathway, which are aminopyrimidine derivatives (N 4 -[(2H-1,3-benzodioxol-5-yl)methyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine), as described by Liu et al. (Angew Chem. Int. Ed. Engl. 44 13): 1987-1990, 2005, incorporated herein by reference).

[0166]

[0167] GSK-inhibitors include small interfering RNA (siRNA, Cell Signaling), lithium (Sigma), kenpaullone (Biomol International, Leost et al., Eur. J. Biochem. 267: 5983-5994, 2000), 6-bromoindirubin-30-acetone oxime (Meyer et al., Chem. Biol. 10: 1255-1266, 2003), SB216763 and SB 415286 (Sigma-Aldrich), as well as FRAT-derived peptides and FRAT family members that prevent the interaction of GSK-3 with lacquer resin. An overview is provided by Meijer et al. (Trends in Pharmacological Sciences 25: 471-480, 2004, incorporated herein by reference). Methods and assays for determining the level of GSK-3 inhibition are known in the art and may include, for example, those described in Liao et al. (Endocrinology 145(6):2941-2949, 2004, incorporated herein by reference).

[0168] In certain embodiments, the Wnt agonist is selected from one or more of: a Wnt family member, R-spondin 1 to 4 (eg, R-spondin 1), Norrin, Wnt3a, Wnt6, and a GSK-inhibitor.

[0169] In certain embodiments, the Wnt agonist comprises or consists of R-spondin 1. R-spondin 1 can be added to the subject culture medium at a concentration of at least about 50 ng / mL, at least about 75 ng / mL, at least about 100 ng / mL, at least about 125 ng / mL, at least about 150 ng / mL, at least about 175 ng / mL, at least about 200 ng / mL, at least about 300 ng / mL, at least about 500 ng / mL. In certain embodiments, R-spondin 1 is about 125 ng / mL.

[0170] In certain embodiments, any specific protein-based Wnt agonist mentioned herein (e.g., R-spondin 1 to R-spondin 4, any Wnt family member, etc.) can be replaced by a natural, synthetic or recombinantly produced homolog or fragment thereof that retains at least about 80%, 85%, 90%, 95%, 99% of the corresponding Wnt agonist activity, and / or a homolog or fragment thereof that shares at least about 60%, 70%, 80%, 90%, 95%, 97%, 99% amino acid sequence identity, as measured by any art-recognized sequence alignment software based on global alignment techniques (e.g., Needleman-Wunsch algorithm) or local alignment techniques (e.g., Smith-Waterman algorithm). The sequence of a representative Wnt agonist mentioned herein is represented in SEQ ID NO.1017.

[0171] During the culture of the subject stem cells, a Wnt family member can be added to the culture medium every day, every two days, every three days, while the culture medium is refreshed, such as every 1, 2, 3, 4, 5 days or more.

[0172] In certain embodiments, the Wnt agonist is selected from: R-spondin, Wnt-3a and Wnt-6, or a combination thereof. In certain embodiments, R-spondin and Wnt-3a are used together as Wnt agonists. In certain embodiments, the R-spondin concentration is about 125 ng / mL, and the Wnt3a concentration is about 100 ng / mL.

[0173] Mitogenic growth factors. Mitogenic growth factors suitable for use in the present invention may include the family of growth factors comprising: epidermal growth factor (EGF) (Peprotech), transforming growth factor alpha (TGFa, Peprotech), basic Fibroblast Growth Factor (bFGF, Peprotech), brain-derived neurotrophic factor (BDNF, R&D Systems) and keratinocyte growth factor (KGF, Peprotech).

[0174] EGF is the effective mitogen of the ectoderm and mesoderm cells of multiple cultures, and has a far-reaching influence on the differentiation of some fibroblasts in vivo and in vitro specific cells and cell culture.EGF precursor exists as a membrane-bound molecule, and it is cut through proteolytic cleavage to produce the 53-amino acid peptide hormone that stimulates cells.EGF can be added in the subject culture medium with a concentration of 1 to 500ng / mL.In certain embodiments, the final EGF concentration in the culture medium is at least about 1,2,5,10,20,25,30,40,45 or 50ng / mL, and is not higher than about 500,450,400,350,300,250,200,150,100,50,30,20ng / mL.In certain embodiments, final EGF concentration is about 1 to 50ng / mL, or about 2 to 50ng / mL, or about 5 to 30ng / mL, or about 5 to 20ng / mL, or about 10ng / mL.

[0175] The same concentration may be used for FGFs, such as FGF10 or FGF7. If more than one FGF is used, such as FGF7 and FGF10, the above FGF concentration may refer to the total concentration of all FGFs used in the culture medium.

[0176] In certain embodiments, any specific mitogenic growth factor mentioned herein (e.g., EGF, TGFa, bFGF, BDNF, KGF, etc.) may be replaced by a natural, synthetic or recombinantly produced homolog or fragment thereof that retains at least about 80%, 85%, 90%, 95%, 99% of the activity of the corresponding mitogenic growth factor, and / or a homolog or fragment thereof that shares at least about 60%, 70%, 80%, 90%, 95%, 97%, 99% amino acid sequence identity, as measured by any art-recognized sequence alignment software based on global alignment techniques (e.g., Nedleman-Wunsch algorithm) or local alignment techniques (e.g., Smith-Waterman algorithm).

[0177] The sequences of representative mitogenic growth factors mentioned herein are represented in SEQ ID NOs-18 to 27.

[0178] During the culturing of the subject stem cells, mitogenic growth factors may be added to the culture medium every day, every 2 days, while the culture medium is refreshed (eg, every day).

[0179] Any member of the bFGF family can be used. In certain embodiments, FGF7 and / or FGF10 are used. FGF7 is also referred to as KGF (keratinocyte growth factor). In certain embodiments, a combination of mitogenic growth factors (e.g., EGF and KGF, or EGF and BDNF) is added to the subject culture medium. In certain embodiments, a combination of mitogenic growth factors (e.g., EGF and KGF, or EGF and FGF10) is added to the subject culture medium.

[0180] BMP inhibitors. Bone morphogenetic proteins (BMPs) bind as dimeric ligands to a receptor complex consisting of two different receptor serine / threonine kinases (type I and type II receptors). Type II receptors phosphorylate type I receptors, leading to activation of this receptor kinase. Type I receptors subsequently phosphorylate specific receptor substrates (such as SMADs), leading to signal transduction pathways leading to transcriptional activity.

[0181] BMP inhibitor used herein includes the reagent that suppresses BMP signal transduction by its receptor.In one embodiment, BMP inhibitor is combined with BMP molecule to form complex, so that BMP activity is neutralized, for example, by preventing or suppressing the combination of BMP molecule and BMP receptor.The example of such BMP inhibitor can include the antibody or its antigen binding portion thereof that has specificity to BMP ligand.Other examples of such BMP inhibitor include the dominant negative mutant of BMP receptor, for example, in conjunction with BMP ligand and prevent ligand from combining with the soluble BMP receptor of natural BMP receptor on cell surface.

[0182] Alternatively, a BMP inhibitor may include an agent used as an antagonist or inverse agonist. This type of inhibitor binds to a BMP receptor and prevents BMP from binding to the receptor. An example of such an agent is an antibody that specifically binds to a BMP receptor and prevents BMP from binding to the antibody BMP receptor.

[0183] In certain embodiments, the BMP inhibitor inhibits the BMP-dependent activity in the cell to at most 90%, at most 80%, at most 70%, at most 50%, at most 30%, at most 10% or about 0% (near complete inhibition) relative to the level of BMP activity in the absence of the inhibitor. As known to those skilled in the art, BMP activity can be determined by, for example, measuring the transcriptional activity of BMP, as exemplified by Zilberberg et al. ("A rapid and sensitive bioassay to measurebone morphogenetic protein activity," BMC Cell Biology 8:41, 2007, incorporated herein by reference).

[0184] Several classes of natural BMP binding proteins are known, including noggin (Peprotech), tenascin and tenascin-like proteins containing a tenascin domain (R&D systems), follistatin and follistatin-related proteins containing a follistatin domain (R&D systems), DAN and DAN-like proteins containing a DAN cystine knot domain (e.g., Cerberus and Gremlin) (R&D systems), sclerostin / SOST (R&D systems), decorin (R&D systems) and alpha-2 macroglobulin (R&D systems) or as described in US 8,383,349. Exemplary BMP inhibitors for use in the methods of the invention are selected from noggin, DAN and DAN-like proteins (including Cerberus and Gremlin) (R&D systems). These diffusible proteins are capable of binding BMP ligands with varying degrees of affinity and inhibiting access of BMPs to their signaling receptors.

[0185] When desired, any of the above-mentioned BMP inhibitors may be added to the subject culture medium alone or in combination.

[0186] In certain embodiments, the BMP inhibitor is noggin. Noggin can be added to the corresponding culture medium at a concentration of at least about 10 ng / mL, or at least about 20 ng / mL, or at least about 50 ng / mL, or at least about 100 ng / mL (e.g., 100 ng / mL).

[0187] In certain embodiments, any specific BMP inhibitor mentioned herein (e.g., Noggin, Tenascin, Follistatin, DAN, Cerberus, Gremlin, Sclerostin / SOST, Decorin, and alpha-2 macroglobulin) may be replaced by a naturally occurring, synthetic, or recombinantly produced homolog or fragment thereof that retains at least about 80%, 85%, 90%, 95%, 99% of the corresponding BMP inhibitory activity, and / or a homolog or fragment thereof that shares at least about 60%, 70%, 80%, 90%, 95%, 97%, 99% amino acid sequence identity, as measured by any art-recognized sequence alignment software based on global alignment techniques (e.g., Nedleman-Wunsch algorithm) or local alignment techniques (e.g., Smith-Waterman algorithm).

[0188] The sequence of a representative BMP inhibitor mentioned herein is shown in SEQ ID NO.19.

[0189] During the culturing of the subject stem cells, a BMP inhibitor may be added to the culture medium every day, every 2 days, every 3 days, or every 4 days, while the culture medium is refreshed every day, every 2 days, every 3 days, or every 4 days, as appropriate.

[0190] VEGF inhibitors. In certain embodiments, the VEGF inhibitor is selected from the group consisting of: aflibercept, pegaptanib, tivozanib, 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hydrochloride, axitinib, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl-)methoxy]quinazolin-4-amine, inhibitors of VEGF-R2 and VEGF-R1, axitinib. Nitrate, N,2-dimethyl-6-(2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)benzo[b]thiophene-3-carboxamide, tyrosine kinase inhibitor of RET / PTC oncogenic kinase, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine, pan-VEGF-R-kinase inhibitor; protein kinase inhibitor, multi-target human epidermal receptor (human epidermal receptor (HER) 1 / 2 and vascular endothelial growth factor receptor (VEGFR) 1 / 2 receptor family tyrosine kinase inhibitors, cediranib, sorafenib, vatalanib, glufanide disodium, VEGFR2 selective monoclonal antibodies, angiozyme, siRNA-based VEGFR1 inhibitors, 5-((7-benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol hydrochloride, any derivatives thereof, and any combination thereof.

[0191] In certain preferred embodiments, the VEGF inhibitor is a VEGF receptor inhibitor, and even more preferably a VEGF receptor kinase inhibitor, such as tivozanib (AV-951), AZD2932, midostaurin (pkc412), BAW2881 (NVP-BAW2881), nintedanib (BIBF 1120), SU5402, SU1498, BFH772, sorafenib, sunitinib, dovitinib (TKI258), semaxanib (SU5416), hypericin, vatalanib, ZM306416, AAL993, SU4312, DMXAA or Foretinib.

[0192] In certain embodiments, the VEGF receptor inhibitor is a multi-tyrosine kinase inhibitor, such as afatinib, imatinib, dacomitinib, dasatinib, ponatinib, KD-019, bosutinib, lapatinib ditosylate, AZD9291, neratinib, poziotinib, S-222611, suramin hexasodium, AL-6802, BGB-102, PB357, pyrotinib, sunitinib, sorafenib tosylate, tosylate, pazopanib, regorafenib, apatinib, axitinib, carbozantinib, lenvatinib, nintedanib, vandetanib, tivozanib, anlotinib, midostaurin, muparfostat, BMS-690514, ENMD-2076, golvatinib, lucitanib, motesanib tesanib), necuparinib, RAF265, famitinib, telatinib, X82, ALNVSP, altiratinib, ABT348, MGCD516, OB318, ODM203, HHGV678, LY-3012207, CS2164, ilorasertib, radotinib, bafetinib, NRCAN-019, ABL001, metatinib tromethamine, rebastinib tosylate, or VX-15.

[0193] Tyrosine kinase inhibitors. In certain embodiments, the culture medium comprises a tyrosine kinase inhibitor, such as nilotinib, ponatinib, dasatinib, gefitinib, erlotinib, sunitinib or cabozantinib. In certain preferred embodiments, the tyrosine kinase inhibitor is a pan-ABL1 kinase inhibitor, such as ponatinib or dasatinib.

[0194] In certain embodiments, the culture medium contains both a VEGF receptor kinase inhibitor and a tyrosine kinase inhibitor, which may be the same or different compounds, such as a combination of ponatinib and tivozanib.

[0195] TGF-β or TGF-β receptor inhibitors. TGF-β signaling is involved in many cellular functions, including cell growth, cell fate, and apoptosis. Signaling generally begins with the binding of TGF-β superfamily ligands to type II receptors, which recruit and phosphorylate type I receptors. Type 1 receptors then phosphorylate SMADs, which act as transcription factors in the nucleus and regulate target gene expression. Alternatively, TGF-β signaling can activate MAP kinase signaling pathways, for example, through p38 MAP kinase.

[0196] The TGF-β superfamily ligands include bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), anti-Mullerian hormone (AMH), activins, nodal, and TGF-β.

[0197] As used herein, TGF-β inhibitors include agents that reduce the activity of the TGF-β signaling pathway. Many different methods of disrupting the TGF-β signaling pathway are known in the art, any of which can be used in conjunction with the subject invention. For example, TGF-β signaling may be disrupted by: inhibiting TGF-β expression through a small interfering RNA strategy; inhibiting furin (TGF-β activating protease); inhibiting the pathway through physiological inhibitors, such as inhibiting BMP through noggin, DAN or DAN-like proteins; neutralizing TGF-β with monoclonal antibodies; inhibiting with small molecule inhibitors of TGF-β receptor kinase 1 (also known as activin receptor-like kinase, ALK5), ALK4, ALK6, ALK7 or other TGFβ-related receptor kinases; inhibiting Smad 2 and Smad 3 signaling by overexpressing its physiological inhibitor Smad7 or by using thioredoxin as a Smad anchor to render Smad inactivatable (Fuchs, Inhibition of TGF-β Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases. Current Signal Transduction Therapy 6(1):29-43(15), 2011).

[0198] For example, a TGF-β inhibitor can target a serine / threonine protein kinase selected from the following: TGF-β receptor kinase 1, ALK4, ALK5, ALK7 or p38. ALK4, ALK5 and ALK7 are all closely related receptors of the TGF-β superfamily. The GI number of ALK4 is 91; the GI number of ALK5 (also known as TGF-β receptor kinase 1) is 7046; and the GI number of ALK7 is 658. An inhibitor of any of these kinases is an inhibitor that causes a decrease in the enzymatic activity of any one (or more) of these kinases. Inhibition of ALK and p38 kinases has previously been shown to be associated with B cell lymphoma (Bakkebo et ah, "TGF^-induced growth inhibition in B-cell lymphoma correlates with Smad 1 / 5signaling and constitutively active p38MAPK," BMC Immunol.11:57, 2010).

[0199] In certain embodiments, the TGF-β inhibitor may bind to and inhibit the activity of a Smad protein, such as R-SMAD or SMAD1 to 5 (ie, SMAD1, SMAD2, SMAD3, SMAD4, or SMAD5).

[0200] In certain embodiments, the TGF-β inhibitor may bind to and reduce the activity of a Ser / Thr protein kinase selected from the group consisting of TGF-β receptor kinase 1, ALK4, ALK5, ALK7, or p38.

[0201] In certain embodiments, the culture medium of the invention comprises an ALK5 inhibitor.

[0202] In certain embodiments, the TGF-β inhibitor or TGF-β receptor inhibitor does not include a BMP antagonist (ie, is an agent other than a BMP antagonist).

[0203] A variety of methods are known for determining whether a substance is a TGF-β inhibitor. For example, a cell assay can be used in which cells are stably transfected with a reporter construct containing the human PAI-1 promoter or Smad binding sites, driving a luciferase reporter gene. Inhibition of luciferase activity relative to a control group can be used as a measure of compound activity (De Gouville et ah, Br. J. Pharmacol. 145(2): 166-177, 2005, incorporated herein by reference). Another example is a luciferase inhibitor for measuring kinase activity. Phosphorus sensor assay (Drew et ah, J. Biomol. Screen. 16(2): 164-173, 2011, incorporated herein by reference).

[0204] The TGF-β inhibitors that can be used in the present invention can be proteins, peptides, small molecules, small interfering RNA, antisense oligonucleotides, aptamers, antibodies or antigen binding portions thereof. The inhibitors can be naturally occurring or synthetic. Examples of small molecule TGF-β inhibitors that can be used in the context of the present invention include, but are not limited to, the small molecule inhibitors listed in Table 1 below:

[0205] Table 1: Small molecule TGF inhibitors targeting receptor kinases

[0206]

[0207] Any one or more inhibitors listed in Table 1 above or combinations thereof can be used as TGF-β inhibitors in the subject invention. In certain embodiments, the combination can include: SB-525334 and SD-208 and A83-01; SD-208 and A83-01; or SD208 and A83-01.

[0208] Those skilled in the art will appreciate that there are many other small molecule inhibitors that are primarily intended to target other kinases but also inhibit TGF-β receptor kinases at high concentrations. For example, SB-203580 is a p38 MAP kinase inhibitor that can inhibit ALK5 at high concentrations (e.g., about 10 μM or more). Any such inhibitor that inhibits the TGF-β signaling pathway can also be used in the present invention. In certain embodiments, A83-01 can be added to the culture medium at a concentration of 10 nM to 10 μM, or 20 nM to 5 μM, or 50 nM to 1 μM. In certain embodiments, A83-01 can be added to the culture medium at about 500 nM. In certain embodiments, A83-01 can be added to the culture medium at a concentration of 350 to 650 nM, 450 to 550 nM, or about 500 nM. In certain embodiments, A83-01 can be added to the culture medium at a concentration of 25 to 75 nM, 40 to 60 nM, or about 50 nM.

[0209] SB-431542 can be added to the culture medium at a concentration of 80 nM to 80 μM, or 100 nM to 40 μM, or 500 nM to 10 μM, or 1 to 5 μM. For example, SB-431542 can be added to the culture medium at about 2 μM.

[0210] SB-505124 can be added to the culture medium at a concentration of 40 nM to 40 μM, or 80 nM to 20 μM, or 200 nM to 1 μM. For example, SB505124 can be added to the culture medium at about 500 nM.

[0211] SB-525334 can be added to the culture medium at a concentration of 10 nM to 10 μM, or 20 nM to 5 μM, or 50 nM to 1 μM. For example, SB525334 can be added to the culture medium at about 100 nM.

[0212] LY 364947 can be added to the culture medium at a concentration of 40 nM to 40 μM, or 80 nM to 20 μM, or 200 nM to 1 μM. For example, LY 364947 can be added to the culture medium at about 500 nM.

[0213] SD-208 may be added to the culture medium at a concentration of 40 nM to 40 μM, or 80 nM to 20 μM, or 200 nM to 1 μM. For example, SD-208 may be added to the culture medium at about 500 nM.

[0214] S JN 2511 can be added to the culture medium at a concentration of 20 nM to 20 μM, or 40 nM to 10 μM, or 100 nM to 1 μM. For example, A83-01 can be added to the culture medium at about 200 nM.

[0215] p38 inhibitors. "p38 inhibitors" may include inhibitors that directly or indirectly negatively regulate p38 signaling, such as agents that bind to at least one p38 isoform and reduce its activity. p38 protein kinase (see GI No. 1432) is part of the mitogen-activated protein kinase (MAPK) family. MAPK is a serine / threonine-specific protein kinase that responds to extracellular stimuli (such as environmental stress and inflammatory cytokines) and regulates a variety of cellular activities, such as gene expression, differentiation, mitosis, proliferation, and cell survival / apoptosis. p38 MAPK exists in α, β, β2, γ, and δ isoforms.

[0216] A variety of methods for determining whether a substance is a p38 inhibitor are known, such as: phosphorylation of Thr180 / Tyr182 at the phospho-specific antibody detection, which provides a complete measurement of cellular p38 activation or inhibition; biochemical recombinant kinase assay; tumor necrosis factor alpha (TNFa) secretion assay; and the DiscoverRx high-throughput screening platform for p38 inhibitors. There are also several p38 activity assay kits (e.g., Millipore, SigmaAldrich).

[0217] In certain embodiments, high concentrations (e.g., greater than 100 nM, or greater than 1 μM, greater than 10 μM, or greater than 100 μM) of p38 inhibitors can have the effect of inhibiting TGF-β. In other embodiments, p38 inhibitors do not inhibit TGF-β signaling.

[0218] A variety of p38 inhibitors are known in the art (eg, see Table 1). In some embodiments, the inhibitor that directly or indirectly negatively regulates p38 signaling is selected from the group consisting of: SB-202190, SB-203580, VX-702, VX-745, PD169316, RO-4402257, and BIRB-796.

[0219] In certain embodiments, the culture medium comprises both: a) an inhibitor that binds to and reduces the activity of any one or more kinases from: ALK4, ALK5, and ALK7; and b) an inhibitor that binds to and reduces the activity of p38.

[0220] In certain embodiments, the culture medium comprises an inhibitor that binds to and reduces the activity of ALK5 and an inhibitor that binds to and reduces the activity of p38.

[0221] In one embodiment, the inhibitor binds to its target (e.g., TGF-β and / or p38) and reduces its activity by more than 10%; more than 30%; more than 60%; more than 80%; more than 90%; more than 95%; or more than 99% compared to a control, as assessed by a cell assay. Examples of cell assays for measuring target inhibition as described above are well known in the art.

[0222] Inhibitors of TGF-β and / or p38 may have an IC50 value of equal to or less than 2000 nM; less than 1000 nM; less than 100 nM; less than 50 nM; less than 30 nM; less than 20 nM or less than 10 mM. The IC50 value refers to the effectiveness of the inhibitor in inhibiting the biological or biochemical function of its target. The IC50 indicates how much of a particular inhibitor is needed to inhibit the kinase by 50%. The IC50 value can be calculated according to the above-mentioned assay method. Inhibitors of TGF-β and / or p38 may exist in a variety of forms, including natural or modified substrates, enzymes, receptors, small organic molecules (e.g., small natural or synthetic organic molecules of up to 2000 Da, preferably 800 Da or less), peptide mimetics, inorganic molecules, peptides, polypeptides, antisense oligonucleotide aptamers, and structural or functional mimetics of these, including small molecules.

[0223] In certain embodiments, inhibitors of TGF-β and / or p38 may also be aptamers. The term "aptamer" as used herein refers to an oligonucleotide chain (DNA or RNA) that can adopt a highly specific three-dimensional conformation. Aptamers are designed to have high binding affinity and specificity to certain target molecules (including extracellular and intracellular proteins). Aptamers can be produced using, for example, a systematic evolution of ligands by exponential enrichment (Systematic Evolution of Ligands by Exponential Enrichment, SELEX) method (see, e.g., Tuerk and Gold, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA Polymerase. Science 249: 505-510, 1990, incorporated herein by reference).

[0224] In certain embodiments, the TGF-β and / or p38 inhibitor may be a small synthetic molecule having a molecular weight of 50 to 800 Da, 80 to 700 Da, 100 to 600 Da, or 150 to 500 Da.

[0225] In certain embodiments, the TGF-β and / or p38 inhibitor comprises a pyridyl imidazole or a 2,4-disubstituted teridine or quinazoline, for example comprising:

[0226]

[0227] Specific examples of TGF-β and / or p38 inhibitors that can be used according to the present invention include, but are not limited to, SB-202190, SB-203580, SB-206718, SB227931, VX-702, VX-745, PD-169316, RO-4402257, BIRB-796, A83-01SB-431542, SB505124, SB-525334, LY 364947, SD-208, SJ 2511 (see Table 2).

[0228] For example, SB-202190 can be added to the culture medium at a concentration of 50 nM to 100 μM, or 100 nM to 50 μM, or 1 μM to 50 μM. For example, SB-202190 can be added to the culture medium at about 10 μM.

[0229] SB-203580 can be added to the culture medium at a concentration of 50 nM to 100 μM, or 100 nM to 50 μM, or 1 μM to 50 μM. For example, SB-203580 can be added to the culture medium at about 10 μM.

[0230] VX-702 can be added to the culture medium at a concentration of 50 nM to 100 μM, or 100 nM to 50 μM, or 1 μM to 25 μM. For example, VX-702 can be added to the culture medium at about 5 μM.

[0231] VX-745 can be added to the culture medium at a concentration of 10 nM to 50 μM, or 50 nM to 50 μM, or 250 nM to 10 μM. For example, VX-745 can be added to the culture medium at about 1 μM.

[0232] PD-169316 can be added to the culture medium at a concentration of 100 nM to 200 μM, or 200 nM to 100 μM, or 1 μM to 50 μM. For example, PD169316 can be added to the culture medium at about 20 μM.

[0233] RO-4402257 can be added to the culture medium at a concentration of 10 nM to 50 μM, or 50 nM to 50 μM, or 500 nM to 10 μM. For example, RO-4402257 can be added to the culture medium at about 1 μM.

[0234] BIRB-796 can be added to the culture medium at a concentration of 10 nM to 50 μM, or 50 nM to 50 μM, or 500 nM to 10 μM. For example, BIRB-796 can be added to the culture medium at about 1 μM.

[0235] For applicable concentrations of the other factors in Table 2, see Table 1 above and associated text.

[0236] Table 2: Exemplary TGF-β and / or p38 inhibitors

[0237] Exemplary TGF-β and / or p38 inhibitors

[0238]

[0239]

[0240] Thus, in some embodiments, an inhibitor that directly or indirectly negatively regulates TGF-β and / or p38 signaling is added to the culture medium at a concentration of 1 nM to 100 μM, 10 nM to 100 μM, 100 nM to 10 μM, or about 1 μM. For example, the total concentration of one or more inhibitors is 10 nM to 100 μM, 100 nM to 10 μM, or about 1 μM.

[0241] Oct4 activator. Oct4 activator is an agent that can activate a reporter gene driven by an Oct4 promoter (e.g., a luciferase gene under the transcriptional control of an Oct4 promoter), and is more preferably capable of activating both a reporter gene driven by an Oct4 promoter and a reporter gene driven by a Nanog promoter. In addition, when added to a reprogramming mixture together with a quadruple reprogramming factor (Oct4, Sox2, c-Myc, and Klf4), an Oct4 activator enhances iPSC reprogramming efficiency and accelerates the reprogramming process. Exemplary Oct4 activators are taught, for example, in the following: U.S. Patent Application 20150191701 and Li et al. (2012) "Identification of Oct4-activating compounds that enhance reprogramming efficiency". PNAS 109 (51): 20853-8.

[0242] In certain embodiments, the Oct4 activator is represented by the formula:

[0243]

[0244] in,

[0245] X 1 is C(R 12 ) or N;

[0246] X 2 is C(R 4 ) or N;

[0247] X 3 is C(R 5 ) or N;

[0248] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12is independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R 2 and R 3 Optionally linked to form a substituted or unsubstituted heterocycloalkyl or a substituted or unsubstituted heteroaryl.

[0249] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 Independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heterocycloalkyl.

[0250] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 Independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.

[0251] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8, R 9 , R 10 , R 11 and R 12 independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, substituted or unsubstituted C1 to C 10 alkyl, substituted or unsubstituted 2- to 10-membered heteroalkyl, or substituted or unsubstituted 3- to 8-membered heterocycloalkyl.

[0252] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, substituted or unsubstituted C1 to C 10 alkyl, or a substituted or unsubstituted 2- to 10-membered heteroalkyl.

[0253] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 Independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, unsubstituted alkyl, unsubstituted heteroalkyl or substituted heterocycloalkyl.

[0254] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R9 , R 10 , R 11 and R 12 Independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, unsubstituted alkyl or unsubstituted heteroalkyl.

[0255] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, unsubstituted C1 to C 10 alkyl, unsubstituted 2- to 10-membered heteroalkyl, or substituted 3- to 8-membered heterocycloalkyl.

[0256] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 independently selected from hydrogen, halogen, -CN, -NO2, -NH2, -CF3, -CCl3, -OH, -SH, -SO3H, -C(O)OH, -C(O)NH2, unsubstituted C1 to C 10 alkyl or unsubstituted 2- to 10-membered heteroalkyl.

[0257] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11and R 12 are independently selected from hydrogen, halogen, unsubstituted C1 to C 10 alkyl or unsubstituted 2- to 10-membered heteroalkyl.

[0258] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 Independently selected from hydrogen, halogen, -N(CH3)2, unsubstituted C1 to C5 alkyl or unsubstituted C1 to C5 alkoxy.

[0259] In certain preferred embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 Independently selected from hydrogen, halogen, -N(CH3)2, unsubstituted C1 to C5 alkyl, methoxy, ethoxy or propoxy.

[0260] In certain embodiments, the Oct4 activator is selected from the group consisting of:

[0261]

[0262] In certain embodiments, the Oct4 activator is OAC1, which has the following structure:

[0263]

[0264] TrkA inhibitors. Representative examples of TrkA inhibitors include BMS-754807, GW441756, PF-06273340, sitrutinib (MGCD516), ANA-12, GNF-5837, Belizatinib (TSR-011), larotrectinib (LOXO-101) sulfate, lestaurtinib, entrectinib (RXDX-101), GNF 5837, and AG-879.

[0265] Preferably, the TrkA inhibitor is selective for TrkA relative to TrkB or TrkC, such as GW441756 and setrectinib (MGCD516).

[0266] Preferably, the TrkA inhibitor is a potent and selective inhibitor of TrkA with an IC50 of 10 nM or less, and an IC50 for inhibiting c-Raf1 and CDK2 that is at least 100-fold higher than the IC50 for inhibiting TrkA, such as GW441756.

[0267] Other representative Trk inhibitors may be those found in US Pat. No. 9,187,489 and International Publication No. WO2013 / 183578, both of which are incorporated herein by reference in their entirety. Exemplary Trk inhibitors include PLX7486 and DS-6051.

[0268] Non-limiting examples of Trk inhibitors can be found in U.S. Publication No. 2015 / 0306086 and International Publication No. WO2013 / 074518, both of which are incorporated herein by reference in their entireties. Exemplary Trk inhibitors include TSR-011.

[0269] Other examples of Trk inhibitors can be found in U.S. Patent No. 8,637,516, International Publication No. WO 2012 / 034091, U.S. Patent No. 9,102,671, International Publication No. WO 2012 / 116217, U.S. Publication No. 2010 / 0297115, International Publication No. WO 2009 / 053442, U.S. Patent No. 8,642,035, International Publication No. WO2009092049, U.S. Patent No. 8,691,221, International Publication No. WO2006131952, all of which are incorporated herein by reference in their entirety. Exemplary Trk inhibitors include GNF-4256, described in Cancer Chemother. Pharmacol. 75(1): 131-141, 2015; and GNF-5837 (N-[3-[[2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-6-yl]amino]-4-methylphenyl]-N′-[2-fluoro-5-(trifluoromethyl)phenyl]-urea), described in ACS Med. Chem. Lett. 3(2): 140-145, 2012, each of which is incorporated herein by reference in its entirety.

[0270] Additional examples of Trk inhibitors include those disclosed in U.S. Publication No. 2010 / 0152219, U.S. Patent No. 8,114,989, and International Publication No. WO 2006 / 123113, all of which are incorporated herein by reference in their entirety. Exemplary Trk inhibitors include AZ623, described in Cancer 117(6):1321-1391, 2011; AZD6918, described in Cancer Biol. Ther. 16(3):477-483, 2015; AZ64, described in Cancer Chemother. Pharmacol. 70:477-486, 2012; AZ-23 ((S)-5-chloro-N2-(1-(5-fluoropyridin-2-yl)ethyl)-N4-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine), described in Mol. Cancer Ther. 8:1818-1827, 2009; and AZD7451; each of which is incorporated by reference in its entirety.

[0271] Trk inhibitors may include those described in U.S. Patent Nos. 7,615,383; 7,384,632; 6,153,189; 6,027,927; 6,025,166; 5,910,574; 5,877,016; and 5,844,092, each of which is incorporated by reference in its entirety.

[0272] Other examples of Trk inhibitors include CEP-751, which is described in Int. J. Cancer 72:672-679, 1997; CT327, which is described in Acta Derm. Venereol. 95:542-548, 2015; compounds described in International Publication No. WO 2012 / 034095; compounds described in U.S. Patent No. 8,673,347 and International Publication No. WO 2007 / 022999; compounds described in U.S. Patent No. 8,338,417; compounds described in International Publication No. WO Compounds described in 2016 / 027754; compounds described in U.S. Patent No. 9,242,977; compounds described in U.S. Publication No. 2016 / 0000783; sunitinib (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide), described in PLoS One 9: e95628, 2014; compounds described in International Publication No. WO 2011 / 133637; compounds described in U.S. Patent No. 8,637,256; compounds described in Expert. Opin. Ther. Pat. 24(7): 731-744, 2014; Expert. Opin. Ther. Pat. 19(3): 305-319, 2009; (R)-2-phenylpyrrolidine-substituted imidazopyridazines, such as (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, as described in ACS Med. Chem. Lett. 6(5): 562-567, 2015; GTx-186 and others, such as PLoS One 8(12): e83380, described in 2013; K252a ((9S-(9α, 10β, 12α))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(methoxycarbonyl)-9-methyl-9,12-epoxy-1H-diindolo [1,2,3-fg: 3′,2′,1′-kl] pyrrolo [3,4-i] [1,6] benzodiazepine Octane-1-one), as described in Mol. Cell Biochem. 339(1-2): 201-213, 2010; 4-aminopyrazolylpyrimidines, such as AZ-23 (((S)-5-chloro-N2-(1-(5-fluoropyridin-2-yl)ethyl)-N4-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine)), as described in J. Med. Chem.51(15):4672-4684, 2008; PHA-739358 (danusertib), as described in Mol. Cancer Ther. 6:3158, 2007; Go 6976 (5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propionitrile), as described in J. Neurochem. 72:919-924, 1999; GW441756 ((3Z)-3-[(1-methylindol-3-yl)methylene]-1H-pyrrolo[3,2-b]pyridin-2-one), as described in IJAE 115:117, 2010; milciclib (PHA-848125AC), as described in J. Carcinog. 12:22, 2013; AG-879 ((2E)-3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-cyano-2-propenethioamide); altiratinib (N-(4-((2-(cyclopropanecarboxamido) 1,1-dicarboxamide); Cabozantinib (N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide); Lesatatinib ((5S,6S,8R)-6-hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5H-16-oxa- 4b,8a,14-triaza-5,8-methanedibenzo[b,h]cyclooctane[jkl]cyclopenta[e]asymmetric indacene 13(6H)-one); dovitinib (4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one mono-2-hydroxypropionic acid hydrate); setrutinib (N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl )pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide); ONO-5390556; Regorafenib (4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide hydrate); VSR-902A; All of the above references are incorporated herein by reference in their entirety. .

[0273] In some embodiments, the Trk inhibitor is selected from: (6R)-9-fluoro-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.1 7,11 .0 2,6 .020,24 ]pentacosane-1(23),7,9,17(24),18,21-hexene-16,25-dione; (6R)-12-oxa-2,16,20,21,24,26-hexaazapentacyclo[16.5.2.1 7,11 .0 2,6 .0 21,25 ] Hexacosane-1(24),7(26),8,10,18(25),19,22-heptane-17-one; (6R)-9-fluoro-13-oxa-2,11,17,21,22,25-hexaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R)-9-fluoro-15-hydroxy-13-oxa-2,11,17,21,22,25-hexaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R,13S)-9-fluoro-13-hydroxy-2,11,15,19,20,23-hexaazapentacyclo-[15.5.2.1 7,11 .0 2,6 .0 20,24 ]pentacosane-1(23),7,9,17(24),18,21-hexene-16,25-dione; (6R,15R)-9-fluoro-15-hydroxy-13-oxa-2,11,17,21,22,25-hexaazapentacyclo-[17.5.2.0 2,6 .0 7 ,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R,13R)-9-fluoro-13-hydroxy-2,11,15,19,20,23-hexaazapentacyclo-[15.5.2.1 7,11 .0 2,6 .0 20,24 ]pentacosane-1(23),7,9,17(24),18,21-hexene-16,25-dione; (6R)-9-fluoro-13-oxa-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.0 2 ,6 .0 7,12 .0 21,25]pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (6R)-9-fluoro-13-oxa-2,11,18,22,23,26-hexaazapentacyclo[18.5.2.0 2,6 .0 7,12 .0 23,27 ] heptacosane-1(26),7,9,11,20(27),21,24-heptane-19-one; (6R)-9-fluoro-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.1 7,11 .0 2, 6 .0 21,25 ]hexacosane-1(24),7,9,18(25),19,22-hexene-17,26-dione; (6R)-9-fluoro-2,11,13,16,20,21,24-heptaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (6R)-9-fluoro-2,11,13,17,21,22,25-heptaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R)-9-fluoro-13,16-dioxa-2,11,20,21,24-pentaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]-pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (6R)-9-fluoro-14-oxa-2,11,18,19,22-pentazapentacyclo[14.5.2.1 7,11 .0 2,6 .0 19,23 ]tetracosane-1(22),7,9,16(23),17,20-hexene-15,24-dione; (6R)-9-fluoro-13,16-dioxa-2,11,17,21,22,25-hexaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R,13R)-9,13-difluoro-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.17,11 .0 2,6 .0 20,24 ]pentacosane-1(23),7,9,17(24),18,21-hexene-16,25-dione; (6R)-9-fluoro-17-methyl-13-oxa-2,11,17,21,22,25-hexaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R)-9,15,15-trifluoro-13-oxa-2,11,17,21,22,25-hexaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R)-9-fluoro-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R)-9-fluoro-13-oxa-2,16,20,21,24-pentaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane; 1-[(6R)-9-fluoro-13-oxa-2,16,20,21,24-pentazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-16-yl]ethan-1-one; 1-[(6R)-9-fluoro-13-oxa-2,16,20,21,24-pentazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-16-yl]-2-hydroxyethane-1-one; (6R)-9-fluoro-13-oxa-2,17,21,22,25-pentazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26] hexacosane-1(25),7,9,11,19(26),20,23-heptane; (6R)-9-fluoro-16-methylsulfonyl-13-oxa-2,16,20,21,24-pentaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane; 2-[(6R)-9-fluoro-13-oxa-2,16,20,21,24-pentazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-16-yl]acetic acid; (6R)-9-fluoro-17-methylsulfonyl-13-oxa-2,17,21,22,25-pentazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] hexacosane-1(25),7,9,11,19(26),20,23-heptane; (6R)-N-ethyl-9-fluoro-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22 ,26 ] hexacosane-1(25),7,9,11,19(26),20,23-heptane-17-carboxamide; (6R)-N-ethyl-9-fluoro-13-oxa-2,16,20,21,24-pentaazapentacyclo-[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-16-carboxamide; (6S)-9-fluoro-4,13-dioxa-2,11,17,21,22,25-hexaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] Hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-3,18-dione; (6S)-9-fluoro-4,13-dioxa-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25]pentacosane-1(24),7(12),8,10,18(25),19,22-heptane-3,17-dione; (6R)-9-fluoro-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (6R)-9-fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (6R,13R)-9-fluoro-13-methyl-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.1 7,11 .0 2,6 .0 20,24 ]pentacosane-1(23),7,9,17(24),18,21-hexene-16,25-dione; (6R,13S)-9-fluoro-13-methyl-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.1 7,11 .0 2,6 .0 20,24 ]pentacosane-1(23),7,9,17(24),18,21-hexene-16,25-dione; (6R)-9-fluoro-15,15-dimethyl-13-oxa-2,11,17,21,22,25-hexaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ]hexacosane-1(25),7,9,11,19(26),20,23-heptane-18-one; (6R)-9-fluoro-15,15-dimethyl-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (6R)-9-fluoro-13-oxa-2,11,16,17,21,25,26,29-octaazahexacyclo[21.5.2.0 2,6 .0 7,12 .0 16,20 .0 26,30] triacontan-1(29),7,9,11,17,19,23(30),24,27-nonan-22-one; (6R)-9-fluoro-13-oxa-2,11,19,21,25,26,29-heptaazahexacyclo[21.5.2.0 2,6 .0 7,12 .0 15,20 .0 26,30 ] triacontan-1(29),7,9,11,15(20),16,18,23(30),24,27-decane-22-one; (6R)-9-fluoro-13,13-dimethyl-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.1 7,11 .0 2,6 .0 20,24 ]pentacosane-1(23),7,9,17(24),18,21-hexene-16,25-dione; (4R,6R,15S)-9-fluoro-4,15-dihydroxy-13-oxa-2,17,21,22,25-pentazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] Hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-18-one; (4R,6S,15S)-9-fluoro-4,15-dihydroxy-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] Hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-18-one; (4R,6R)-9-fluoro-4-hydroxy-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] Hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-18-one; (4R,6S)-9-fluoro-4-hydroxy-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.0 2,6 .0 7, 12 .0 22,26 ] Hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-18-one; (4R,6R)-9-fluoro-4-hydroxy-13-oxa-2,16,20,21,24-pentaazapentacyclo[16.5.2.0 2,6 .0 7,12 .021,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (4R,6S)-9-fluoro-4-hydroxy-13-oxa-2,16,20,21,24-pentazapentacyclo[16.5.2.0 2,6 .0 7,12 .0 21,25 ]pentacosane-1(24),7,9,11,18(25),19,22-heptane-17-one; (4R,6R,15R)-9-fluoro-4,15-dihydroxy-13-oxa-2,17,21,22,25-pentazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] Hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-18-one; (4R,6S,15R)-9-fluoro-4,15-dihydroxy-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-18-one; and (15S)-4,4,9-trifluoro-15-hydroxy-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.0 2,6 .0 7,12 .0 22,26 ] Hexacosane-1(25),7(12),8,10,19(26),20,23-heptane-18-one, or a pharmaceutically acceptable salt thereof.

[0274] In some embodiments, the Trk inhibitor is selected from: (R)-N-tert-butyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(3-methylpyridin-2-yl)pyrazolo[1,5-a]-pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Amide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((5-methylfuran-2-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-hydroxy-2-methylpropane-2-yl)pyrazolo[1,5-a] pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-methyl-1-morpholinopropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidine-4-carboxylic acid; (R)-2-(1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyl)piperidine -4-yl)acetic acid; (R)-N-cyclopropyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclobutyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((2S)-bicyclo[2.2.1]heptane-2-yl)-5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-(hydroxymethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)((S)-3-hydroxypyrrolidin-1-yl)methanone; (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)((R)-3-hydroxypyrrolidin-1-yl)methanone; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((1-methyl-1H-imidazol-4-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((1-methyl-1H-pyrazol-4-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((1-methyl-1H-pyrazol-4-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(1-methyl-1H-imidazol-5-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(1-methyl-1H-imidazol-5-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-(1H-imidazol-4-yl)ethyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((R)-2,3-dihydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N,N-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-(1H-imidazol-1-yl)ethyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-2,3-dihydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxyazetidin-1-yl)methanone;(R)-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxy-3-methylazetidin-1-yl)methanone; trans-4-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)cyclohexanecarboxylic acid; 5-((R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1 ,5-a]pyrimidine-3-carboxamide; (R)-N-tert-butyl-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclopropyl-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-cyanopropane-2-yl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(cyanomethyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2 pyrimidine-3-carboxamide; (R)-5-((2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2, (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-(methylsulfonyl)piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1-sulfamoylpiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(methylsulfonamido)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-sulfamoylethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-N-cyclopropyl-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)-N-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(4-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (diastereomer 1); 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(4-hydroxy-4-methylcyclohexyl)pyrazolo[1 ,5-a]pyrimidine-3-carboxamide (diastereomer 2); (R)-N-cyclopropyl-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-tert-butyl-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)-N-(2-morpholinoethyl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((S)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide [1,5-a]pyrimidine-3-carboxamide; N-((R)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-methyl-1-(methylsulfonamido)propan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-amino-2-methylpropyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-tert-butyl-5-(4,4-difluoro-2-( (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1,3-dihydroxy-2-methylpropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((3S,4R)-3-fluoropiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((S)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;N-((R)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-(trifluoromethyl)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclopropyl-5-(5-(2, (R)-N-(2-cyanopropan-2-yl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-(methylsulfonyl)piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(1-fluoro-2-methylpropan-2-yl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide -(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; ((R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide; a]pyrimidine-3-carboxamide; (R)-N-cyclopropyl-5-(2-(3-fluoro-5-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(3-fluoro-5-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclopropyl-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-tert-butyl-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(1-fluoro-2-methylpropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-1-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide)-cyclopropanecarboxylic acid; R)-N-cyclopropyl-5-(2-(3-fluoro-5-(2-morpholinoethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-(2-morpholinoethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclopropyl-5-(2-(5-fluoro-2-(2-morpholinoethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-2,3-dihydroxypropoxy)pyrazolo[1-,5-a]pyrimidine-3-carboxamide Amine; (R)-5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclopropyl-5-(2-(5-fluoro-2-(2-methoxyethoxy)phenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(3-hydroxy-3-methylazetidine-1 -yl)methanone; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)(pyrrolidin-1-yl)methanone; (R)-N-(5-fluoropyridin-2-yl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)(3-methoxyazetidin-1-yl)methanone;N-(3-chloro-2-fluoropropyl)-5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-(trifluoromethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((cis)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Carboxamide; (R)-N-cyclobutyl-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-methylcyclobutyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((1S,2S)-2-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((1S,2R)-2-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide ; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((1S,3S)-3-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(cyclopropylmethyl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-(hydroxymethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)(3-hydroxyazetidin-1-yl ) ketone; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((S)-2-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((R)-2-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxyethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;N-(1-cyclopropylethyl)-5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((R)-1-hydroxypropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((S)-1-hydroxypropane-2-yl)pyrazolo[1,5-a]pyrimidine pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-methoxypropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxy-3-methoxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((trans)-2-hydroxycyclopentyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((S)-1-hydroxy-3-methylbutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((R)-1-hydroxy-3-methylbutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((R)-1-cyclopropylethyl)-5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((S)-1-cyclopropylethyl)-5-( (R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(3-hydroxy-2,2-dimethyl-propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-azetidin-1-yl(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)methanone; (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-yl)(3-(hydroxymethyl)azetidin-1-yl)methanone;(5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)((S)-3-hydroxypyrrolidin-1-yl)methanone; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((R)-1,1,1-trifluoropropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((S)-1,1,1-trifluoropropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((S)-1,1,1-trifluoropropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide -(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-hydroxy-2-methylpropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((1R,2R)-2-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2,2-difluoroethyl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5 -((1R,2S)-2-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((1R,2R)-2-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(piperidin-1-yl)methanone; 5-((R)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((2R,3S,4S)-3-(hydroxymethyl)bicyclo[2.2 1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)(3-hydroxyazetidin-1-yl)methanone; 5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-tert-butyl 3-(5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)propylcarbamate;(R)-N-(3-aminopropyl)-5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((S)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((S)-3-chloro-2-hydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((R)-3-chloro-2-hydroxypropyl)-5-((R) -2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-chloroethoxy)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)(3-hydroxy-3-methylazetidin-1-yl)methanone; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(3-hydroxypropyl)pyrazolo[1,5 -a]pyrimidine-3-carboxamide; N-(2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((R)-2,3-dihydroxypropyl)-5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(4-hydroxybutyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-tert-butoxyethoxy)-5-(2-( (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-((1S,3S)-3-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxyethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-((S)-2-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-((R)-2-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(1,3-dihydroxypropane-2-yl)-5-(2-(5-fluoro-2-methoxypyridin- (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(6-oxo-1,6-dihydropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(1-(methylsulfonyl)piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-chloroethyl)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-chloroethyl)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; -(2-bromoethoxy)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-hydroxyethyl)pyrazolo[1,5a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((1S,3S)-3-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(4-hydroxypiperidin-1-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(2-methoxyethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(1,3-dihydroxypropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((2S,3R)-1,3-dihydroxybutane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((2S,3S)-1,3-dihydroxybutane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((2R,3S)-1,3-dihydroxybutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-1-hydroxypropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-1-hydroxybutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-1-hydroxybutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; -(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-1-hydroxy-3-methylbutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-cyclopropyl-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-cyclopropyl-5-(2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo-[1,5-a]pyrimidine- 3-carboxamide; (R)-N-tert-butyl-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclobutyl-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxyethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-((R)-2-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-(1-methylcyclopropyl)pyrazolo[1,5 -a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-(2-methoxyethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)(3-hydroxyazetidin-1-yl)methanone; (R)-5-(2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-(1-(hydroxymethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-2-methylpyridin-3 -yl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-((cis)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-((1S,3S)-3-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-((1R,2R)-2 -hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl)-N-((R)-quinuclidine-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-((1S,3S)-3-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-5-(2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-tert-butyl-5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-chloroethyl)-5-(2-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-cyclopropyl-5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)- pyrimidine-3-carboxamide; 5-((2R)-2-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-cyclopropyl-5-((2R)-2-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R)-2-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide -a]pyrimidine-3-carboxamide; N-cyclopropyl-5-((2R)-2-(3-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R)-2-(3-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-cyclopropyl-5-((2R)-2-(2-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R)-2-(2-(2,3-dihydroxypropoxy)-5-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide a]pyrimidine-3-carboxamide; 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N-((R)-1,1,1-trifluoropropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N-((S)-1,1,1-trifluoropropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;5-((2R,5S)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl)-N-isopropyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N-((S)-1,1,1-trifluoropropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2R,4S)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl)-N- Methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((2S,5R)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-N-((S)-1,1,1-trifluoropropane-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-(5-(2-(2-amino-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(azetidine alkyl-1-yl)methanone; (R)-tert-butyl 3-(5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)propylcarbamate; (R)-N-(3-aminopropyl)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(2-tert-butoxyethoxy)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(2 -hydroxyethoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-tert-butyl-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-isopropylpyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclopropyl-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-(6-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-cyclobutyl-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(cyclopropylmethyl)pyrazolo[1,5-a]pyrimidine pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 5-((R)-2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-((1R,2R)-2-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide N-((R)-1-cyclopropylethyl)-5-((R)-2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((S)-1-cyclopropylethyl)-5-((R)-2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Formamide; 5-((R)-2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-((trans)-4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)pyrrolidin-1-yl)-N-(5-fluoropyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(3-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; (R)- N-(3-ethyl-1H-pyrazol-5-yl)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; and (R)-5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl)-N-(1-isopropyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof. ;

[0275] In some embodiments, the Trk inhibitor is selected from: 5-fluoro-2-[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyridine-3-cyano; ((2E)-3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-cyano-2-propenethioamide); 2,2-dichloro-N-[3-[(7-chloroquinolin-4-yl)amino]propyl]-N-methylacetamide; N-[3-[[2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-6-yl]amino]-4-methylphenyl]-N′-[2-fluoro-5-(trifluoromethyl)- )phenyl]-urea; (S)-5-chloro-N2-(1-(5-fluoropyridin-2-yl)ethyl)-N4-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-(S)-N-(1-(5-fluoropyrimidin-2-yl)ethyl)-3-(5-isopropoxy-1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-amine, 4-diamine; 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propionitrile; 1,3-dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one; or a pharmaceutically acceptable salt thereof.

[0276] In some embodiments, the Trk inhibitor is selected from: (2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}-amino)-2-(4-fluorophenyl)ethanol; 5-bromo-N 4 -(3-cyclopropyl-1H-pyrazol-5-yl)-N 2-[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine; (2R)-2-({5-chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}-amino)-2-(4-fluorophenyl)ethanol; (2R)-2-({5-chloro-4-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol; (3S)-3-({5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin- 2-[(5-chloro-2-{[(1S)-1-(4-fluorophenyl)ethyl]amino}-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]-pyrimidin-4-yl}amino)propane e-1,3-diol; 2-[(5-chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-{[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl)amino}propane-1,3-diol; 5-chloro-N-methylpropaneamide 4 -(5-cyclopropyl-1H-pyrazol-3-yl)-N 2 -[(1S)-(4-Fluoro-phenyl)-ethyl]-6-(4-methyl-piperazine-1-yl)-pyrimidine-2,4-diamine; (2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl}amino)-2-(4-fluorophenyl)ethanol; and 2-[(5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-{[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidin-4-yl)amino]propane-1,3-diol; or a pharmaceutically acceptable salt thereof.

[0277] In some embodiments, the Trk inhibitor is selected from: 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea hydrochloride; trans-1-(4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; trans-1-(4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(1,3-dimethyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-tert-butyl-1-(pyridin-3-yl)-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-tert-butyl-1-(4-fluorophenyl)-1H-pyrazol-5-yl)-3-(trans- 1-(2-methoxy-ethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(1,3-diphenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-tert-butyl-1-(2-fluorophenyl)-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea;1-(3-tert-butyl-1-(3-fluorophenyl)-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(pyridin-3-yl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-methyl-1H-pyrazol-5-yl)urea; 1- (trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)thiourea; 1-(2-(3-fluorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(2-(4-fluorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-cyclopentyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4- 1-(1-ethyl-3-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(1,3-dimethyl-4-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)- 1-(3-tert-butyl-1-o-tolyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-tert-butyl-1-m-tolyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-methyl-4-phenyl-1H-pyrazol-5-yl)urea; 1-(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea;1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(1-methyl-1H-pyrazol-4-yl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(3-tert-butyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(pyridin-2-yl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(6,6-dimethyl-2-phenyl -2,4,5,6-tetrahydrochloropenta[c]pyrazol-3-yl)-3-(trans-1-(2-methoxyethyl)-4-phenyl-pyrrolidin-3-yl)urea; 1-(7,7-dimethyl-2-phenyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-3-(trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-(pyridin-4-yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; trans-1-(4-(3-fluorophenyl)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea 1-(4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea; trans-1-(4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea; trans-1-(4-(3-chlorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea Urea; trans-1-(4-(2-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea; trans-1-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)-3-(1-(2-methoxyethyl)-4-(thien-2-yl)pyrrolidin-3-yl)urea; 1-((3,4-trans)-4-(2,4-dimethylthiazol-5-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(trans-1-(2-methoxyethyl)-4-(; oxazol-5-yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(trans-4-(iso1-((3,4-trans)-1-(2-methoxyethyl)-4-(3-methoxyphenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(1-(2-methoxyethyl)-4-(thiazol-2-yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2 -phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(1,3-diphenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)urea; 1-(1,4-dimethyl-3-phenyl-1H-pyrazol-5-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(pyridin-3-yl) )-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1,1′-dimethyl-1H,1′H-3,4′-bipyrazol-5-yl)urea; 1-(3-(3-cyanophenyl)-1-methyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-(4-cyanophenyl)-1-methyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(imidazo[1,2-a]pyridin-5-yl)-1-methyl-1H-pyrazol-5-yl)urea; 1-(4-chloro-1,3-diphenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-1,3-diphenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-methyl-1-phenyl-1H- 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1,3-dimethyl-4-phenyl-1H-pyrazol-5-yl)urea; 1-(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1-methyl-3-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-(4-Bromo-1-methyl-3-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-cyano-3-(cyanomethyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-(2-cyanopropan-2-yl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea -3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-methyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(oxetan-3-ylmethoxy)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-((3-methyloxetan-3-yl)methoxy)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea -yl)-3-(3-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; tert-butyl 3-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea)-2-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(2H)-carboxylate; 1-(3-isopropyl-4-methyl-1-phenyl-1H-pyrazol-5-yl) )-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-furo[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3,4- dimethyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-furo[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-furo[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-4,6-dihydro-2H-furo[3,4-c]pyrazol-3-yl)urea 1-(3-(1-hydroxy-2-methylpropane-2-yl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(5-epoxy-2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea -methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(thien-2-yl)-1H-pyrazol-5-yl)urea;1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3-(methoxymethyl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3-(methoxymethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-p-tolyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidine -3-yl)-3-(1-methyl-3-m-tolyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-o-tolyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(3-methoxyphenyl)-1-methyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxyphenyl)-1-methyl-1H- 1-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)urea; 1-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3-(4-methoxyphenyl)-1-methyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)-3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl) 1-((3S,4R)-4-(2,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(3-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea;

[0278] 1-(3-(1-hydroxy-2-methylpropane-2-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1-hydroxy-2-methylpropane-2-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; methyl 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-methyl-1H-pyrazol-5-yl)benzoate; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-methyl-1H-pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(methoxymethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(4-(methylthio)phenyl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(methoxymethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(3-methoxypropyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(4-(2-methoxyethoxy)phenyl)-1-methyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methoxy-3-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(hydroxymethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxyethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxyethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)- 3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxyethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; trans-1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-1-(2-methoxyethyl)-4 -phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-(cyanomethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluoro-phenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(4-methoxybenzyloxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-fluoroethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxy-2-methylpropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxy-2-methylpropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea )-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl) -3-(3-(2-hydroxyethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(2-cyclohexyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(pyridin-4-yl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(5-methyl 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1,4-dimethyl-3-(5-methylpyrazin-2-yl)-1H-pyrazol-5-yl)urea; ethyl 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-phenyl-1H-pyrazole-4-carboxylate; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(pyrazin-2-yl)-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-1-methyl-4-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethoxy-1-methyl-4-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)urea dihydrochloride; 1-(5-acetyl-2-phenyl-2,4,5,6 -tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-(hydroxymethyl)-3-(methoxymethyl)-1-phenyl-1H-pyrazol-5-yl)urea; 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-methyl-1H-pyrazol-3-yl)benzoic acid; 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-methyl-1H-pyrazol-3-yl)benzamide; 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-1-methyl-1H-pyrazol-3-yl)-N-methylbenzamide; 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-1-methyl-1H-pyrazol-3-yl)-N,N-dimethylbenzamide; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(4-(hydroxy 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-(4-(methylsulfonyl)phenyl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro-3-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro-1-methyl-3-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro-1,3-diphenyl-1H-pyrazol-5-yl)urea; 2-methoxyethyl 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-methyl-1H-pyrazol-3-yl)benzoate; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5,5-diepoxy-2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)urea; 1-(5, 5-Diepoxy-2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5,5-diepoxy-2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-(methylsulfonyl)ethoxy)-1-phenyl-1H-pyrazol-5-yl )urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-(hydroxymethyl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((R)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((S)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea -yl) urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxyethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl) urea hydrochloride; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl) urea hydrochloride; 1-((3R,4S)-4-hydroxy-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl) urea;1-((3R,4S)-4-fluoro-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(trans-4-phenyl-1-(2-(trifluoromethoxy)ethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(trans-1-(2-(methylthio)ethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-1-((S)-2-methoxypropyl)-4-phenylpyrrolidin-3 -yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3,4-trans)-4-phenyl-1-(4,4,4-trifluorobutyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-1-(cyanomethyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-1-(cyanomethyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(3-(2-methoxyethoxy)-4-methyl 1-((3,4-trans)-1-(cyanomethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-1-(cyanomethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 2-((3R,4S)-3-phenyl-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea)pyrrolidin-1-yl)acetamide; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-( urea; 1-((trans)-1-(3,3,4,4,4-pentafluorobutyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((trans)-1-ethyl-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((trans)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea;1-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)-3-((trans)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-(3-(2-methoxyethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((trans)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-((trans)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl 2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)-3 -((3S,4R)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-(3-(2-methoxyethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3- 1-((3S,4R)-4-(3-fluorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(3-(2-methoxyethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea; 1-((3R,4S)-4-(3-fluorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4 ,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,3S)-4-(3-fluorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-((trans)-1-(1,3-difluoropropane-2-yl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; (trans)-tert-butyl 3-(3-methoxyphenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea)pyrrolidine-1-carboxylate;1-((trans)-4-(3-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-((trans)-4-(pyridin-2-yl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-((trans)-4-(4-fluorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((trans)-4-(4-chlorophenyl)-1-(2,2,2 -trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((trans)-4-(2-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-((trans)-4-(pyridin-3-yl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-((trans)-4-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea urea; 1-((trans)-4-(4-fluorophenyl)-1-(2,2-difluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(1H-pyrazol-3-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(3-methyl-1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(3-(trifluoromethyl)-1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-((R)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3,4-dimethyl-1-phenyl-1 H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-(3-methoxypropyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-(2-methoxyethoxy)-4-methyl-1-phenyl -1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1H-pyrazol-4-yl)pyrrolidin-3-yl)-3-(3-(2-hydroxy-2-methylpropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(1-methyl-1H-pyrazol-5-yl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-1-(1-methyl-1H-pyrazol-5-yl)-4-phenyl 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(1-methyl-1H-pyrazol-5-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3R,4S)-4-(3,5-difluorophenyl)-1-(1-methyl-1H-pyrazol-5-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-phenylpyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyphenyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-fluorophenyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(4-fluorophenyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)- 1-(2-methylphenyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyphenyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-chlorophenyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-chlorophenyl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-phenyl-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-1-(2,6- 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxypyridin-4-yl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxypyridin-3-yl)-4-phenylpyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxypyridin-3-yl)-4-phenylpyrrolidin-3-yl)urea )-4-phenylpyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-1-(2-methoxypyridin-3-yl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-1-(2-methoxypyridin-3-yl)-4-phenylpyrrolidin-3-yl)-3-(4-methyl-1,3-diphenyl-1H-pyrazol-5-yl)urea; 1-(4-bromo-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-1-(2-methoxypyridin-3-yl)-4-phenylpyrrolidin-3-yl)urea;1-(4-bromo-1,3-diphenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxypyridin-3-yl)-4-phenylpyrrolidin-3-yl)urea; 1-((3S,4R)-1-((1,2,3-thiadiazol-4-yl)methyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-1-((1,2,3-thiadiazol-4-yl)methyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4 R)-1-((1,2,3-thiadiazol-4-yl)methyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(3-(cyanomethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-1-((1,2,3-thiadiazol-4-yl)methyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,11′H-3,4′-bipyrazol-5-yl)urea; 1-((3S,4R)-1-((1,2,3-thiadiazol-4-yl)methyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-1H -imidazol-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1,3-dimethoxypropane-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1-methoxypropane-2-yl)pyrrolidin-3-yl )-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((trans)-4-(4-fluorophenyl)-1-(2-(methylamino)ethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((trans)-1-((1H-imidazol-2-yl)methyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; methyl 3-methoxy-2-((trans)-3-phenyl-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea)pyrrolidin-1-yl)propanoate;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1-methoxypropane-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1-hydroxy-3-methoxypropane-2-yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(3-hydroxy-1-methoxy-3-methylbutane-2-yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea 2-((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea)pyrrolidin-1-yl)-3-methoxypropanoic acid hydrochloride; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(1-hydroxy-3-methoxypropane-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1 -(1-hydroxy-3-methoxypropane-2-yl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-1-phenyl-4-(trifluoromethyl)-1H-pyrazol-5-yl)urea; 1-(3-(2-fluoroethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea 1-(3-(cyanomethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea;1-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-(3-((R)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; (R,S) 1-((2.α.,3.β.,4.α.)-2-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; (R,S)-1-((3(3,4.α.,5.α.)-5-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-((S)-1,1,1-trifluoro-3-hydroxypropane-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-((S)-1,1,1-trifluoro-3-hydroxypropane-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; -4-(3,4-difluorophenyl)-1-((S)-1,1,1-trifluoro-3-methoxypropane-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-((S)-1,1,1-trifluoro-3-methoxypropane-2-yl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)-3-((3S,4R) -4-(3,4-difluorophenyl)-1-((R)-1,1,1-trifluoro-3-methoxypropane-2-yl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-((R)-1,1,1-trifluoro-3-methoxypropane-2-yl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methyl-4-(methylthio)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(3-methoxypropyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-(1,1-difluoro-2-hydroxyethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-(1,1-difluoro-2-hydroxyethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-(3-(1,1-difluoro-2-hydroxyethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-(1,1-difluoro-2-hydroxyethyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxyethyl)-4-methyl-1-phenyl-1 H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxyethyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxy-2-methylpropyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxypropyl)-4-methyl-1-phenyl- 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; ethyl 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl-1-phenyl-1H-pyrazole-3-carboxylate; 5-(3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide;1-(trans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(trans-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(trans-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl) 1-(trans-4-(3-chlorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazol]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(5-methyl-1,3,4-; oxadiazole-2-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(3-methyl-1,2,4- oxadiazole-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(3-(trifluoromethyl)-1,2,4- oxadiazole-5-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(3-(trifluoromethyl)-1,2,4- oxadiazole-5-yl)-1H-pyrazol-5-yl)urea; 5-(3-(trans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide; 5-(3-(trans-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide; 1-(trans-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1- 1-(trans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4,5′-trimethyl-1-phenyl-1H,1′H-[3,3′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (1′,4,5′-trimethyl-1-phenyl-1H,1′H-[3,3′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4,5′-trimethyl-1-phenyl-1H,1′H-[3,3′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2′,4,5′-trimethyl-1-phenyl-1H,2′H-[3,3′-bipyrazole]-5-yl)urea; 1-(4-cyclopropyl-1′-methyl-1-phenyl-1H,1 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-isopropyl-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazol-1-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-ethyl-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(4-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(3-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(2-fluorophenyl)-1′,4-dimethyl-1 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(3-chlorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(1-(3-chloro-4-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(1-(3-chloro-2-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole] 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(4-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(3-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(3-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea -1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(2-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(3-chlorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(1-(3-chloro-4-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-(1-(3-chloro-2-fluorophenyl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(2,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3-cyanophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H ,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(4-cyanophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(p-tolyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1 ,3-diphenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1,3-diphenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4,5-trifluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1,3-diphenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1,3-diphenyl-1H-pyrazol-5-yl)urea; bromo-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazol]-5-yl)-3-(trans-1-(2-methoxyethyl)-4-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazol]-5-yl)-3-((trans-1-(2-methoxyethyl)-4-(1,2,3-thiadiazol-4-yl)pyrrolidin-3-yl)urea;1-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-1-(2-methoxyethyl)-4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)urea; 1-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-((3R,4S)-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea 1-(3-(2-fluoroethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-(2-fluoroethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(trans-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3 -(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 1-(trans-4-(5-chloropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(trans-4-(5-chloropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(trans-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1,3-diphenyl-1H-pyrazol-5-yl)urea; 1-(1′,4-dimethyl -1-phenyl-1H,1′H-[3,4′-bipyrazol-1-5-yl)-3-(trans-4-(5-fluoropyridin-2-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazol]-5-yl)-3-((3S,4R)-4-(3-fluoropyridin-4-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-1H-1,2,4-triazol-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-(2-methoxyethyl)-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(3-cyano-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; -((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-(2-hydroxyethyl)-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methyl-2H-1,2,3-triazol-4-yl)-1 -phenyl-1H-pyrazol-5-yl)urea; 1-(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5-methyl-6-oxo-2-phenyl-2,4,5,6-tetrahydropyrrolo[3,4- c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5-methyl-6-oxo-2-phenyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-((5-methyl-1,3,4-; 1-(4-chloro-3-ethoxy-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-fluoro-1-phenyl-1H-pyrazol-5-yl)urea; 1-(4-bromo-3-(2-hydroxy-2-methylpropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4 1-(4-chloro-3-(2-hydroxy-2-methylpropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxybutyloxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; ethyl 2-((5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxy-2-methylpropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxy-2-methylpropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-hydroxy-2-methylpropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((R)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((R)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-((R)-3,3,3-trifluoro-2-hydroxypropoxy)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl- 3-((S)-3,3,3-trifluoro-2-hydroxypropoxy)-1H-pyrazol-5-yl)urea; 1-(4-chloro-3-(2-hydroxy-2-methylpropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(2-hydroxy-2-methylpropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-((R)-2-hydroxypropoxy)-1-phenyl-1 H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-((R)-2-hydroxypropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-((R)-2-hydroxypropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-((R) 1-(4-bromo-3-((R)-2-hydroxypropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-((R)-2-hydroxypropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-((R)-2-hydroxypropoxy)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((R)-2-hydroxybutoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((R)-2-hydroxybutoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((R)-2-hydroxybutoxy)-4-methyl-1-phenyl-1 H-pyrazol-5-yl)urea; ethyl 4-bromo-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-1-phenyl-1H-pyrazole-3-carboxylate; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-(2-methoxyethyl)-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazol-1-5-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-(2-methoxyethyl)-4-methyl-1- Phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methyl-2H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methyl-2H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methyl-2H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; tert-butyl 4-(2-((5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)ethyl)piperazine-1-carboxylate;trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2H-indazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2H-indazol-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-( 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(pyrazin-2-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-(pyridazin-4-yl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl-1-phenyl-1H-pyrazol-3-yl dimethylcarbamate; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl 1-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea; 1-(3-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea;1-(3-((S)-2-(tert-butyldimethylsilyloxy)propoxy)-4-methyl-1-phenyl-1-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea; 1-(3-(2-hydroxy-2-methylpropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea; 1-(3-((S)-2-(tert-butyldimethylsilyloxy)-3-methoxypropoxy)-4-methyl-1-phenyl-1H- 1-(4-chloro-3-(methoxy-methyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-(methoxy-methyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(methoxy-methyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-(4-bromo-3-(methoxy-methyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(methoxy-methyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-(methoxy-methyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; )-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(1,1-difluoro-2-hydroxyethyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(1,1-difluoro-2-hydroxyethyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-(4-chloro-3-(1,1-difluoro-2-hydroxyethyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-((S)-2-hydroxypropyl)-1-phenyl-1H-pyrazol-5-yl)-3((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-((R)-2-hydroxypropyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3 1-(4-bromo-3-((R)-2-hydroxypropyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(2-hydroxy-2-methylpropyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(2-hydroxy-2-methylpropyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(3-methyl-1,2,4-; 1-(4-Bromo-3-(2-cyanopropan-2-yl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-Chloro-3-(2-cyanopropan-2-yl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-Bromo-3-(2-cyanopropan-2-yl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; -1'-methyl-1-phenyl-1H,1'H-[3,4'-bipyrazole]-5-yl)-3-((3S,4R)-4(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-1'-methyl-1-phenyl-1H,1'H-[3,4'-bipyrazole]-5-yl)-3-((3S,4R)-4(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-1'-methyl-1-phenyl-1H,1'H-[3,4'-bipyrazole]-5-yl)-3-((3S,4R)-4(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1 -(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-phenyl-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1,3-diphenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-1,3-diphenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-(4-bromo-1,3-diphenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1′-methyl-1-phenyl-1H,1′H-[3,4′-difluorophenyl] 1-(4-Fluoro-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-trans-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-trans-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-(4-bromo-1,3-diphenyl-1H-pyrazol-5-yl)-3-(trans-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1,3-diphenyl-1H-pyrazol-5-yl)-3-(trans-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-(trans-4-(5-fluoropyridin-2-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4 -(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(4-bromo-1′-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(5-fluoropyridin-3-yl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4,5-trifluorophenyl)-1 -(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′- (4-methoxybenzyl)-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazol]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-(4-methoxybenzyl)-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazol]-5-yl)urea trifluoroacetate; 2-(4-chloro-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-phenyl-1H-pyrazol-3-yl)acetate; 1-(4-chloro-3-(2- 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(cis-3-hydroxycyclobutyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(trans-3-hydroxycyclobutyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-(4-chloro-3-(cis-3-hydroxycyclobutyl)-1-phenyl-1H-pyrazol-5-yl)3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-((1r,3S)-3-hydroxycyclobutyl)-1-phenyl-1H-pyrazol-5-yl)-3-(trans-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)3-(3-(cis-3-hydroxycyclobutyl)-4-methyl-1-phenyl-1H- 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(trans-3-hydroxycyclobutyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(cis-3-hydroxycyclobutyl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(trans-3-hydroxycyclobutyl)- 4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N,N,4-trimethyl-1-phenyl-1H-pyrazole-3-carboxamide Pyrazole-3-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N-ethyl-4-methyl-1-phenyl-1H-pyrazole-3-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N-isopropyl-4-methyl-1-phenyl-1H-pyrazole-3-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-1-phenyl-1H-pyrazole-3-carboxamide;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-(hydroxymethyl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)urea; 1-((3S,4R)-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)urea 1-((3S,4R)-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)urea; 2-((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea)pyrrolidin-1-yl)acetate; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-hydroxypropyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-1-(2-cyanoethyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 2-((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea)pyrrolidin-1-yl)-N-methylacetamide; 1-(1-cyclohexane 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(3-hydroxy-2-(hydroxymethyl)propoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl)urea; 1-(3-(2,2-difluoroethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl) 1-(4-chloro-1-phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1-phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-(4-chloro-1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-1-phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea )urea; 1-(4-chloro-3-phenyl-1-(pyridin-3-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(5-fluoropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(5-fluoropyridin-3-yl)-4-methyl-1-(pyridin-3-yl)-1H-pyrazol- 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,3′-bipyrazole]-5-yl)urea; 1-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,3′-bipyrazole]-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-[3,3′-bipyrazole]-5-yl)urea -bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2′,4-dimethyl-1-phenyl-1H,2′H-[3,3′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(5-fluoropyridin-3-yl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl -1-(5-methylpyridin-3-yl)-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(1-(5-chloropyridin-3-yl)-1′,4-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-1′-(2,2,2-trifluoro-1-(2,2,2-trifluoroethoxy)ethyl)-1H,1′H-[3,4′-bipyrazole]-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-1′-(2,2,2-trifluoroethyl)-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(1′-(cyclopropylmethyl)-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(1′-(cyclopropanecarbonyl)-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1′-(methylsulfonyl)-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-isopropyl-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1′-(methylsulfonyl)-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea -3-yl)-3-(4-methyl-1-phenyl-3-(pyrimidin-5-yl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,3′,4-trimethyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(1′-cyclopropyl-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylthiazol-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-(2-aminopyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1 -(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2,4-dimethylthiazol-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2,6-dimethylpyridin-4-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-(6-aminopyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)- 3-((3S,4R)4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea;1-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea; 1-(3-(2-aminopyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3((3R,4S)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea bis(2,2,2-trifluoroacetate); 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′-ethyl- 4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)urea; 1-(1′-ethyl-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethanesulfonate; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl) -3-(3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-(dimethylamino)pyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-(2-(dimethylamino)pyrimidin-5-yl)-4 1-(1′-ethyl-4-methyl-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-cyclopropyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-cyclopropyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea -yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(2-(piperazin-1-yl)ethoxy)-1H-pyrazol-5-yl)urea trihydrochloride; 1-(3-(benzyloxy)-4-chloro-1-methyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea trihydrochloride; 2-((5-(3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea -4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)acetic acid; 2-((5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)-N-ethylacetamide; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-ethyl-3-(2-hydroxy-2-methylpropoxy)-1-phenyl-1H-pyrazol-5-yl)urea;1-(3-(2-aminoethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; N-(2-((5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)ethyl)methanesulfonamide; N-(2-((5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)ethyl 1-(3-(2-(4-acetylpiperazin-1-yl)ethoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 2-((5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)acetamide; N-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-3-ethoxy-1-phenyl-1H-pyrazol-4-yl) 1-(4-amino-3-ethoxy-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-(2-hydroxyethyl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-(4-methylpiperazin-1-yl)ethoxy)-1-phenyl- 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-morpholino-2-oxoethoxy)-1-phenyl-1H-pyrazol-5-yl)urea; 4-bromo-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-phenyl-1H-pyrazole-3-carboxylic acid; 4-bromo-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-N-methyl-1-phenyl-1H-pyrazole-3-carboxamide;4-bromo-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N-methoxy-1-phenyl-1H-pyrazole-3-carboxamide; 1-(4-chloro-1′-(2-methoxyethyl)-1-phenyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((S)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl -1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((R)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-((R)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea; 1-(3-((S)-2,3-dihydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1 -(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea; 1-(3-((S)-2-hydroxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxy-3-methoxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-((S)-2-hydroxy-3-methoxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-((S)-2-hydroxy-3-methoxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea; 1-(3-((R)-2-hydroxy-3-methoxypropoxy)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea;1-(4-bromo-1,1′-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1,1′-dimethyl-1H,1′H-[3,4′-bipyrazole]-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4 -(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; tert-butyl 4-(4-chloro-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-phenyl-1H-pyrazol-3-yl)piperidin-1-carboxylate; 1-(4-chloro-1-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-3-(3,5-dimethylisothiazolyl; 2-(4-chloro-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; (R)-tert-butyl 2-(4-chloro-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea )-1-phenyl-1H-pyrazol-3-yl)pyrrolidine e-1-carboxylate / ester; (S)-tert-butyl 2-(4-chloro-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-1-phenyl-1H-pyrazol-3-yl)pyrrolidine e-1-carboxylate / ester; 1-(4-bromo-1-phenyl tert-butyl 4-(4-bromo-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea 1-(4-bromo-1-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-bromo-3-(3,5-dimethylisothiazolyl)piperidin-1-carboxylate; tert-Butyl 2-(4-bromo-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-phenyl-1H-pyrazol-3-yl)pyrrolidine e-1-carboxylate / ester; tert-Butyl 4-((4-bromo-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-1-phenyl-1H-pyrazol-3-yl)methoxy)piperidine-1-carboxylate / ester ester; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-phenyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)urea dihydrochloride; 1-(4-chloro-1-phenyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea dihydrochloride; 1-(4-bromo-1-phenyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea dihydrochloride 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-((R)-pyrrolidin-2-yl)-1H-pyrazol-5-yl)urea dihydrochloride; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-((S)-pyrrolidin-2-yl)-1H-pyrazol-5-yl)urea dihydrochloride; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-((S)-pyrrolidin-2-yl)-1H-pyrazol-5-yl)urea dihydrochloride; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-((S)-pyrrolidin-2-yl)-1H-pyrazol-5-yl)urea dihydrochloride; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-chloro-1-phenyl-3-((S)-pyrrolidin-2-yl)-1H-pyrazol-5-yl)urea dihydrochloride;1-(4-bromo-1-phenyl-3-((R)-pyrrolidin-2-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea dihydrochloride; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-phenyl-3-((piperidin-4-yloxy)methyl)-1H-pyrazol-5-yl)urea dihydrochloride; 1-(4-chloro-1-phenyl-3-((piperidin-4-yloxy)methyl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl) 1-(4-bromo-1-phenyl-3-((piperidin-4-yloxy)methyl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea dihydrochloride; 1-(4-bromo-3-(1-(methylsulfonyl)piperidin-4-yl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea dihydrochloride; 1-(3-(1-acetylpiperidin-4-yl)-4-bromo-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4-chloro-1-phenyl-3-(1-(trifluoromethylsulfonyl)piperidin-4-yl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea hydrochloride; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-((R)-1-(methylsulfonyl)pyrrolidin-2-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-(3-((R)-1-acetylpyrrolidin-2-yl)-4-methyl-1 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-((R)-1-methylpyrrolidin-2-yl)-1-phenyl-1H-pyrazol-5-yl)urea dihydrochloride; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-((S)-1-methylpyrrolidin-2-yl)-1-phenyl-1H-pyrazol-5-yl)urea dihydrochloride;1-(4-bromo-3-((1-(methylsulfonyl)piperidin-4-yloxy)methyl)-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(3-((1-acetylpiperidin-4-yloxy)methyl)-4-bromo-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(4-isopropyl-5-oxo-4,5-dihydro-1,3,4-; oxadiazole-2-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4- 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-1-phenyl-3-(pyrazin-2-yloxy)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (3-methoxy-1-phenyl-4-(trifluoromethyl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-1-phenyl-4-(trifluoromethyl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-1-phenyl-4-(trifluoromethyl)-1H-pyrazol-5-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-1-phenyl-4-(trifluoromethyl)-1H-pyrazol-5-yl)urea 1-((trans)-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)urea; 1-((trans)-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)urea 1-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)-3-(4-methyl-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)urea; 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)urea; 1-((trans)-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)urea;1-(4-cyano-3-methoxy-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-((3S,4R)-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)urea; 1-(4-cyano-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 1-(4 -cyano-5-oxo-2-phenyl-2,5-dihydro-1H-pyrazol-3-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-3-methoxy-1-phenyl-1H-pyrazole-4-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-3-methyl-1-phenyl-1H-pyrazole-4-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea)-3-methyl-1-phenyl-1H-pyrazole-4-carboxamide; -3-((3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3-ethyl-1-phenyl-1H-pyrazole-4-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide; 5-(3-((trans)-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3-methyl-1-phenyl-1H-pyrazole-4-carboxamide; 5-(3-((trans)-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3-methyl-1-phenyl-1H-pyrazole-4-carboxamide -3-methyl-1-phenyl-1H-pyrazole-4-carboxamide; 5-(3-((trans)-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3-methyl-1-phenyl-1H-pyrazole-4-carboxamide; 5-(3-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3-methyl-1-phenyl-1H-pyrazole-4-carboxamide; 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-1-phenyl-1H-pyrazole-4-carboxamide;5-(3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-1-phenyl-1H-pyrazole-4-carboxamide; 1-(4-bromo-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)guanidine dihydrochloride; 1-(4-bromo-3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)thiourea; 1-((3S,4R)-4-(3,4 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)thiourea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1′,4-dimethyl-1-phenyl-1H,1′H-3,4′-bipyrazol-5-yl)thiourea; oxazol-5-yl)thiourea; trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenylpyrazolo[1,5-a1pyridin-3-yl)urea; trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(pyrazolo[1,5-a]pyridin-3-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(pyrazolo[1,5-a]pyridin-3-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5-methyl-3-phenyl-1-(pyrazin-2-yl)-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5-methyl-3-phenyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-ethyl-5-methyl-3-phenyl-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5-methyl-3-phenyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)urea 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methyl-1-phenyl-1H-pyrazol-4-yl)urea; 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)urea; or a pharmaceutically acceptable salt thereof. ;

[0279] In some embodiments, the Trk inhibitor is selected from: 5-chloro-N 4 -(5-cyclopropyl-1H-pyrazol-3-yl)-N 2 -(1-phenylethyl)pyrimidine-2,4-diamine; 5-bromo-N 4 -(3-ethyl-1H-pyrazol-5-yl)-N 2 -(1-phenylethyl)pyrimidine-2,4-diamine; N 4 -(3-tert-butyl-1H-pyrazol-5-yl)-5-chloro-N 2 -(1-phenylethyl)pyrimidine-2,4-diamine; N 4 -(3-cyclopropyl-1H-pyrazol-5-yl)-N 2-(1-phenylethyl)-5-(trifluoromethyl)pyrimidine-2,4-diamine; 5-bromo-N 4 -(3-cyclopropyl-1H-pyrazol-5-yl)-N 2 -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine; 5-bromo-N 4 -(3-cyclopropyl-1H-pyrazol-5-yl)-N 2 -[(1S)-1-phenylpropyl]pyrimidine-2,4-diamine; 5-bromo-N 4 -(3-cyclopropyl-1H-pyrazol-5-yl)-N 2 -[(1S)-1-(4-nitrophenyl)ethyl]pyrimidine-2,4-diamine; (2R)-2-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2yl}amino)-2-phenylethanol; 5-bromo-N 4 -(5-cyclopropyl-1H-pyrazol-3-yl)-N 2 -(1-phenylethyl)pyrimidine-2,4-diamine; 5-chloro-N 4 -(5-cyclopropyl-1H-pyrazol-3-yl)-N 2 -(1-phenylpropyl)pyrimidine-2,4-diamine.

[0280] Syk inhibitors. Particularly in those embodiments without a feeder layer, the culture medium may also contain a SYK (spleen tyrosine kinase) inhibitor. Representative SYK inhibitors may be selected from: entosterinib (GS-9973), fostamatinib (R788), R406, seletinib (PRT062070) and TAK-659.

[0281] In some embodiments, the Syk inhibitor is entolinib, which has the following structure:

[0282]

[0283] The chemical name of entolinib is 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine. Entolinib or a pharmaceutically acceptable salt, solvate or polymorph thereof can be prepared according to the procedures described in U.S. Patent Nos. 8,748,607 and 8,450,321, and U.S. Patent Application Publication No. 2015 / 0038505.

[0284] In some embodiments, the Syk inhibitor is a compound of the formula: or an ester, stereoisomer, or tautomer thereof:

[0285]

[0286] Where R1 is:

[0287]

[0288] in represents the point of attachment to the rest of the compound of the formula,

[0289] R2 is H or 2-hydroxyethoxy, R3 is H or methyl, and R4 is H or methyl.

[0290] In one embodiment, each of R2, R3 and R4 is H, and R1 is as defined above. In one embodiment, R2 is H, R3 is methyl, and R4 is H, and R1 is as defined above. In one embodiment, R2 is H, R3 is H, and R4 is methyl, and R1 is as defined above. In one embodiment, R2 is 2-hydroxyethoxy, R3 is methyl, and R4 is H, and R1 is as defined above. In one embodiment, R2 is 2-hydroxyethoxy, R3 is methyl, and R4 is H, and R1 is as defined above. In one embodiment, R2 is 2-hydroxyethoxy, R3 is methyl, and R4 is H, and R1 is as defined above.

[0291] In one embodiment, the SYK inhibitor is selected from:

[0292]

[0293]

[0294]

[0295] Suitable Syk inhibitors are described in US Pat. No. 9,290,050.

[0296] As used in the present invention, Syk inhibitors include those compounds disclosed in U.S. Patent Nos. 9,290,050 and 6,432,963 and U.S. Patent Application Publication No. US2004 / 0029902 A1, each of which is incorporated herein by reference in its entirety. Exemplary Syk inhibitors from these references include, but are not limited to:

[0297] 2-(2-aminoethylamino)-4-(3-methylanilino)pyrimidine-5-carboxamide,

[0298] 2-(2-aminoethylamino)-4-(3-trifluoromethylanilino)pyrimidine-5-carboxamide,

[0299] 2-(4-aminobutylamino)-4-(3-trifluoromethylanilino)pyrimidine-5-carboxamide,

[0300] 2-(2-aminoethylamino)-4-(3-bromoanilino)pyrimidine-5-carboxamide,

[0301] 2-(2-aminoethylamino)-4-(3-nitroanilino)pyrimidine-5-carboxamide,

[0302] 2-(2-aminoethylamino)-4-(3,5-dimethylanilino)pyrimidine-5-carboxamide,

[0303] 2-(2-aminoethylamino)-4-(2-naphthylamino)pyrimidine-5-carboxamide,

[0304] 2-(cis-2-aminocyclohexylamino)-4-(3-methylanilino)pyrimidine-5-carboxamide,

[0305] 2-(cis-2-aminocyclohexylamino)-4-(3-bromo-anilino)pyrimidine-5-carboxamide,

[0306] 2-(cis-2-aminocyclohexylamino)-4-(3,5-dichloroanilino)pyrimidine-5-carboxamide and 2-(cis-2-aminocyclohexylamino)-4-(3,4,5-trimethoxyanilino)pyrimidine-5-carboxamide,

[0307] N2,N4-[(2,2-dimethyl-4H-benzo[1,4] Oxazine-3-one)-6-yl]-5-fluoro-2,4-pyrimidinediamine,

[0308] N4-(3,4-dichlorophenyl)-5-fluoro-N2-(indazolin-6-yl)-2,4-pyrimidinediamine,

[0309] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-(1-methyl-indazolin-5-yl)-2,4-pyrimidinediamine,

[0310] N2,N4-bis(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine,

[0311] N2,N4-bis(3,4-ethylenedioxyphenyl)-5-fluoro-2,4-pyrimidinediamine,

[0312] N4-(1,4-benzo Oxazine-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0313] N2,N4-bis(3-aminophenyl)-5-fluoro-2,4-pyrimidinediamine,

[0314] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[3-(N-methylamino)-carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0315] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0316] N4-(3-hydroxyphenyl)-5-trifluoromethyl-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0317] 5-Fluoro-N4-[(1H)-indol-6-yl]-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0318] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0319] 5-Fluoro-N2-(3-methylaminocarbonylmethyleneoxyphenyl)-N4-[2-H-pyrido[3,2-b]-1,4- Oxazine-3(4H)-on-6-yl]-2,4-pyrimidinediamine,

[0320] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[3-(2-hydroxyethylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0321] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidine-diamine,

[0322] N2, N4-bis(indol-6-yl)-5-fluoro-2,4-pyrimidinediamine,

[0323] 5-Fluoro-N2-[2-(2-hydroxy-1,1-dimethylethylamino)carbonylbenzofuran-5-yl]-N4-(3-hydroxyphenyl)-2,4-pyrimidinediamine,

[0324] N2-[3-(N2,3-dihydroxypropylamino)carbonylmethyleneoxyphenyl]-N4-(3,4-ethylenedioxyphenyl)-5-fluoro-2,4-pyrimidinediamine,

[0325] N2-(3,5-dimethoxyphenyl)-N4-(3,4-ethylenedioxyphenyl)-5-fluoro-2,4-pyrimidinediamine,

[0326] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[3-(1,3- [(2-(((((((((((((((((- ...

[0327] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[3-(N-methylamino)-carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0328] 5-Fluoro-N2-(3-hydroxyphenyl)-N4-[4-(3-phenyl-1,2- oxadiazole-5-yl)methyleneoxyphenyl]-2,4-pyrimidinediamine,

[0329] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-(indazolin-6-yl)-2,4-pyrimidinediamine,

[0330] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-(indazolin-6-yl)-2,4-pyrimidinediamine,

[0331] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-(1-methyl-indazolin-5-yl)-2,4-pyrimidinediamine,

[0332] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-(1-methyl-indazolin-5-yl)-2,4-pyrimidinediamine,

[0333] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[4-(3-phenyl-1,2,4- oxadiazole-5-yl)methyleneoxyphenyl]-2,4-pyrimidinediamine,

[0334] N4-(3,5-dimethyl-4-hydroxyphenyl)-5-fluoro-N2-[3-[2-(N-morpholino)ethyleneoxy]phenyl]-2,4-pyrimidinediamine,

[0335] N4-(3,5-dimethyl-4-hydroxyphenyl)-5-fluoro-N2-[3-[2-(N-morpholino)ethyloxy]phenyl]-2,4-pyrimidine-diamine,

[0336] N4-(3-chloro-4-hydroxy-5-methylphenyl)-5-fluoro-N2-[3-[2-(N-morpholino)ethyloxy]phenyl]-2,4-pyrimidinediamine,

[0337] N2-(3-tert-butylcarbonylaminophenyl)-N4-(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine,

[0338] N4-(3-tert-butylphenyl)-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-5-fluoro-2,4-pyrimidine-diamine,

[0339] N4-(3-tert-butylphenyl)-N2-[3-(N2,3-dihydroxypropylamino)carbonylmethyleneoxyphenyl]-5-fluoro-2,4-pyrimidinediamine,

[0340] N2-[3-(N2,3-dihydroxypropylamino)carbonylmethyleneoxyphenyl]-5-fluoro-N4-(3-isopropylphenyl)-2,4-pyrimidinediamine,

[0341] N4-[4-(cyanomethyleneoxy)phenyl]-5-fluoro-N2-(3-hydroxyphenyl)-2,4-pyrimidinediamine,

[0342] N4-(3,5-dimethyl-4-hydroxyphenyl)-5-fluoro-N2-[3-(N-piperazinyl)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0343] N4-(3,5-dimethyl-4-hydroxyphenyl)-5-fluoro-N2-[3-[2-(N-piperazinyl)ethoxy]phenyl]-2,4-pyrimidine-diamine dihydrochloride,

[0344] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[4-(2-hydroxyethyloxy)phenyl]-2,4-pyrimidinediamine,

[0345] N4-(1,4-benzo Oxazine-3-one-6-yl)-5-fluoro-N2-(3-hydroxyphenyl)-2,4-pyrimidinediamine, (+ / -)-5-fluoro-N2-[(N-methylacetamido-2)-3-phenoxy]-N4-(2-methyl-1,4-benzo Oxazine-6-yl)-2,4-pyrimidinediamine,

[0346] N2-(1,4-benzo Oxazine-3-one-6-yl)-5-fluoro-N4-(3-hydroxyphenyl)-2,4-pyrimidinediamine,

[0347] N4-(3-chloro-4-trifluoromethoxyphenyl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0348] 5-Fluoro-N4-(3-hydroxy-4-methylphenyl)-N2-[3-[(N-methylamino)carbonylmethyleneoxy]phenyl]-2,4-pyrimidinediamine,

[0349] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-methyl-3-[(N-methylamino)carbonylmethyleneoxy]phenyl]-2,4-pyrimidinediamine,

[0350] 5-Fluoro-N4-(3-hydroxy-4-methoxyphenyl)-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0351] N4-(3-chloro-4-methylphenyl)-5-fluoro-N2-[3-(N-methylamino)-carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0352] N4-(3-chloro-4-methoxyphenyl)-5-fluoro-N2-[3-[(N-methylamino)carbonylmethyleneoxy]phenyl]-2,4-pyrimidinediamine,

[0353] 5-Fluoro-N4-1(1H)-indol-5-yl]-N2-[3-[(N-methylamino)carbonylmethyleneoxy]phenyl]-2,4-pyrimidine-diamine,

[0354] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[1-(methoxycarbonyl)methyl-indazolin-5-yl]-2,4-pyrimidinediamine,

[0355] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[1-(3-hydroxypropyl)indazolin-6-yl]-2,4-pyrimidinediamine,

[0356] N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[1-(3-hydroxypropyl)indazolin-5-yl]-2,4-pyrimidinediamine,

[0357] 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[1-(3-hydroxypropyl)indazolin-5-yl]-2,4-pyrimidinediamine,

[0358] 5-fluoro-N2-[1-(3-hydroxypropyl)indazolin-5-yl]-N4-(4-isopropoxyphenyl)-2,4-pyrimidinediamine, N4-(3,4-ethylenedioxyphenyl)-5-fluoro-N2-[1-[2(N-methylaminocarbonyl)ethyl]-indazolin-5-yl]-2,4-pyrimidinediamine,

[0359] 5-Fluoro-N4-(4-isopropoxyphenyl)-N2-[1-[2(N-methylaminocarbonyl)ethyl]-indazolin-5-yl]-2,4-pyrimidinediamine,

[0360] N4-[(2,2-dimethyl-4H-benzo[1,4] Oxazine-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethylene-oxy)phenyl]-2,4-pyrimidinediamine,

[0361] N4-[(2,2-dimethyl-4H-benzo[1,4] Oxazine-3-one)-6-yl]-5-fluoro-N2-(1-methylindazoline-5-yl)-2,4-pyrimidinediamine,

[0362] N4-[(2,2-difluoro-4H-benzo[1,4] Oxazine-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine,

[0363] N4-1(2,2-dimethyl-4H-5-pyridinol-1,4] Oxazine-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine,

[0364] 5-Fluoro-N2-(3-methylaminocarbonylmethyleneoxyphenyl)-N4-[2H-pyrido[3,2-b]-1,4- Oxazine-3(4H)-on-6-yl]-2,4-pyrimidinediamine,

[0365] N4-(4-amino-3,4-dihydro-2H-1-benzopyran-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0366] N4-(3-chloro-4-hydroxy-5-methylphenyl)-5-fluoro-N2-[3-[2-(N-piperazinyl)ethoxy]phenyl]-2,4-pyrimidinediamine, and

[0367] N4-(3-methylcarbonyloximephenyl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine,

[0368] or a salt thereof.

[0369] LPA receptor antagonists. Particularly in those embodiments without a feeder layer, the culture medium may also contain an LPA receptor antagonist, such as an antagonist that inhibits the production of phosphoinositides induced by LPA1 and LPA3 (each with a Ki of 1000 μM or less), and significantly less inhibits LPA2, LPA4, LPA5, and LPA6 (i.e., each with a Ki of 5000 μM or less). Ki16198 is a preferred LPA receptor antagonist and is the methyl ester of Ki16425.

[0370] Other LPA receptor antagonists include H2L5765834, H2L5186303, Ki 16425, Ro 6842262, and CLPA5 4.

[0371] In one aspect, provided herein is an LPA receptor inhibitor having a structure shown in US20170042915A1 or a salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer or isomer thereof, such as one of the following structures:

[0372]

[0373]

[0374] GSK3 inhibitors. Particularly in those embodiments without a feeder layer, the culture medium may also include a GSK3 inhibitor. Exemplary GSK3 inhibitors include CHIR-99021 (CT99021) HCl, SB216763, CHIR-98014, TWS119, Tideglusib, SB415286, CHIR-99021 (CT99021), AZD2858, AZD1080, AR-A014418, TDZD-8, LY2090314, BIO-acetone oxime, IM-12, 1-Azakenpaullone, indirubin, and 6-BIO.

[0375] Suitable GSK-3 inhibitors, methods for their synthesis and assays for GSK inhibition are also described, for example, in WO 03 / 004472, WO 03 / 055492, WO 03 / 082853, WO 2004 / 018455, WO 2004 / 037791, 06 / 001754, WO07 / 040436, WO 07 / 040438, WO 07 / 040439, WO 07 / 040440, WO08 / 002244, WO08 / 002245 and Coghlan et al. Chemistry & Biology 2000, 7(10):793-803. For example, GSK-3 inhibitors are also reviewed in, for example, Cohen et al. Nature Reviews Drug Discovery 2004, 3: 479-487; Kramer et al. International Journal of Alzheimer's Disease Volume 2012, Article ID 381029, 32 pages; and Eldar-Finkelman et al., Front Mol Neurosci. 2011; 4: 32. In one embodiment, the GSK-3 inhibitor is lithium, such as a lithium salt, such as lithium carbonate, lithium citrate, lithium chloride, lithium orotate, lithium bromide or lithium chloride. In another embodiment, the GSK-3 inhibitor is 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) or 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione (SB-415286), whose structure is shown below:

[0376]

[0377] (Designated in the literature as SB216763 and SB-415286).

[0378] Other GSK3 inhibitors include 6-BIO, hymenialdisine, dibromocantharelline, CT98014, CT98023, CT99021, TWS119, AR-A014418, AZD-1080, kenpaullone, alsterpaullone, cazpaulllone, aloisine A, manzamine A, palinurine, tricantine, TDZD-8, NP00111, P031115, P031112 (tideglusib), HMK-32 and L803-mts, whose chemical structures and syntheses are described or mentioned in Eldar-Finkelman et al., Front Mol Neurosci. 2011; 4:32.

[0379] CK2 Inhibitors. Particularly in those feeder-free embodiments, the culture medium may also include a CK2 inhibitor, such as CX-4945 (Silmitasertib), CX-8184, DMAT, ellagic acid, or TTP22.

[0380] Other exemplary CK2 inhibitors are the CK2 inhibitors taught in PCT Publication WO 2017 / 070137 A1, such as the following compounds:

[0381]

[0382] including enantiomers, diastereomers, tautomers, acceptable salts, prodrugs, hydrates or solvates thereof, wherein

[0383] R4 is selected from: 1 to 3 R e Substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, and 1 to 3 R e substituted heterocyclic group;

[0384] The two R7 groups and the nitrogen atom to which they are both attached together form a 4- to 7-membered monocyclic or 7- to 12-membered bicyclic heterocyclic ring containing carbon atoms and selected from NR 8a , O and S(O)2 and substituted with 1 to 4 Rs;

[0385] R8 is independently selected at each occurrence from H, F, Cl, Br, e Substituted C 1-4 Alkyl, =O(ketone), 1 to 5 R e Substituted C 2-4Alkenyl,

[0386] -(CHR g ) r OR b ,-CHR g ) r S(0) p R c ,-(CHR g ) r C(=O)(CHR g ) r R d ,-(CHR g ) r NR a R a ,-(CHR g ) r C(=O)NR a R a ,-(CHR g ) r C(=O)NR a S(O) p R c ,-(CHR g ) r NR a (CR g R g ) r C(=O)R d ,-(CHR g ) r NR a C(=O)OR b ,-(CHR g ) r OC(=O)(CHR g ) r R d ,-(CHR g ) r OC(=O)(CHR g ) r C(=O)OR d ,-(CHR g ) r OC(=O)(CHR g ) r C(=O)NR a R a ,-(CHR g ) r OC(=O)(CHR g ) r NR a C(=O)R b,-(CHR g ) r OC(=O)(CHR g ) r NR a R a ,-(CHR g ) r NR a C(=O)NR a R a ,-(CHR g ) r C(=O)(CH2) r OR b ,-(CHR g ) r C(=O)(CHR g ) r OC(=O)R b ,-(CHR g ) r S(0)2NR a R a ,-(CHR g ) r NR a S(0) p NR a R a ,-(CHR g ) r NR a S(0) p R c ,-OPO3H,

[0387] 1 to 5 R e Substituted-(CHR g ) r -C 3-6 Cycloalkyl, with 1 to 4 R e Substituted-(CHR g ) r -aryl and 1 to 4 R e Substituted-(CHR g ) r -heterocyclic group;

[0388] R 8a Selected from H, 1 to 5 R e Substituted C 1-4 Alkyl, with 1 to 5 R e Substituted C 2-4 Alkenyl,

[0389] -(CHR g ) r OR b,-(CHR g ) r S(0) p R c ,-(CHR g ) r C(=O)(CHR g ) r Rd,-CHR g ) r NRaRa,(CHR g ) r C(=O)NRaRa,-(CHR g ) r C(=O)NR a S(O) p R c ,-(CHR g ) r NR a (CR g R g ) r C(=O)Rd,-(CHR g ) r NHC(=O)OR b ,-(CHR g ) r OC(=O)(CHR g ) r R d ,-(CHR g ) r OC(=O)(CHR g ) r C(=O)OR d ,-(CHR g ) r OC(=O)(CHR g ) r C(=O)NR a R a ,-(CHR g ) r OC(=O)(CHR g ) r NR a C(=O)R b ,-(CHR g ) r OC(=O)(CHR g ) r NR a R a ,-(CHR g ) r NR a (CHR g )r C(=O)NR a R a ,-(CHR g ) r C(=O)OR b ,-(CHR g ) r C(=O)(CHR g ) r OC(=O)R b ,-(CHR g ) r S(O)2NR a R a ,-(CHR g ) r NR a S(O) p NR a R a ,-(CHR g R a S(O) p R c ,-OPO3H,

[0390] 1 to 5 R e Substituted-(CHR g ) r -C 3-6 Cycloalkyl, with 1 to 4 R e Substituted-(CHR g ) r -aryl and 1 to 4 R e Substituted-(CHR g ) r -heterocyclic group;

[0391] R a independently selected at each occurrence from H, CN, e Substituted C 1-6 Alkyl, with 1 to 5 R e Substituted C 2-6 alkenyl, 1 to 5 R e Substituted C 2-6 Alkynyl, with 1 to 5 R e Substituted -(CH2) r -C3-iocarbocyclyl, and 1 to 5 R e Substituted -(CH2) r -heterocyclic group; or R a and R a Together with the nitrogen atom to which they are both attached, they form a e substituted heterocycle;

[0392] R b independently selected at each occurrence from H, 1 to 5 R e Substituted C 1-6 Alkyl, with 1 to 5 R e Substituted C 2-6 alkenyl, with 1 to 5 R e Substituted C 2-6 Alkynyl, with 1 to 5 R e Substituted -(CH2) r -C3-heterocarbocyclyl, and 1 to 5 R e Substituted -(CH2) r -heterocyclic group;

[0393] R c independently selected at each occurrence from 1 to 5 R e Substituted C1-6 alkyl, 1 to 5 R e Substituted C 2-6 alkenyl, 1 to 5 R e Substituted C 2-6 Alkynyl, C 3-6 Carbocyclic and heterocyclic groups;

[0394] R d independently selected at each occurrence from H, OH, e Substituted C 1-6 Alkyl, with 1 to 5 R e Substituted C 2-6 alkenyl, 1 to 5 R e Substituted C 2-6 Alkynyl, with 1 to 5 R e Substitute -(CH2) r -C3-heterocarbocyclyl, and 1 to 5 R e Substituted -(CH2) r -heterocyclic group;

[0395] R e independently selected at each occurrence from H, N3, 1 to 5 R f Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, (CH2) r -Heterocyclic group, F, Cl, Br, -(CH2) r CN, NO2, =O, -OPO3H, -OSi(C 1-4 Alkyl)3, (CH2) r OC1-5 Alkyl, -(CH2) r O(CH2) r OC 1-5 Alkyl, -(CH2) r OH, -(CH2) r S(O)2C 1-5 Alkyl, -(CH2) r S(O)2R f 、-(CH2) r NHS(O)2C 1-5 Alkyl, -S(O)2NH2, -SH, -(CH2) r NR f R f 、-(CH2) r NHC(=O)OR f 、-(CH2) r NHC(=O)R f 、-(CH2) r NHC(=NH)NR f R f 、-(CH2) r C(=O)(CH2) r R f , and -(CH2) r C(=O)OR f ;

[0396] R f is independently selected at each occurrence from H, -CH2OH, -(CH2) r OC 1-5 Alkyl, C 1-5 Alkyl (optionally substituted with F, Cl, OH, NH2), C optionally substituted with NH2 3-6 Cycloalkyl, -(CH2) r S(O)PC 1-4 Alkyl, -NHC(=O)C 1-4 Alkyl, -C(=O)NH2, -C(=O)OC 1-4 Alkyl, -C(=O)C 1-4 Alkyl, -(CH2) r -phenyl, optionally substituted with alkyl and CN -(CH2) r -heterocyclic group, or R f and R f Together with the nitrogen atom to which they are both attached, they form an optionally C 1-4 Alkyl substituted heterocycle;

[0397] R g is independently selected at each occurrence from H, F, OH and C1-5 alkyl;

[0398] p is independently selected at each occurrence from 0, 1, and 2; and

[0399] r is independently selected from 0, 1, 2, 3, 4 and 5 at each occurrence.

[0400] Notch agonist. The culture medium of the present invention may additionally comprise a Notch agonist. Notch signaling has been shown to play an important role in cell fate determination as well as cell survival and proliferation. Notch receptor proteins can interact with many surface-bound or secreted ligands, including but not limited to Jagged-1, Jagged-2, Δ-1 or Δ-like 1, Δ-like 3, Δ-like 4, etc. After ligand binding, the Notch receptor is activated by a series of cleavage events involving members of the ADAM protease family and by intramembrane cleavage regulated by the gamma secretase presinilin. The result is that the intracellular domain of Notch translocates to the nucleus, where it transcriptionally activates downstream genes.

[0401] As used herein, "Notch agonists" include molecules that stimulate Notch activity in cells by at least about 10%, at least about 20%, at least about 30%, at least about 50%, at least about 70%, at least about 90%, at least about 100%, at least about 3 times, 5 times, 10 times, 20 times, 50 times, 100 times, 200 times, 500 times, 1000 times or more relative to the level of Notch activity in the absence of the Notch agonist. As known in the art, Notch activity can be determined by, for example, measuring the transcriptional activity of Notch, by the 4xwtCBF1-luciferase reporter construct described by Hsieh et al. (Mol. Cell. Biol. 16: 952-959, 1996, incorporated herein by reference).

[0402] In certain embodiments, the Notch agonist is selected from: Jagged-1, Δ-1 and Δ-like 4, or an active fragment or derivative thereof. In certain embodiments, the Notch agonist is a DSL peptide (Dontu et al., Breast Cancer Res., 6: R605-R615, 2004) having an amino acid sequence CDDYYYGFGCNKFCRPR (SEQ ID NO: 36). The DSL peptide (ANA spec) can be used at a concentration of 10.mu.M to 100nM, or at least 10μM and not higher than 100nM. In certain embodiments, the final concentration of Jagged-1 is about 0.1 to 10μM; or about 0.2 to 5μM; or about 0.5 to 2μM; or about 1μM.

[0403] In certain embodiments, any specific Notch agonist mentioned herein, e.g., Jagged-1, Jagged-2, Δ-1, and Δ-like 4, may be replaced by a natural, synthetic, or recombinantly produced homolog or fragment thereof that retains at least about 80%, 85%, 90%, 95%, 99% of the activity of the corresponding Notch agonist, and / or a homolog or fragment thereof that shares at least about 60%, 70%, 80%, 90%, 95%, 97%, 99% amino acid sequence identity, as measured by any art-recognized sequence alignment software based on a global alignment technique (e.g., the Nedleman-Wunsch algorithm) or a local alignment technique (e.g., the Smith-Waterman algorithm).

[0404] The sequences of representative Notch agonists mentioned herein are shown in SEQ ID NOs. 28 to 35.

[0405] During the first 1 to 2 weeks of culturing stem cells, the Notch agonist may be added to the culture medium every 1, 2, 3, or 4 days.

[0406] Nicotinamide. The culture medium of the present invention may be additionally supplemented with nicotinamide or an analog, precursor or mimetic thereof, such as methylnicotinamide, benazamid, pyrazinamide, thymidine or nicotinic acid. Nicotinamide may be added to the culture medium to a final concentration of 1 to 100 mM, 5 to 50 mM, or preferably 5 to 20 mM. For example, nicotinamide may be added to the culture medium to a final concentration of about 10 mM. Similar concentrations of nicotinamide analogs, precursors or mimetics may also be used alone or in combination.

[0407] Extracellular matrix (ECM). Extracellular matrix (ECM) is used interchangeably with "basement membrane matrix" herein, and is secreted by connective tissue cells and comprises a variety of polysaccharides, water, elastin and proteins, which may comprise proteoglycans, collagen, entactin (nidogen), fibronectin, fibrinogen, fibrillin, laminin and hyaluronic acid. ECM can provide suitable matrix and microenvironment conduction (conductive) for selecting and culturing subject stem cells.

[0408] In certain embodiments, the subject stem cell is attached to or contacts with ECM. Different types of ECM are known in the art, and may include different compositions, including different types of proteoglycans and / or different proteoglycan combinations. ECM may be provided by culturing cells (e.g., some fibroblasts) that produce ECM. Examples of cells producing extracellular matrix include chondrocytes that mainly produce collagen and proteoglycans; fibroblasts that mainly produce type IV collagen, laminin, interstitial procollagen, and fibronectin; and colon myofibroblasts that mainly produce collagen (I, III, and V types), chondroitin sulfate proteoglycans, hyaluronic acid, fibronectin, and tenascin-C.

[0409] In certain embodiments, at least some of the ECM is produced by the murine 3T3-J2 clone, which can be grown in MATRIGEL TM The top of basement membrane matrix (BD Biosciences) served as a feeder cell layer.

[0410] Alternatively, the ECM may be provided commercially. Examples of commercially available extracellular matrices are extracellular matrix proteins (Invitrogen) and MATRIGEL TM Basement membrane matrix (BD Biosciences). Using ECM to culture stem cells can enhance long-term survival of stem cells and / or the persistence of undifferentiated stem cells. Alternatives can be fibrin substrates or fibrin gels or scaffolds, such as glycerolated allografts depleted of primary cells.

[0411] In certain embodiments, the ECM used in the methods of the present invention comprises at least two different glycoproteins, such as two different types of collagen or collagen and laminin. The ECM can be a synthetic hydrogel extracellular matrix, or a naturally occurring ECM. In certain embodiments, the ECM is composed of MATRIGEL TM Basement membrane matrix (BD Biosciences) was provided and contains laminin, entactin, and collagen IV.

[0412] Culture medium. The cell culture medium used in the method of the present invention can include any cell culture medium, such as a culture medium buffered at about pH 7.4 (e.g., about pH 7.2 to 7.6) with a carbonate-based buffer. Many commercially available tissue culture media may be suitable for the method of the present invention, including but not limited to Dulbecco's modified Eagle medium (DMEM, such as DMEM without L-glutamine but containing high glucose), Minimal Essential Medium (MEM), Knockout-DMEM (KO-DMEM), Glasgow Minimal Essential Medium (G-MEM), Basal Medium Eagle (BME), DMEM / Ham's F12, Advanced DMEM / Ham's F12, Iscove Modified Dulbecco's Medium and Minimal Essential Media (MEM), Ham's F10, Ham's F-12, Medium 199 and RPMI 1640 culture medium.

[0413] The cells can be cultured in an atmosphere comprising 5% to 10% CO2 (e.g., at least about 5% but not more than 10% CO2, or about 5% CO2). In certain embodiments, the cell culture medium is DMEM / F12 (e.g., a 3:1 mixture) or RPMI 1640 supplemented with L-glutamine, insulin, penicillin / streptomycin and / or transferrin. In certain embodiments, Advanced DMEM / F12 or Advanced RPMI is used, which is optimized for serum-free culture and already contains insulin. Advanced DMEM / F12 or Advanced RPMI culture medium can be further supplemented with L-glutamine and penicillin / streptomycin. In certain embodiments, the cell culture medium is supplemented with one or more of the purified, natural, semi-synthetic and / or synthetic factors described herein. In certain embodiments, the cell culture medium is supplemented with about 10% fetal bovine serum (FBS) that is not heat-inactivated prior to use. Additional supplements may also be added to the culture medium, such as Serum-free supplement (Invitrogen), N-acetylcysteine ​​(Sigma) and / or N2 serum-free supplement (Invitrogen) or Neurobasal (Gibco), TeSR (StemGent).

[0414] In certain embodiments, the culture medium may contain one or more antibiotics to prevent contamination (e.g., penicillin / streptomycin). In certain embodiments, the culture medium may have an endotoxin content less than 0.1 endotoxin units / mL, or may have an endotoxin content less than 0.05 endotoxin units / mL. Methods for determining the endotoxin content of the culture medium are known in the art.

[0415] The cell culture medium according to the invention allows epithelial stem cells to survive and / or proliferate and / or differentiate on the extracellular matrix.The term "cell culture medium" as used herein is synonymous with "culture medium", "culture medium" or "cell culture medium".

[0416] The improved (growth) medium of the present invention comprises (a) a ROCK (Rho kinase) inhibitor in the basal medium; (b) a Wnt agonist; (c) a mitogenic growth factor; (d) a TGF-β signaling pathway inhibitor, such as a TGF-β inhibitor, or a TGF-β receptor inhibitor); and (e) insulin or IGF; and the medium optionally further comprises a bone morphogenetic protein (BMP) antagonist.

[0417] Therefore, in one aspect, the present invention provides a base medium comprising: insulin or insulin-like growth factor; T3 (3,3′,5-triiodo-L-thyronine); hydrocortisone; adenine; EGF; and 10% fetal bovine serum (not heat-inactivated), in DMEM:F12 3:1 medium supplemented with L-glutamine.

[0418] In certain embodiments, the basal medium comprises approximately: 5 μg / mL insulin; 2×10″9 M T3 (3,3′,5-triiodo-L-thyronine); 400 ng / mL hydrocortisone; 24.3 μg / mL adenine; 10 ng / mL EGF; and 10% fetal bovine serum (not heat-inactivated) in DMEM:F12 3:1 medium supplemented with 1.35 mM L-glutamine.

[0419] In certain embodiments, the concentration of each medium component mentioned in the preceding paragraph is independently 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95%, or 2, 3, 5, 10, 20 times higher than the corresponding listed value. For example, in an illustrative medium, the insulin concentration can be 6 μg / mL (20% higher than the listed 5 μg / mL), the EGF concentration can be 5 ng / mL (50% lower than the listed 10 ng / mL), and the remaining components each have the same concentrations listed above.

[0420] In a related aspect, the invention provides a basal medium containing cholera enterotoxin. In other embodiments, the basal medium does not contain cholera enterotoxin.

[0421] The basal medium may also contain one or more antibiotics, such as Pen / Strep and / or gentamicin.

[0422] By adding one or more of the above factors, the basal medium can be used to produce a modified growth medium (or simply modified medium).

[0423] 4. Protein sequences of representative culture media factors

[0424] Several representative (non-limiting) protein factors used in the culture medium and methods of the present invention are provided below. For each listed factor, many homologues or functional equivalents are known in the art and can be easily retrieved from public databases (e.g., GenBank, EMBL and / or NCBI RefSeq, to ​​name a few). Additional proteins or peptide fragments thereof, or polynucleotides encoding them, including functional homologues from humans or non-human mammals, can be easily retrieved from public sources by, for example, sequence-based retrieval (e.g., NCBI BLASTp or BLASTn or both).

[0425] BMP inhibitors

[0426] Noggin: (GenBank: AAA83259.1), Homo sapiens:

[0427]

[0428] Tenascin (GenBank: AAG35767.1), Homo sapiens:

[0429]

[0430] Follistatin (GenBank: AAH04107.1), Homo sapiens:

[0431]

[0432] DNA (GenBank: BAA92265.1), Homo sapiens:

[0433]

[0434] Cerberus (NCBI Reference Sequence: NP_005445.1), Homo sapiens

[0435]

[0436] Gremlin (GenBank: AAF06677.1), Homo sapiens

[0437]

[0438] Sclerostin / SOST (GenBank: AAK13451.1), Homo sapiens:

[0439]

[0440] Decorin (GenBank: AAB60901.1), Homo sapiens:

[0441]

[0442] α-2 macroglobulin (GenBank: EAW88590.1), Homo sapiens:

[0443]

[0444] Wnt agonists

[0445] R-spondin 1 (GenBank: ABC54570.1), Homo sapiens:

[0446]

[0447] R-spondin 2 (NCBI Reference Sequence: NP_848660.3), Homo sapiens:

[0448]

[0449] R-spondin 3 (NCBI Reference Sequence: NP_116173.2), Homo sapiens:

[0450]

[0451] R-spondin 4 (NCBI Reference Sequence: NP_001025042.2), Homo sapiens: isoform 1

[0452]

[0453] R-spondin 4 (NCBI Reference Sequence: NP_001035096.1), Homo sapiens: isoform 2

[0454]

[0455] Norrin

[0456] Norrin precursor [Homo sapiens]

[0457] NCBI reference sequence: NP_000257.1

[0458]

[0459] Mitogenic Factors

[0460]

[0461] TGFa Homo sapiens: pre-transforming growth factor alpha isoform 1 pre-protein [Homo sapiens] NCBI Reference Sequence: NP_003227.1

[0462]

[0463] Pro-transforming growth factor alpha isoform 2 preprotein [Homo sapiens] NCBI Reference Sequence: NP_001093161.1

[0464]

[0465] Transforming Growth Factor Alpha [Synthetic Construct]

[0466] GenBank: AAX43291.1

[0467]

[0468] TGFα, which contains:

[0469]

[0470] 5. Methods for Differentiating Stem Cells

[0471] Separated stem cells (e.g., epithelial stem cells) can be induced to differentiate into differentiated cells that are typically present in the tissue or organ from which the stem cells were derived or separated. Other tissues include fallopian tubes, endometrium (uterus), male efferent ducts, male epididymis, male vas deferens, male ejaculatory ducts, male bulbourethral glands, and seminal vesicles. Differentiated cells can express markers characteristic of differentiated cells and can be easily distinguished from stem cells that do not express such differentiated cell markers.

[0472] 6. Landmarks

[0473] Typically, gene expression of all of the markers described below can be measured at the RNA level. Additionally, expression of certain markers can also be detected by protein expression using, for example, antibodies specific for the protein encoded by the marker gene.

[0474] 7. How to use

[0475] In another aspect, the present invention provides for use of subject stem cells isolated from various cultures in drug discovery screening, toxicity assays, animal-based disease models, or medicine (eg, regenerative medicine).

[0476] Genetic manipulation of cloned stem cells. For example, stem cells separated by the method of the present invention are suitable for various types of genetic manipulation, including the introduction of exogenous genetic material that can regulate the expression of one or more target genes of interest. For example, such gene therapy can be used, for example, in a method for repairing damaged or diseased tissue. In short, any suitable vector, including adenovirus, lentivirus (elntiviral) or retroviral gene delivery vehicle (see below), can be used to deliver genetic information such as DNA and / or RNA to any subject stem cell. Technicians can replace or repair specific genes targeted in gene therapy. For example, normal genes can be inserted into non-specific positions in the diseased cell genome to replace non-functional genes. In another example, abnormal gene sequences can be replaced by normal gene sequences through homologous recombination. Alternatively, selective reversion mutations can restore genes to their normal functions. Another example is to change the regulation of specific genes (the degree of gene opening or closing). Preferably, stem cells are treated in vitro by gene therapy methods and subsequently transferred to mammals, preferably people who need treatment.

[0477] Any art-recognized genetic manipulation method can be applied to the stem cells thus isolated, including infection and transfection (eg, via viral vectors) with various types of nucleic acid constructs.

[0478] For example, heterologous nucleic acid (e.g., DNA) can be introduced into the subject stem cell by physical treatment (e.g., electroporation, sonoporation, optical transfection, protoplast fusion, impalefection, hydrodynamic delivery, nanoparticles, magnetofection), using chemical materials or biological vectors (viruses). Chemical-based transfection can be based on calcium phosphate, cyclodextrin, polymers (e.g., cationic polymers such as DEAE-dextran or polyethyleneimine), highly branched organic compounds such as dendrimers, liposomes (e.g., cationic liposomes, lipofection such as lipofection using lipofectamine, etc.), or nanoparticles (with or without chemical or viral functionalization).

[0479] A nucleic acid construct comprises a nucleic acid molecule of interest and is generally capable of directing the expression of the nucleic acid molecule of interest in a cell into which it has been introduced.

[0480] In certain embodiments, the nucleic acid construct is an expression vector in which a nucleic acid molecule encoding a gene product, such as a polypeptide, or a nucleic acid that antagonizes polypeptide expression (e.g., siRNA, miRNA, shRNA, antisense sequence, aptamer, ribozyme, etc.) is operably linked to a promoter capable of directing expression of the nucleic acid molecule in a target cell (e.g., an isolated stem cell).

[0481] The term "expression vector" generally refers to a nucleic acid molecule that is capable of affecting the expression of a gene / nucleic acid molecule contained therein in a cell that is compatible with such a sequence. These expression vectors generally include at least a suitable promoter sequence and optionally a transcription termination signal. A nucleic acid or DNA or nucleotide sequence encoding a polypeptide is incorporated into a DNA / nucleic acid construct that can be introduced into an in vitro cell culture as identified in the method of the invention and expressed therein.

[0482] The DNA construct prepared for introduction into a specific cell usually comprises a replication system recognized by the cell, an expected DNA segment encoding a desired polypeptide, and transcription and translation initiation and termination regulatory sequences operably connected to the segment encoding the polypeptide. A DNA segment is "operably connected" when it has a functional relationship with another DNA segment. For example, if a promoter or enhancer stimulates the transcription of a sequence, it is operably connected to a coding sequence. If the DNA of a signal sequence is expressed as a preprotein that participates in polypeptide secretion, it is operably connected to the DNA encoding the polypeptide. Usually, the DNA sequence operably connected is continuous, and in the case of a signal sequence, it is both continuous and in the reading stage. However, enhancers do not need to be continuous with the coding sequence that they control its transcription. Connection is accomplished by connecting at a convenient restriction site or at an adapter or joint that replaces its insertion.

[0483] The selection of an appropriate promoter sequence generally depends on the host cell selected for expressing the DNA segment. Examples of suitable promoter sequences include eukaryotic promoters known in the art (see, e.g., Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Third Edition, 2001). Transcriptional regulatory sequences generally include heterologous enhancers or promoters recognized by cells. Suitable promoters include CMV promoters. Expression vectors including replication systems and transcriptional and translational regulatory sequences and insertion sites for polypeptide coding segments can be used. Examples of feasible combinations of cell lines and expression vectors are described in Sambrook and Russell (2001, supra) and Metzger et al. (1988) Nature 334: 31-36.

[0484] Some aspects of the present invention relate to the use of an expression vector or a nucleic acid construct comprising a nucleotide sequence as defined above, wherein the vector is a vector suitable for gene therapy. Vectors suitable for gene therapy are known in the art, such as those described in: Anderson (Nature 392: 25-30, 1998); Walther and Stein (Drugs 60: 249-71, 2000); Kay et al. (Nat. Med. 7: 33-40, 2001); Russell (J. Gen. Virol. 81: 2573-604, 2000); Amado and Chen (Science 285: 674-6, 1999); Federico (Curr. Opin. Biotechnol. 10: 448-53, 1999); Vigna and Naldini (J. Gene Med. 2: 308-16, 2000); Marin et al. (Mol. Med. Today 3: 396-403, 1997); Peng and Russell (Curr. Opin. Biotechnol. 10:454-7, 1999); Sommerfelt (J. Gen. Virol. 80:3049-64, 1999); Reiser (Gene Ther. 7:910-3, 2000); and references cited therein (all incorporated by reference). Examples include integrating and non-integrating vectors, such as those based on retroviruses, adenoviruses (AdV), adeno-associated viruses (AAV), lentiviruses, poxviruses, alphaviruses, and herpes viruses.

[0485] Particularly suitable gene therapy vectors include adenovirus (Ad) and adeno-associated virus (AAV) vectors. These vectors infect a wide range of dividing and non-dividing cell types. In addition, adenovirus vectors are capable of high levels of transgene expression. However, due to the episomal nature of adenovirus and AAV vectors after cell entry, these viral vectors are best suited for therapeutic applications that require only transient expression of the transgene (Russell, J. Gen. Virol. 81:2573-2604, 2000; Goncalves, Virol J. 2(1):43, 2005), as described above. As reviewed by Russell (2000, supra), preferred adenovirus vectors are modified to reduce host responses. The safety and efficacy of AAV gene transfer have been extensively studied in humans, with encouraging results in the liver, muscle, CNS, and retina (Manno et al., Nat. Medicine 2006; Stroes et al., ATYB 2008; Kaplitt, Feigin, Lancet 2009; Maguire, Simonelli et al. NEJM 2008; Bainbridge et al., NEJM 2008).

[0486] AAV2 is the most characterized serotype for gene transfer studies in both humans and experimental models. AAV2 exhibits a natural tropism for skeletal muscle, neurons, vascular smooth muscle cells, and hepatocytes. Other examples of non-integrating vectors based on adeno-associated viruses include AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and pseudotyped AAV. The use of non-human serotypes (such as AAV8 and AAV9) may be useful for overcoming these immune responses in subjects, and clinical trials have just begun (ClinicalTrials dot gov Identifier: NCT00979238). For gene transfer into hepatocytes, adenovirus serotype 5 or AAV serotypes 2, 7, or 8 have been shown to be effective vectors and are therefore preferred Ad or AAV serotypes (Gao, Molecular Therapy 13: 77-87, 2006).

[0487] An exemplary retroviral vector for use in the present invention is a lentiviral-based expression construct. Lentiviral vectors have the unique ability to infect non-dividing cells (Amado and Chen, Science 285: 674-676, 1999). Methods for constructing and using lentiviral-based expression constructs are described in the following: U.S. Patent Nos. 6,165,782, 6,207,455, 6,218,181, 6,277,633, and 6,323,031 and Federico (Curr. Opin. Biotechnol. 10: 448-53, 1999) and Vigna et al. (J. Gene Med. 2: 308-16, 2000). In general, gene therapy vectors will be the same as the above-mentioned expression vectors in that they contain a nucleotide sequence encoding a gene product (e.g., a polypeptide) of the present invention to be expressed, whereby the nucleotide sequence is operably linked to an appropriate regulatory sequence, as described above. Such a regulatory sequence will contain at least a promoter sequence. Suitable promoters for expressing the nucleotide sequence encoding the polypeptide from a gene therapy vector include, for example, the cytomegalovirus (CMV) intermediate early promoter, a viral long terminal repeat promoter (LTR) (e.g., a promoter from murine Moloney leukaemia virus (MMLV) Rous sarcoma virus), or HTLV-1, simian virus 40 (SV 40) early promoter, and the herpes simplex virus thymidine kinase promoter. Additional suitable promoters are described below.

[0488] Several inducible promoter systems have been described that can be induced by the application of small organic or inorganic compounds. Such inducible promoters include those controlled by heavy metals, such as the metallothionine promoter (Brinster et al, Nature 296:39-42, 1982; Mayo et al, Cell 29:99-108, 1982), RU-486 (progesterone antagonist)) (Wang et al, Proc. Natl. Acad. Sci. USA 91:8180-8184, 1994), steroids (Mader and White, Proc. Natl. Acad. Sci. USA 90:5603-5607, 1993), tetracycline (Gossen and Bujard, Proc. Natl. Acad. Sci. USA 89:5547-5551, 1992; U.S. Patent No. 5,464,758; Furth et al, Proc. Natl. Acad. Sci. USA 89:5547-5551, 1992; U.S. Patent No. 5,464,758; Furth et al, Proc. Natl. Acad. Sci. USA 91:8180-8184, 1994), al, Proc. Natl. Acad. Sci. USA 91:9302-9306, 1994; Howe et al, J. Biol. Chem. 270:1416814174, 1995; Resnitzky et al, Mol. Cell. Biol. 14:1669-1679, 1994; Shockett et al, Proc. Natl. Acad. Sci. USA 92:6522-6526, 1995) and the tTAER system based on a multi-chimeric trans-activator composed of the tetR polypeptide as the activation domain of VP16 and the ligand binding domain of the estrogen receptor (Yee et al, 2002, US 6,432,705).

[0489] In addition to the above-mentioned polymerase II promoter, suitable promoters for nucleotide sequences encoding small RNAs for knocking down specific genes (see below) by RNA interference also include polymerase III promoters. RNA polymerase III (pol III) is responsible for the synthesis of a variety of small nuclear and cytoplasmic non-coding RNAs, including 5S, U6, adenovirus VA1, vault, telomerase RNA and tRNA. The promoter structures of a large number of genes encoding these RNAs have been determined, and it has been found that RNA pol III promoters are divided into three types of structures (for review, see Geiduschek and TocchiniValentini, Annu. Rev. Biochem. 57: 873-914, 1988; Willis, Eur. J. Biochem. 212: 1-11, 1993; Hernandez, J. Biol. Chem. 276: 26733-36, 2001). Particularly suitable for expressing siRNA is the type 3 RNA polIII promoter, in which transcription is driven by cis-acting elements present only in the 5'-flanking region (i.e., upstream of the transcription start site). The upstream sequence elements include the traditional TATA box (Mattaj et al., Cell 55: 435-442, 1988), the proximal sequence element and the distal sequence element (DSE; Gupta and Reddy, Nucleic Acids Res. 19: 2073-2075, 1991).

[0490] Examples of genes controlled by type 3 pol III promoters are U6 small nuclear RNA (U6snRNA), 7SK, Y, MRP, HI and telomerase RNA genes (see, e.g., Myslinski et al, Nucl. Acids Res. 21:2502-09, 2001).

[0491] Gene therapy vectors may optionally include a second or one or more additional nucleotide sequences encoding a second or additional polypeptide. The second or additional polypeptide may be a (selection) marker polypeptide that allows identification, selection and / or screening of cells containing an expression construct. Suitable marker proteins for this purpose are, for example, fluorescent protein GFP and selection marker genes HSV thymidine kinase (for selection on HAT culture medium), bacterial hygromycin B phosphotransferase (for selection on hygromycin B), Tn5 aminoglycoside phosphotransferase (for selection on G418), and dihydrofolate reductase (DHFR) (for selection on methotrexate), CD20, low affinity nerve growth factor gene. The sources and methods of use for obtaining these marker genes are provided in the following: Sambrook and Russell, Molecular Cloning: A Laboratory Manual (3rd Edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York, 2001.

[0492] Alternatively, if deemed necessary, the second or additional nucleotide sequence may encode a polypeptide that provides a fail-safe mechanism that allows the subject from the transgenic cell to be cured. Such nucleotide sequences, often referred to as suicide genes, encode a polypeptide that is capable of converting a prodrug into a toxic substance that is capable of killing the transgenic cell in which the polypeptide is expressed. Suitable examples of such suicide genes include, for example, the E. coli cytosine deaminase gene or one of the thymidine kinase genes from herpes simplex virus, cytomegalovirus, and varicella-zoster virus, in which case ganciclovir may be used as a prodrug to kill IL-10 transgenic cells in a subject (see, e.g., Clair et al., Antimicrob. Agents Chemother. 31: 844-849, 1987).

[0493] In order to knock down the expression of a specific polypeptide, a gene therapy vector or other expression construct is used to express a desired nucleotide sequence preferably encoding an RNAi agent, which is an RNA molecule capable of RNA interference or a part of an RNA molecule capable of RNA interference. Such RNA molecules are called siRNA (short interfering RNA, including, for example, short hairpin RNA). The desired nucleotide sequence comprises an antisense codon DNA encoding an antisense RNA for a region of a target gene mRNA, and / or a sense codon DNA encoding a sense RNA for the same region of a target gene mRNA. In the DNA construct of the present invention, the antisense and sense codon DNAs are operably linked to one or more promoters capable of expressing antisense and sense RNAs, respectively, as defined above. "siRNA" includes small interfering RNA, which is a short-length double-stranded RNA that is non-toxic in mammalian cells (Elbashir etah, Nature 411: 494-98, 2001; Caplen et al, Proc. Natl. Acad. Sci. USA 98: 9742-47, 2001). The length is not necessarily limited to 21 to 23 nucleotides. As long as it does not show toxicity, the length of the siRNA is not particularly limited. "siRNA" can be, for example, at least about 15, 18 or 21 nucleotides and up to 25, 30, 35 or 49 nucleotides. Alternatively, the double-stranded RNA portion of the final transcription product of the siRNA to be expressed can be, for example, at least about 15, 18 or 21 nucleotides, and up to 25, 30, 35 or 49 nucleotides.

[0494] "Antisense RNA" is preferably an RNA strand having a sequence complementary to the target gene mRNA, and is considered to induce RNAi by binding to the target gene mRNA.

[0495] "Sense RNA" has a sequence complementary to the antisense RNA, and anneals with the complementary antisense RNA to form siRNA.

[0496] In this context, the term "target gene" includes genes whose expression will be silenced due to the siRNA to be expressed by this system, and can be selected arbitrarily. As the target gene, it is preferred to select genes whose sequence is known but whose function remains to be elucidated, and genes whose expression is considered to be the cause of disease. It has been determined that the target gene can be a gene whose genomic sequence has not yet been fully elucidated, as long as the partial sequence of the mRNA of the gene has at least 15 nucleotides or more nucleotides (which is a length that can be combined with one chain (antisense RNA chain) of siRNA). Therefore, even if the full-length sequences of genes, expressed sequence tags (ESTs) and mRNA parts (some of which (preferably at least 15 nucleotides) have been elucidated) have not yet been determined, they can also be selected as "target genes".

[0497] The double-stranded RNA portion of the siRNA in which the two RNA chains are paired is not limited to a completely paired portion, and may contain a non-paired portion due to a mismatch (the corresponding nucleotides are not complementary), a bulge (one chain lacks a corresponding complementary nucleotide), etc. The non-paired portion may be contained to the extent that it does not interfere with the formation of the siRNA. As used herein, a "bulge" may contain 1 to 2 non-paired nucleotides, and the double-stranded RNA region of the siRNA in which the two RNA chains are paired preferably contains 1 to 7, more preferably 1 to 5 bulges.

[0498] The term "mispairing" used herein may be included in the double-stranded RNA region of the siRNA in which two RNA chains are paired, preferably 1 to 7 in quantity, more preferably 1 to 5. In some mispairings, one nucleotide is guanine and the other is uracil. Such mispairing is due to a mutation from C to T, G to A or its mixture in the DNA encoding the sense RNA, but is not particularly limited to them. In addition, in the present invention, the double-stranded RNA region of the siRNA in which two RNA chains are paired may contain both protrusions and mispairings, preferably 1 to 7 in quantity, more preferably 1 to 5. Such non-pairing parts (mispairing or protrusions, etc.) can suppress the recombination between the following antisense and sense code DNA, and stabilize the following siRNA expression system. In addition, although it is difficult to sequence the stem-loop DNA that does not contain non-pairing parts in the double-stranded RNA region of the siRNA in which two RNA chains are paired, sequencing is enabled by introducing mispairing or protrusions as described above. In addition, the siRNA containing mispairing or protrusions in the paired double-stranded RNA region has the advantage of being stable in Escherichia coli or animal cells.

[0499] As long as siRNA can silence the expression of target gene due to its RNAi effect, the terminal structure of siRNA can be blunt or sticky (protruding). Sticky (protruding) terminal structure is not limited to 3' protrusion, and can also include 5' protruding structure, as long as it can induce RNAi effect. In addition, the number of protruding nucleotides is not limited to 2 or 3 reported, as long as the protrusion can induce RNAi effect, it can be any number. For example, the protrusion is composed of 1 to 8, preferably 2 to 4 nucleotides. Here, the total length of siRNA with sticky terminal structure is expressed as the sum of the length of the paired double-stranded part and the length of the pair containing the protruding single strand at both ends. For example, in the case of 19bp double-stranded RNA part and 4 nucleotides protruding at both ends, the total length is expressed as 23bp. In addition, due to the low specificity of the protruding sequence to the target gene, it is not necessarily complementary (antisense) or identical (meaning) to the target gene sequence. Furthermore, as long as the siRNA can maintain its gene silencing effect on the target gene, the siRNA may contain low molecular weight RNA (which may be a natural RNA molecule such as tRNA, rRNA or viral RNA, or an artificial RNA molecule) (e.g., in the overhang at one end thereof).

[0500] In addition, as described above, the terminal structure of "siRNA" must be a cut-off structure at both ends, and may have a stem-loop structure in which the ends of one side of the double-stranded RNA are connected by a linker RNA ("shRNA"). The length of the double-stranded RNA region (stem-loop portion) can be, for example, at least 15, 18 or 21 nucleotides and at most 25, 30, 35 or 49 nucleotides long. Alternatively, the length of the double-stranded RNA region as the final transcription product of the siRNA to be expressed is, for example, at least 15, 18 or 21 nucleotides and at most 25, 30, 35 or 49 nucleotides long.

[0501] In addition, the length of the joint is not particularly limited, as long as its length does not hinder the pairing of the stem portion.For example, for the inhibition of the recombinant between the stable pairing of the stem portion and the DNA encoding the part, the joint portion can have a clover-leaf tRNA structure.Even if the joint length hinders the pairing of the stem portion, the joint portion can be, for example, constructed to include an intron, so that during the precursor RNA is processed into mature RNA, the intron is excised, thereby allowing the pairing of the stem portion.In the case of stem-loop siRNA, there is no either end (head or tail) of the RNA of the ring structure may have a low-molecular-weight RNA.As mentioned above, this low-molecular-weight RNA can be a natural RNA molecule, such as tRNA, rRNA, snRNA or viral RNA, or an artificial RNA molecule.

[0502] In order to express antisense and sense RNA from antisense and sense code DNA respectively, DNA construct of the present invention comprises promoter as defined above.In construct, the number and position of promoter can be selected arbitrarily in principle, as long as it can express antisense and sense code DNA.As a simple example of DNA construct of the present invention, a tandem expression system can be formed, wherein the promoter is located upstream of antisense and sense code DNA.This tandem expression system can produce siRNA with above-mentioned cut-off structure at two ends.In stem-loop siRNA expression system (stem expression system), antisense and sense code DNA are arranged in opposite directions, and these DNA are connected to construct unit by joint DNA.Promoter is connected to one side of this unit to build stem-loop siRNA expression system.Here, the length and sequence of joint DNA are not particularly limited, and it can have any length and sequence, as long as its sequence is not a terminator sequence and its length and sequence do not hinder the pairing (as described above) of stem part in the mature RNA production process.For example, the DNA encoding above-mentioned tRNA etc. can be used as joint DNA.

[0503] In both the tandem and stem-loop expression systems, the 5' end may have a sequence that can promote transcription from a promoter. More specifically, in the case of tandem siRNA, the efficiency of siRNA production can be improved by adding a sequence that can promote transcription from a promoter at the 5' end of the antisense and sense code DNA. In the case of stem-loop siRNA, such a sequence can be added at the 5' end of the above-mentioned unit. As long as the silencing of the target gene by siRNA is not hindered, the transcript from such a sequence can be used in a state connected to the siRNA. If this state hinders gene silencing, it is preferred to use a trimming tool (e.g., a ribozyme known in the art) to trim the transcript. The technician will know that antisense and sense RNA can be expressed in the same vector or in different vectors. To avoid adding too many sequences downstream of sense and antisense RNA, it is preferred to place a transcription terminator at the 3' end of each chain (chain encoding antisense and sense RNA). The terminator can be a sequence of four or more continuous adenine (A) nucleotides.

[0504] Genome editing. Genome editing can be used to change the genome sequence of a subject cloned stem cell (including cloned cancer (or other disease) stem cells) by introducing a heterologous transgene or by inhibiting the expression of a target endogenous gene. Such genetically engineered stem cells can be used for regenerative medicine (see below) or wound healing. Therefore, in certain embodiments, the subject method of regenerative medicine (see below) includes using a subject stem cell whose genome sequence has been modified by genome editing.

[0505] Genome editing can be performed using any art-recognized technology, such as ZFN / TALEN or CRISPR technology (see review Gaje et ah, Trends in Biotech. 31 (7): 397-405, 2013, the entire text of which and all references cited therein are incorporated herein by reference). Such technology enables one to manipulate almost any gene in a variety of cell types and organisms, thereby enabling a wide range of genetic modifications to be achieved by inducing DNA double-strand (DSB) breaks that stimulate error-prone non-homologous end joining (NHEJ) or homology-directed repair (HDR) (at a specific genomic location).

[0506] Zinc finger nuclease (Zinc-finger nuclease, ZFN) and transcription activator-like effector nuclease (TALEN) are chimeric nucleases, which are composed of programmable, sequence-specific DNA binding modules connected to non-specific DNA cleavage domains. They are artificial restriction endonucleases (RE) produced by fusing zinc finger or TAL effector DNA binding domains with DNA cleavage domains. Zinc finger (ZF) or transcription activator-like effector (TALE) can be engineered to bind any desired target DNA sequence and fused with the DNA cleavage domain of RE to produce engineered restriction endonucleases (ZFN or TALEN) with specificity for the desired target DNA sequence. After ZFN / TALEN is introduced into cells, it can be used for genome in situ editing. In fact, the versatility of ZFN and TALEN can be extended to effector domains beyond nucleases, such as transcription activators and repressors, recombinases, transposases, DNA and histone methyltransferases, and histone acetyltransferases, to affect genome structure and function.

[0507] The Cys2-His2 zinc finger domain is one of the most common types of DNA binding motifs present in eukaryotes and represents the second most commonly encoded protein domain in the human genome. A single zinc finger has about 30 amino acids in a conserved ββα configuration. The key to applying zinc finger proteins to specific DNA recognition is to develop non-natural arrays containing more than three zinc finger domains. This progress has been facilitated by the structure-based discovery of highly conserved linker sequences, which enable the construction of synthetic zinc finger proteins that recognize DNA sequences of 9 to 18 bp in length. This design has been shown to be the best strategy for constructing zinc finger proteins that recognize continuous DNA sequences that are specific in complex genomes. Suitable zinc fingers can be obtained by modular assembly methods (e.g., using a pre-selected library of zinc finger modules generated by selecting a large combinatorial library or by rational design). Such zinc finger domains have been developed that recognize almost all of the 64 possible nucleotide triplets, and the pre-selected zinc finger modules can be connected in series with a target DNA sequence containing a series of these DNA triplets. Alternatively, selection-based methods (e.g., oligomerized pool engineering (OPEN)) can be used to select new zinc finger arrays from random libraries that take into account context-dependent interactions between adjacent fingers. A combination of these two approaches has also been used.

[0508] Engineered zinc fingers are commercially available. Sangamo Biosciences (Richmond, CA, USA) has collaborated with SigmaAldrich (St. Louis, MO, USA) to develop a proper (propriety) platform (CompoZr) for zinc finger construction that allows researchers to completely bypass zinc finger construction and validation, and thousands of proteins are already available. Broadly speaking, zinc finger protein technology enables the targeting of almost any sequence.

[0509] TAL effectors are proteins secreted by plant pathogenic Xanthomonas (context-dependent interaction) bacteria whose DNA binding domain contains a repeated, highly conserved sequence of 33 to 34 amino acids, with the exception of amino acids 12 and 13. These two positions are highly variable (repeat variable diresidues, or RVDs) and show a strong correlation with specific nucleotide recognition. This simple relationship between amino acid sequence and DNA recognition allows engineering of specific DNA binding domains by selecting combinations of repeat segments containing appropriate RVDs. Like zinc fingers, modular TALE repeats are linked together to recognize continuous DNA sequences. Many effector domains can be used to fuse TALE repeats for targeted genetic modification, including nucleases, transcription activators, and site-specific recombinases. Rapid assembly of customized TALE arrays can be achieved using strategies including: "Golden Gate" molecular cloning, high-throughput solid phase assembly, and ligation-independent cloning techniques, all of which can be used in the present invention for genome editing of cloned stem cells.

[0510] TALE repeats can be easily assembled using many tools available in the art, such as a TALEN library targeting 18,740 human protein-coding genes (Kim et al., Nat. Biotechnol. 31, 251-258, 2013). Custom-designed TALE arrays are also commercially available from, for example, Cellectis Bioresearch (Paris, France), Transposagen Biopharmaceuticals (Lexington, KY, USA), and Life Technologies (Grand Island, NY, USA).

[0511] Non-specific DNA cleavage domains from the end of the RE, such as the Fok1 endonuclease (or Fok1 cleavage domain variants, such as Sharkey, which have mutations designed to increase cleavage specificity and / or cleavage activity), can be used to construct hybrid nucleases that are active in yeast assays (and also active in plant cells and animal cells). To increase ZFN activity, transient low-temperature culture conditions can be used to increase nuclease expression levels; co-delivery of site-specific nucleases with DNA end-processing enzymes can also be used, as well as the use of fluorescent surrogate reporter vectors that allow enrichment of ZFN- and TALEN-modified cells. The specificity of ZFN-mediated genome editing can also be improved by using zinc finger nickases (ZFNickases), which exploit the discovery that induction of nicked DNA stimulates HDR without activating the error-prone NHEJ repair pathway.

[0512] The simple relationship between the amino acid sequence of the TALE binding domain and the DNA recognition allows for a designable protein. A publicly available software program (DNAWorks) can be used to calculate oligonucleotides suitable for assembly in a two-step PCR. Many modular assembly schemes for generating engineered TALE constructs have also been reported and known in the art. Both methods provide a systematic approach to engineering DNA binding domains, which is conceptually similar to the modular assembly method used to generate zinc finger DNA recognition domains.

[0513] Once the TALEN genes have been assembled, they are introduced into target cells using any art-recognized method on a carrier (e.g., electroporation or transfection, using cationic lipid-based reagents, using plasmid vectors, various viral vectors (e.g., adenovirus, AAV, and integrase-deficient lentiviral vectors (IDLV))). Alternatively, TALEN can be delivered to cells as mRNA, which eliminates the possibility of genomic integration of proteins expressing TALEN. It can also significantly improve the level of homology-directed repair (HDR) and the success rate of introgression during gene editing. Finally, purified ZFN / TALEN proteins can also be delivered directly to cells. This method does not bring the risk of insertional mutagenesis, and makes it less off-target than a delivery system that relies on expression from nucleic acids, and can therefore be optimally used for studies that require precise genome engineering in cells (e.g., instant stem cells).

[0514] TALEN can be used to edit the genome by inducing double-strand breaks (DSBs), to which cells respond with repair mechanisms. Non-homologous end joining (NHEJ) reconnects DNA from either side of a double-strand break, with very little or no annealed sequence overlap. A simple heteroduplex cleavage assay can be run, which detects any difference between the two alleles amplified by PCR. The cleavage products can be observed on a simple agarose gel or slab gel system. Alternatively, DNA can be introduced into the genome by NHEJ in the presence of exogenous double-stranded DNA fragments.

[0515] Homology-directed repair can also introduce foreign DNA at DSBs, as the transfected double-stranded sequence serves as a template for the repair enzymes. TALENs have been used to generate stably modified human embryonic stem cells and induced pluripotent stem cell (iPSC) clones to generate knockout C. elegans, rats, and zebrafish.

[0516] For stem cell-based therapies, ZFNs and TALENs are able to correct the underlying cause of the disease, thereby permanently eliminating symptoms through precise genome modification. For example, ZFN-induced HDR has been used to directly correct pathogenic mutations associated with X-linked severe combined immunodeficiency (SCJD), hemophilia B, sickle cell disease, al-antitrypsin deficiency, and many other genetic diseases by repairing defective target genes or by knocking out target genes. In addition, these site-specific nucleases can also be used to safely insert therapeutic transgenes into subject stem cells at specific "safe harbor" locations in the human genome. Such technology can be used in combination with the stem cells of the present invention for gene therapy, including therapy based on autologous stem cell transplantation, in which one or more genes of cloned (diseased or normal) stem cells are manipulated to increase or decrease / eliminate the expression of target genes.

[0517] Alternatively, the CRISPR / Cas system can also be used to effectively induce targeted genetic changes into subject stem cells. The CRISPR / Cas (CRISPR-associated) system or "Clustered Regulatory Interspaced Short Palindromic Repeats" is a locus containing multiple short direct repeats and provides acquired immunity to bacteria and archaea. The CRISPR system relies on crRNA and tracrRNA to perform sequence-specific silencing of invading exogenous DNA. The term "tracrRNA" represents trans-activating chimeric RNA, which is a non-coding RNA that promotes crRNA processing and is necessary for activating RNA-guided cutting by Cas9. CRISPR RNA or crRNA is base-paired with tracrRNA to form a dual RNA structure, which guides the Cas9 endonuclease to reach the complementary DNA site for cutting.

[0518] There are three types of CRISPR / Cas systems: In the type II system, Cas9 is used as an RNA-guided DNA endonuclease that cuts DNA after crRNA-tracrRNA target recognition. In bacteria, the CRISPR system provides acquired immunity against invading foreign DNA through RNA-guided DNA cutting. By redesigning crRNA, the CRISPR / Cas system can be retargeted to cut almost any DNA sequence. In fact, the CRISPR / Cas system has been demonstrated to be directly transplanted into human cells by co-delivering a plasmid expressing the Cas9 endonuclease and the necessary crRNA components. These programmable RNA-guided DNA endonucleases have demonstrated targeted integration and multiple gene disruption capabilities in iPS cells, and can therefore be similarly used in subject stem cells.

[0519] Cancer stem cells. The methods and reagents of the present invention also enable the culture and isolation of cancer-derived cancer stem cells (CSCs) from epithelial tissue samples / biopsies or from other stratified regenerative tissues, which in turn can be used for many applications that were previously impossible or impractical to perform, in part due to the inability to obtain such CSCs in single cell clone form and in large quantities.

[0520] For example, a CSC library established from a single patient using the method of the present invention can compare patient-matched sensitive and resistant clones for directed drug discovery work. Certain genes in resistant clones may be upregulated or downregulated compared to sensitive clones. Inhibitors for upregulated genes can be further validated as drug target genes, for example, by testing the ability of target genes to be downregulated in resistant clones and determining their effect on drug resistance. Conversely, restoring or overexpressing downregulated genes in resistant clones can also overcome drug resistance.

[0521] Thus, in one aspect, the present invention provides a drug discovery method for identifying genes that are up-regulated or down-regulated in drug-resistant CSC clones using CSCs isolated using the subject methods and culture media, the method comprising: (1) obtaining a plurality of cell clones from a cancer tissue (e.g., a tissue from a cancer patient) using the methods of the present invention; (2) contacting the plurality of cell clones with one or more compounds (e.g., a cancer drug) under conditions in which a small percentage (e.g., no more than 1%, 0.5%, 0.2%, 0.1%, 0.05%, 0.01% or less) of the drug-resistant clones survive; (3) comparing the gene expression profiles of the drug-resistant clones and sensitive clones (e.g., one or more of the plurality of cell clones randomly selected prior to step (2) that may be sensitive to drug treatment), thereby identifying genes that are up-regulated or down-regulated in the surviving drug-resistant clones.

[0522] In certain embodiments, the method further comprises inhibiting the expression of genes upregulated in surviving drug-resistant clones. For example, upregulated genes can be upregulated in two or more surviving drug-resistant clones from the same patient or from different patients, from the same type of tumor or different types of tumors. In certain embodiments, the upregulated genes can be specific to the patient from whom the CSC is isolated. This helps to design personalized drugs or treatment plans for patients.

[0523] In certain embodiments, the method further comprises restoring or increasing the expression of genes down-regulated in surviving drug-resistant clones. For example, down-regulated genes can be down-regulated in two or more surviving drug-resistant clones from the same patient or from different patients, from the same type of tumor or different types of tumors. In certain embodiments, the down-regulated genes can be specific to the patient from whom the CSC was isolated. This also helps to design personalized drugs or treatment plans for patients.

[0524] In a related aspect, the present invention provides a drug discovery method, the method using CSCs isolated using the subject method and culture medium to identify candidate compounds that inhibit the growth of drug-resistant CSCs or promote the killing of drug-resistant CSCs, the method comprising: (1) using the method of the present invention, obtaining multiple cell clones from cancer tissue (e.g., tissue from a cancer patient); (2) contacting the multiple cell clones with one or more compounds (e.g., cancer drugs) under conditions in which a small percentage (e.g., no more than 1%, 0.5%, 0.2%, 0.1%, 0.05%, 0.01% or less) of drug-resistant clones survive; (3) contacting the surviving drug-resistant clones with a plurality of candidate compounds, and (4) identifying one or more candidate compounds that inhibit the growth of surviving drug-resistant clones or promote the killing of surviving drug-resistant clones. In certain embodiments, the method is performed using a high-throughput screening format for candidate drugs targeting resistant cells.

[0525] In certain embodiments, the method further comprises testing the identified candidate compound for general toxicity to matched sensitive clones (e.g., one or more multiple cell clones randomly selected prior to step (2) that may be sensitive to drug treatment) and / or matched healthy cells from the same patient from which the CSCs were isolated. Preferably, any identified candidate compound specifically or preferentially inhibits the growth of drug-resistant CSCs or promotes the killing of drug-resistant CSCs compared to matched sensitive clones and / or matched healthy cells.

[0526] In certain embodiments, the healthy cells are patient-matched normal stem cells similarly isolated using the methods and reagents of the invention.

[0527] The above embodiments are based in part on the following findings: in many cases, drug-resistant CSCs grow slower than drug-sensitive clones. Although not wishing to be bound by any particular theory, the applicant believes that slow growth may be the result of altered gene expression in drug-resistant CSCs that is used to escape chemotherapy. Therefore, it is expected that certain agents may preferentially inhibit the growth of drug-resistant cells or kill drug-re...

Claims

1. A defined culture medium for isolating stratified epithelial stem cells and maintaining their epigenetics stably during multiple passages in culture, the culture medium comprising: a basal culture medium; and each of a ROCK (Rho kinase) inhibitor, a mitogenic growth factor, insulin or IGF, a TrkA inhibitor, ponatinib and an Oct4 activator, the culture medium comprising at least one of a VEGF inhibitor, a tyrosine kinase inhibitor and FGF10 or an FGF10 agonist, wherein Jagged-1, nicotinamide and R-spondin are absent in the culture medium, and wherein the culture medium supports epigenetically stable growth and proliferation of stem cells derived from stratified epithelial tissue in culture.

2. The defined medium of claim 1, wherein the medium further comprises a TGFβ signaling pathway inhibitor and / or a bone morphogenetic protein (BMP) antagonist.

3. The defined medium of claim 1, which allows the cells to be passaged in a feeder-free manner and further comprises a SYK inhibitor, an LPA receptor antagonist, a GSK3 inhibitor, and a CK2 inhibitor.

4. The defined medium of any one of claims 1 to 3, wherein the epithelial stem cells are in contact with an extracellular matrix or another biological matrix.

5. The defined medium of any one of claims 1 to 3, wherein the stem cells are isolated from a tissue sample obtained from normal epithelial tissue.

6. The defined medium of any one of claims 1 to 3, wherein the stem cells are isolated from a tissue sample obtained from a diseased epithelial tissue.

7. The defined medium of claim 6, wherein the diseased epithelial tissue is from an inflammatory or autoimmune patient.

8. The defined medium of any one of claims 1 to 3, wherein the stem cells are isolated from a tissue sample obtained from a tumor.